GeneWiki enables you to enrich the annotation of genes and transcripts. Please submit or edit a GeneWiki note (500 characters max) related to a gene, its transcripts, or proteins. When possible include PubMed identifiers or web resource links (URL addresses). Please ensure that the additions will have widespread use. For additional information, check the GeneWiki help document.
Murine Brca2 shares multiple properties with human BRCA2 including its regulation during the cell cycle, localization to nuclear foci, and interaction with Brca1 and Rad51. (Mus musculus) PubMed
2.
Loss of Brca2 increases in vivo somatic mutation acquisition and synergizes with ionizing radiation exposure. (Mus musculus) PubMed
3.
Genomic organization and expression of the mouse Brca2 gene (Mus musculus) PubMed
4.
crystal structure of a COOH terminal BRCA2 domain bound to DSS1; demonstrate that this BRCA2 domain binds single-stranded DNA and show that BRCA2 stimulates RAD51-mediated recombination in vitro (Mus musculus) PubMed
5.
The extreme carboxy-terminal region encoded by exon 27 is vital for BRCA2 function in mice, perhaps because it is required for a fully functional interaction between BRCA2 and RAD51, though it is less severe than truncations that delete some BRC motifs. (Mus musculus) PubMed
6.
BRCA2 has a role in modulating M phase progression (Mus musculus) PubMed
7.
interplay between Brca2 and mitotic checkpoint has been suggested in the maintenance of genetic fidelity (Mus musculus) PubMed
8.
BRCA2-deficient spermatocytes fail to progress beyond the early prophase I stage of meiosis. (Mus musculus) PubMed
9.
Brca2 knockout mouse is less susceptible to chemically indeced tumorigenesis. (Mus musculus) PubMed
10.
results show that BRCA2 deficiency impairs the completion of cell division by cytokinesis (Mus musculus) PubMed
11.
Brca2 plays an important role in the response to DNA damage in the small intestine. (Mus musculus) PubMed
12.
In the small intestine, deletion of cells lacking Brca2 is necessary to avoid the development of potentially tumorigenic clones in this tissue. (Mus musculus) PubMed
13.
Homozygous germ-line mutation in exon 27 of Brca2 disrupts the Fancd2-Brca2 pathway in the homologous recombination-mediated DNA interstrand cross-links' repair, but does not affect meiosis. (Mus musculus) PubMed
14.
These findings include extensive in vivo data demonstrating that germline Brca2 and p53 mutations cooperatively affect animal survivals, tumor susceptibilities, and tumor onsets. (Mus musculus) PubMed
15.
Whereas conventional Brca1 and Brca2 mouse mutants did not reveal a strong phenotype in a heterozygous setting, most homozygous mutations caused embryonic lethality. [REVIEW] (Mus musculus) PubMed
16.
These results identify a novel role for FoxM1 in the transcriptional response during DNA damage/checkpoint signaling and show a novel mechanism by which Chk2 protein regulates expression of DNA repair enzymes. (Mus musculus) PubMed
BRCA2 is required for neurogenesis and suppression of medulloblastoma. (Mus musculus) PubMed
19.
Loss of Rad51 function as a critical underlying factor in the homologous recombination defect in the Brca2-depleted cells. (Mus musculus) PubMed
20.
Article describes the involvement of BRCA2 in O6-alkylguanine DNA alkyltransferase (AGT)-mediated repair of O6-methylguanine adducts. (Mus musculus) PubMed
21.
The sister chromatid exchange events stimulated by Tim reduction were largely mediated via a Brca2/Rad51-dependent mechanism and were additively increased by deletion of the Blm helicase. (Mus musculus) PubMed
22.
heterozygosity for a BRCA2 mutation has a distinct phenotype in DT40 cells (Mus musculus) PubMed
23.
FA proteins work together with BRCA2/Rad51-mediated homologous recombination in double strand break repair, whereas the FA pathway plays a role that is independent of the CTD of BRCA2 in interstrand cross-link repair (Mus musculus) PubMed
24.
Results suggest that Rad51 binding by the C-terminal Brca2 motif is dispensable for the execution of homologous DNA recombination but instead links the disassembly of Rad51 complexes to mitotic entry. (Mus musculus) PubMed
25.
3 novel polymorphic markers were developed for LOH(loss of heterozygosity) analysis of canine BRCA2 and identified a dog with LOH with some variations in the functional domains. (Mus musculus) PubMed
26.
The results suggest that RAD51 and BRCA2 are upregulated in the majority of lymph node metastases of canine mammary tumors. (Mus musculus) PubMed
27.
this study indicates that BRCA1 and BRCA2 contribute to the risk of canine mammary tumors in English springer spaniels (Mus musculus) PubMed
28.
Simultaneous deletion of Brca2 and the tumour suppressor Trp53 in prostate epithelia gave rise to focal hyperplasia and atypical cells (Mus musculus) PubMed
29.
critical roles for brca2 in ovarian development and tumorigenesis in reproductive tissues (Mus musculus) PubMed
30.
Germline heterozygosity for a pathogenic Brca2 truncation suffices to promote pancreatic ductal adenocarcinomas driven by Kras(G12D), irrespective of Trp53 status. (Mus musculus) PubMed
31.
BRCA1 and BRCA2 heterozygosity in embryonic stem cells reduces radiation-induced Rad51 focus formation but is not associated with radiosensitivity. (Mus musculus) PubMed
32.
BRCA2 associates with telomeres during the S and G2 phases of the cell cycle and facilitates the loading of RAD51 onto telomeres. (Mus musculus) PubMed
33.
Trp53 signaling must be modified before inactivation of the Brca2 wild-type allele, irrespective of Kras status, for Brca2-deficient cells to form pancreatic tumors (Mus musculus) PubMed
34.
The novel role of Brca2 in organizing the vertebrate egg nucleus may provide new insights into the origin of ovarian cancer (Mus musculus) PubMed
35.
Data suggest that the growth-suppressive effect of CHK1 inhibition in BRCA2-mutant tumors can be opposed by concurrent KRAS activation and TP53 mutations. (Mus musculus) PubMed
36.
FANCD1/BRCA2 played notably important roles in the repair of TMZ-induced DNA damage. (Mus musculus) PubMed
37.
Loss of Brca2 function predisposes the exocrine pancreas to profound DNA damage, and the frequency of invasive neoplasia is accentuated by the concomitant deregulation of p53 (Mus musculus) PubMed
38.
BRCA2 might serve as a platform to recruit various RAD51 mediators at the appropriate position at the DNA-damage site. (Mus musculus) PubMed
39.
Findings suggest that BRCA2 mutants containing truncations of the BRC repeat sequences may affect canine RAD51 binding strength. This may provide insight into effects of missense or truncation mutations in BRCA2 in canine tumours. (Mus musculus) PubMed
40.
BRCA2 is required for telomere homeostasis and may be particularly important for the replication of G-rich telomeric lagging strands. (Mus musculus) PubMed
41.
Data indicate four variations (1366 T > G, 2609A > C, 7126ins/delGTT, and 10204ins/delAAA) in the BRCA2 gene. (Mus musculus) PubMed
42.
Two canine BRCA2 mutations (T1425P and K1435R) in BRC repeat 3 (BRC3), derived from mammary tumor samples. These mutations affected the interaction of canine BRC3 with RAD51 (Mus musculus) PubMed
43.
data showed that silencing of BRCA2 promoted cell proliferation, migration and invasion in vitro; data reported here demonstrate that BRCA2 may be a promising therapeutic targets for pancreatic ductal adenocarcinoma progression (Mus musculus) PubMed
44.
one SNP in exon 9 of BRCA1 and one SNP in exon 24 of BRCA2 were found to be significantly associated with canine mammary tumours (Mus musculus) PubMed
45.
BRCA2 accumulates DNA damage, which triggers checkpoint signalling and ARF activation (Mus musculus) PubMed
46.
Results suggest that cellular levels of Brca2 and Rad51 are mutually dependent on each other, and that low levels of these proteins provide selective pressure for reduction of p53, which permits cell growth (Mus musculus) PubMed
47.
genetic stability, and hematopoietic differentiation potential of gene-corrected Brca2(Delta) (27/) (Delta) (27) iPSCs, achievements and limitations in the application of current reprogramming approaches in hematopoietic stem cell therapy are also discussed. (Mus musculus) PubMed
48.
Carcinogenesis in zebrafish with combined mutations in tp53 and brca2 typically requires biallelic mutation or loss of at least one of these genes. (Mus musculus) PubMed
49.
the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2 (Mus musculus) PubMed
50.
BRCA2 directly represses the expression of IFN-related genes (Mus musculus) PubMed
51.
BRCA2-mediated sequestration of nuclear RAD51 serves to prevent inappropriate DNA interactions. (Mus musculus) PubMed
52.
we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP inhibition. (Mus musculus) PubMed
53.
BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair. (Mus musculus) PubMed
54.
Heterozygous and homozygous Brca2 mutation may lead to dysfunction in T cell populations. (Mus musculus) PubMed
55.
Merit40 mutation exacerbated ICL-induced chromosome instability in the context of concomitant Brca2 deficiency but not in conjunction with Fancd2 mutation. (Mus musculus) PubMed
56.
Canine BRCA2 has two polymorphisms (T1425P and K1435R) influencing the interaction with RAD51. (Mus musculus) PubMed
57.
we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 and Trp53 heterozygosity . (Mus musculus) PubMed
58.
we generated a Brca2 knock-in mouse model lacking exons 4-7 and demonstrated that these exons are dispensable for viability as well as tumor-free survival. This study provides the first in vivo evidence of the functional significance of a minor transcript of BRCA2 that can play a major role in the survival of humans who are homozygous for a clearly pathogenic mutation. (Mus musculus) PubMed
59.
the data suggest for the first time that brca2/fancd1 is essential for vertebrate kidney ontogeny. (Mus musculus) PubMed
60.
Data indicate the importance of breast cancer 1 protein (BRCA1)/breast cancer 2 protein (BRCA2) function in cranial neural crest cells (CNCCs) during craniofacial skeletal formation. (Mus musculus) PubMed
61.
The functional consequence of Parp1 heterozygosity on BRCA2 loss is demonstrated by a significant increase in tumorigenesis in Brca2 knockout mice. (Mus musculus) PubMed
62.
Results suggest that the greater reliance on homology-directed repair (HDR) in the proliferating mammary gland, rather than a specific dependence on breast cancer 2 protein (BRCA2), may increase its susceptibility to tumorigenesis incurred by BRCA2 mutation. (Mus musculus) PubMed
63.
BRCA2-proficient and deficient cells are radiosensitised by HT, indicating that HT does not exclusively act by inhibition of HR. (Mus musculus) PubMed
64.
Individual deletion of Palb2, Brca1 or Brca2 genes in pancreas per se using Pdx1-Cre was insufficient to cause tumors, but it reduced pancreata size. Concurrent expression of mutant KrasG12D and p53R270H, with tumor suppressor inactivated strains in Palb2-KPC, Brca1-KPC or Brca2-KPC, accelerated pancreatic ductal adenocarcinoma (PDAC) development. (Mus musculus) PubMed
65.
BRCA2 role in the alternative lengthening of telomeres pathway and break-induced replication. (Mus musculus) PubMed
66.
HSF2BP Interacts with a Conserved Domain of BRCA2 and Is Required for Mouse Spermatogenesis. (Mus musculus) PubMed
67.
BRCA2 binds to the C-terminus of MEILB2, resulting in the formation of the BRCA2-MEILB2-BRME1 ternary complex. (Mus musculus) PubMed
68.
Symmetric neural progenitor divisions require chromatin-mediated homologous recombination DNA repair by Ino80. (Mus musculus) PubMed
69.
crystal structure of a COOH terminal BRCA2 domain bound to DSS1; demonstrate that this BRCA2 domain binds single-stranded DNA and show that BRCA2 stimulates RAD51-mediated recombination in vitro (Rattus norvegicus) PubMed
70.
Brca2-/- rats show a phenotype of growth inhibition and sterility in both sexes. Aspermatogenesis in the Brca2-/- rats is due to a failure of homologous chromosome synapsis (Rattus norvegicus) PubMed
71.
Besides BRCA1/2 further high-risk breast cancer genes are known; however they account only for a small fraction of inherited breast cancer cases. Most of them are involved in rare cancer predisposition syndromes. (Rattus norvegicus) PubMed
72.
Observational study of gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
73.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
74.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
75.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
76.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
77.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
78.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
79.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
80.
Observational study of gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
81.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
82.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
83.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
84.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
85.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
86.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
87.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
88.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
89.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
90.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
91.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
92.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
93.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
94.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
95.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
96.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
97.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
98.
Clinical trial of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
99.
Observational study of gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
100.
Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
101.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
102.
Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
103.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
104.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
105.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
106.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
107.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
108.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
109.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
110.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
111.
Observational study of gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
112.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
113.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
114.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
115.
Observational study of gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
116.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
117.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
118.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
119.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
120.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
121.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
122.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
123.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
124.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
125.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
126.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
127.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
128.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
129.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
130.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
131.
Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
132.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
133.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
134.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
135.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
136.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
137.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
138.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
139.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
140.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
141.
Observational study of healthcare-related. (HuGE Navigator) (Homo sapiens) PubMed
142.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
143.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
144.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
145.
Observational study of healthcare-related. (HuGE Navigator) (Homo sapiens) PubMed
146.
Observational study of healthcare-related. (HuGE Navigator) (Homo sapiens) PubMed
147.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
148.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
149.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
150.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
151.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
152.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
153.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
154.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
155.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
156.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
157.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
158.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
159.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
160.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
161.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
162.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
163.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
164.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
165.
Meta-analysis and HuGE review of genotype prevalence, gene-disease association, gene-gene interaction, gene-environment interaction, and genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
166.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
167.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
168.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
169.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
170.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
171.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
172.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
173.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
174.
Observational study of genotype prevalence and gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
175.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
176.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
177.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
178.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
179.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
180.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
181.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
182.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
183.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
184.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
185.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
186.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
187.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
188.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
189.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
190.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
191.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
192.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
193.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
194.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
195.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
196.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
197.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
198.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
199.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
200.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
201.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
202.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
203.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
204.
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
205.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
206.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
207.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
208.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
209.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
210.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
211.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
212.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
213.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
214.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
215.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
216.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
217.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
218.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
219.
Meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
220.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
221.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
222.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
223.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
224.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
225.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
226.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
227.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
228.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
229.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
230.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
231.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
232.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
233.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
234.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
235.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
236.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
237.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
238.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
239.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
240.
Observational study of healthcare-related. (HuGE Navigator) (Homo sapiens) PubMed
241.
Observational study of healthcare-related. (HuGE Navigator) (Homo sapiens) PubMed
242.
Observational study of healthcare-related. (HuGE Navigator) (Homo sapiens) PubMed
243.
Observational study of healthcare-related. (HuGE Navigator) (Homo sapiens) PubMed
244.
Observational study of gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
245.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
246.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
247.
Observational study of healthcare-related. (HuGE Navigator) (Homo sapiens) PubMed
248.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
249.
Observational study of healthcare-related. (HuGE Navigator) (Homo sapiens) PubMed
250.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
251.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
252.
Observational study of healthcare-related. (HuGE Navigator) (Homo sapiens) PubMed
253.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
254.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
255.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
256.
Observational study of gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
257.
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
258.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
259.
Observational study of healthcare-related. (HuGE Navigator) (Homo sapiens) PubMed
260.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
261.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
262.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
263.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
264.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
265.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
266.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
267.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
268.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
269.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
270.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
271.
Observational study of gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
272.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
273.
Observational study of genotype prevalence and genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
274.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
275.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
276.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
277.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
278.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
279.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
280.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
281.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
282.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
283.
Observational study of genotype prevalence and genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
284.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
285.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
286.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
287.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
288.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
289.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
290.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
291.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
292.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
293.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
294.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
295.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
296.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
297.
Meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
298.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
299.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
300.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
301.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
302.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
303.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
304.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
305.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
306.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
307.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
308.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
309.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
310.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
311.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
312.
Meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
313.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
314.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
315.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
316.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
317.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
318.
Observational study of genotype prevalence and gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
319.
Observational study of gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
320.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
321.
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
322.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
323.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
324.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
325.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
326.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
327.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
328.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
329.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
330.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
331.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
332.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
333.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
334.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
335.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
336.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
337.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
338.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
339.
Observational study and meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
340.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
341.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
342.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
343.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
344.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
345.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
346.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
347.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
348.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
349.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
350.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
351.
Observational study and genome-wide association study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
352.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
353.
Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
354.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
355.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
356.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
357.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
358.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
359.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
360.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
361.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
362.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
363.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
364.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
365.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
366.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
367.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
368.
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
369.
Observational study of genotype prevalence and gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
370.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
371.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
372.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
373.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
374.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
375.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
376.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
377.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
378.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
379.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
380.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
381.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
382.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
383.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
384.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
385.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
386.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
387.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
388.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
389.
Meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
390.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
391.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
392.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
393.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
394.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
395.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
396.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
397.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
398.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
399.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
400.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
401.
Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
402.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
403.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
404.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
405.
Observational study and meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
406.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
407.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
408.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
409.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
410.
Meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
411.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
412.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
413.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
414.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
415.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
416.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
417.
Meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
418.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
419.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
420.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
421.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
422.
Genome-wide association study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
423.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
424.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
425.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
426.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
427.
Observational study of gene-disease association and genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
428.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
429.
Observational study of gene-disease association and genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
430.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
431.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
432.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
433.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
434.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
435.
Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
436.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
437.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
438.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
439.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
440.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
441.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
442.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
443.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
444.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
445.
Observational study of gene-disease association, gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
446.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
447.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
448.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
449.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
450.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
451.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
452.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
453.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
454.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
455.
Observational study of gene-disease association and genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
456.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
457.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
458.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
459.
Observational study and meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
460.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
461.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
462.
Observational study and meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
463.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
464.
Observational study and meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
465.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
466.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
467.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
468.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
469.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
470.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
471.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
472.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
473.
Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
474.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
475.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
476.
Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
477.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
478.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
479.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
480.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
481.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
482.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
483.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
484.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
485.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
486.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
487.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
488.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
489.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
490.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
491.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
492.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
493.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
494.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
495.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
496.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
497.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
498.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
499.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
500.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
501.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
502.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
503.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
504.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
505.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
506.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
507.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
508.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
509.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
510.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
511.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
512.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
513.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
514.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
515.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
516.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
517.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
518.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
519.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
520.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
521.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
522.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
523.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
524.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
525.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
526.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
527.
Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
528.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
529.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
530.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
531.
Meta-analysis of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
532.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
533.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
534.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
535.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
536.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
537.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
538.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
539.
Observational study of genotype prevalence. (HuGE Navigator) (Homo sapiens) PubMed
540.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
541.
Uncategorized study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
542.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
543.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
544.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
545.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
546.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
547.
Suppression of tumorigenicity of rat liver tumor cells by human chromosome 13: evidence against the involvement of pRb and BRCA2 (Homo sapiens) PubMed
548.
BRCA1 and BRCA2 mutations in Russian familial breast cancer (Homo sapiens) PubMed
549.
Germline mutation in BRCA2 associated with hypersensitivity to radiation (Homo sapiens) PubMed
550.
A low frequency of recurrent BRCA2 mutations has been found in breast and ovarian cancers in Spain. (Homo sapiens) PubMed
551.
Three Chinese cases carrying the recurrent BRCA2 mutation 3337C>T show sharing of some alleles, suggesting some degree of shared ancestry but not sufficient to demonstrate founder effect. (Homo sapiens) PubMed
552.
minor role of exon 1 among Sudanesse breast cancer patients (Homo sapiens) PubMed
553.
mutagen sensitivity of blood lymphocytes from women carrying brca2 mutatioon (Homo sapiens) PubMed
554.
Contribution of BRCA2 germline mutations to hereditary breast/ovarian cancer in Germany. (Homo sapiens) PubMed
555.
BRCA2 N372H polymorphism associated with modest recessively inherited risk of breast cancer in Australian women (Homo sapiens) PubMed
556.
somatic mutations in BRCA2 and high frequency of allelic loss occurs in sporadic male breast cancer (Homo sapiens) PubMed
557.
Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status (Homo sapiens) PubMed
558.
Cells from carriers of mutations in one allele of the BRCA1 or BRCA2 genes have no gross defects in their ability to rejoin radiation-induced DNA breaks. (Homo sapiens) PubMed
559.
cell lines derived from Fanconi anemia B and D1 patients have biallelic mutations in BRCA2 and express truncated BRCA2 proteins (Homo sapiens) PubMed
560.
BRCA2 exons 10 & 11 were studied by the protein truncation test, & BRCA2 exons 9, 17, 18 and 23 with the SSCP assay on genomic DNA from early-onset breast cancer patients by PCR. 2 frameshifts, 3 missense mutations, and a polymorphism were found. (Homo sapiens) PubMed
561.
Results demonstrate the importance of BRCA2 in the development of ovarian cancer in this Turkish population. (Homo sapiens) PubMed
562.
The 999del5 mutation in the BRCA2 gene explains a substantial proportion of familial risk of breast cancer in Iceland. (Homo sapiens) PubMed
563.
first BRCA2 missense mutation shown to be a predicted deleterious protein-truncating mutation and suggests a potentially useful method for determining the clinical significance of a subset of the many unclassified variants in BRCA1 and BRCA2 (Homo sapiens) PubMed
564.
Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. (Homo sapiens) PubMed
565.
eight of the most common reported missense mutations in BRCA1 and BRCA2 occurring in patients tested for hereditary risk of breast and ovarian cancers (Homo sapiens) PubMed
566.
crystal structure of a COOH terminal BRCA2 domain bound to DSS1; demonstrate that this BRCA2 domain binds single-stranded DNA and show that BRCA2 stimulates RAD51-mediated recombination in vitro (Homo sapiens) PubMed
567.
relation of gene to various cancers, especially breast and ovarian cancers (Homo sapiens) PubMed
Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy (Homo sapiens) PubMed
570.
recent findings regarding BRCA2 in breast cancer - review (Homo sapiens) PubMed
571.
BBRCA2 gene mutation in unselected women with ovarian and early breast cancer in Mongolia predicts the genetic predisoposition to these diseases. (Homo sapiens) PubMed
572.
crystal structure of a complex between an evolutionarily conserved sequence in BRCA2 (the BRC repeat) and the RecA-homology domain of RAD51 (Homo sapiens) PubMed
573.
Two BRCA2 missense variants were identified in breast cancer patients in India. (Homo sapiens) PubMed
574.
BRCA2 mutation, 7883delTTAA, was identified in breast cancer patients in China. (Homo sapiens) PubMed
575.
BRCA2 2663-2664insA and rare variants were identified in breast cancer patients in Mexico. (Homo sapiens) PubMed
576.
Germline mutations in BRCA2 account for breast neoplasms predisposition in the majority of families. (Homo sapiens) PubMed
577.
highly recurrent BRCA2 splice site mutation (IVS16-2A>G) in three breast cancer-only families (Homo sapiens) PubMed
578.
BRCA2 has a more specific role in DNA repair, regulating the activity of RAD51(review) (Homo sapiens) PubMed
579.
cancer-predisposing mutation compromises interaction between BRCA2 and replication protein A (Homo sapiens) PubMed
580.
The BRCA2 gene plays a significant role in the familial breast cancer phenotype in the Cypriot population. (Homo sapiens) PubMed
581.
mutation analysis of this gene in a case of familial endometriosis (Homo sapiens) PubMed
582.
Our data support an important role for BRCA2 germline mutations in a subpopulation of families with familial pancreatic cancer. (Homo sapiens) PubMed
583.
S-phase RAD51 foci form normally in CAPAN-1 cells expressing truncated BRCA2. The observed BRCA2-dependent & independent formation of RAD51 foci shows that intact BRCA2 is not required for RAD51 focus formation per se. (Homo sapiens) PubMed
584.
BRCA2 germline mutation is associated with fallopian tube cancer. (Homo sapiens) PubMed
585.
polymorphisms in BRCA2 is associated with esophageal squamous cell carcinoma (Homo sapiens) PubMed
586.
Changes in the topoisomerase I activity in V-C8 cells are due to the defective function of the Brca2 gene. (Homo sapiens) PubMed
587.
Average cumulative risks in BRCA2-mutation carriers by age 70 years were 45% (95% confidence interval 31%-56%) for breast cancer and 11% (2.4%-19%) for ovarian cancer (Homo sapiens) PubMed
588.
germline BRCA2 mutations are not associated with an increased risk for lymphoid malignancies (Homo sapiens) PubMed
589.
Founder mutations are present within the Scottish/Northern Irish population and have implications for the organisation of molecular screening services. (Homo sapiens) PubMed
590.
wild-type BRCA2, but not a tumor-specific truncated mutant BRCA2, synergizes with the nuclear receptor coactivator p160 GRIP1 to enhance transcriptional activation by androgen receptor (Homo sapiens) PubMed
591.
major role of Brca2 in mediating cell survival after irradiation is in the S and G(2) phases of the cell cycle (Homo sapiens) PubMed
592.
Androgen receptor expression is absent in BRCA1-mutated breast tumors when compared to BRCA2-mutated cases, indicating that BRCA2-mutated tumors may be different. (Homo sapiens) PubMed
593.
BRCA2 has a role in modulating M phase progression (Homo sapiens) PubMed
594.
None of the BRCA 1 or 2 mutations were detected in the ovarian cancer patient group. (Homo sapiens) PubMed
595.
Recurrent BRCA2 mutations have no role in predisposition to prostate cancer in Finland. (Homo sapiens) PubMed
596.
The product of the BRCA2 gene has a function relating to the differentiation of epithelial tissue in the breast in response to the hormones of pregnancy. (Homo sapiens) PubMed
597.
Eight novel BRCA2 mutations identified in breast and ovarian cancers may be deleterious cancer predisposing mutations. (Homo sapiens) PubMed
598.
the spectrum of BRCA2 mutations in African Americans (Homo sapiens) PubMed
599.
In general, OC use, childbearing and breastfeeding do not differ between BRCA1/2 carriers and non-carriers with ovarian cancer. However, the effects of tubal ligation may differ between BRCA1 carriers and non-carriers. (Homo sapiens) PubMed
600.
BRCA2 is epistatic to FA genes for ICL repair, but not for damage-induced modification of FANCD2 and may act downstream form FANCD2. (Homo sapiens) PubMed
601.
study from South India, on BRCA1, BRCA2 & CHEK2 mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer (Homo sapiens) PubMed
602.
BRCA2 mutation is associated with serous carcinoma of ovary (Homo sapiens) PubMed
603.
risks of breast and ovarian cancer were determined for Ashkenazi Jewish women with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2 (Homo sapiens) PubMed
604.
Data report the isolation of a holoenzyme complex termed BRCC containing BRCA1, BRCA2, and RAD51, which displays increased association with p53 following DNA damage and ubiquitinates p53 in vitro. (Homo sapiens) PubMed
605.
inactivation of the FANC-BRCA pathway is relatively common in solid tumors and may be related to tobacco and alcohol exposure (Homo sapiens) PubMed
606.
fiver germline mutations in cases of familial esophageal squamous cell carcinoma suggests role in genetic susceptibility (Homo sapiens) PubMed
607.
The remarkable clinical overlap between sporadic EMSY amplification and familial BRCA2 deletion implicates a BRCA2 pathway in sporadic breast and ovarian cancer. (Homo sapiens) PubMed
608.
In transgenic mice, rescues embryonic lethality and mice develop normally. (Homo sapiens) PubMed
609.
Molecular analysis revealed biallelic BRCA2/FANCD1 mutations in a kindred with solid tumors in childhood. (Homo sapiens) PubMed
610.
Novel germline deleterious pathogenic, protein truncating frameshift and non-sense mutations were detected in exon 11 of BRCA2 in breast-ovarian cancer families. (Homo sapiens) PubMed
611.
heterozygosity for germ-line mutations in BRCA2 results in development of progesterone receptor A predominance. (Homo sapiens) PubMed
612.
Man with a history of clinically diagnosed right breast cancer who subsequently tested positive for the breast cancer susceptibility gene BRCA2 and received a diagnosis of mammographically detected left breast cancer at screening. (Homo sapiens) PubMed
613.
Allelic loss at the BRCA2 locus may be of use as a negative predictor for metastases-free and overall survival in breast cancer patients. (Homo sapiens) PubMed
614.
BRCA1-related breast cancers are more frequently estrogen receptor (ER) negative than are either BRCA2-related or nonhereditary breast cancers. (Homo sapiens) PubMed
615.
identified 6 children in 5 kindreds exhibiting the co-occurrence of BRCA2 mutations, FA, and early onset acute leukemia (Homo sapiens) PubMed
616.
BRCA1 and BRCA2 mutations may have a role in progression of ovarian cancer (Homo sapiens) PubMed
617.
BRCA mutations were present in 12.7% of the high risk patients, compared with 2.8% of the unselected patients. (Homo sapiens) PubMed
618.
Our results suggest that there is a field effect of early genetic events preceding morphologic changes in the mammary glands of BRCA mutation carriers. (Homo sapiens) PubMed
619.
FANCD2 and BRCA2 can be coimmunoprecipitated from cell extracts of both human and Chinese hamster wild-type cells, thus confirming that the interaction occurs in vivo (Homo sapiens) PubMed
620.
Cancer variation associated with the position of the mutation in the BRCA2 gene in 7 different neoplasms and the differences in cancer risk remain to be explored. (Homo sapiens) PubMed
621.
BRCA2 mutations could not be detected among unrelated non-Ashkenazi-Jewish high risk families in Israel. (Homo sapiens) PubMed
622.
Identification and evaluation of 55 genetic variations in the BRCA1 and the BRCA2 genes of patients from 50 Japanese breast cancer families (Homo sapiens) PubMed
623.
RAD51D polymorphism is not associated with BRCA1 or 2 genes in breast cancer. (Homo sapiens) PubMed
624.
results demonstrate that monoubiquitination of FANCD2, which is regulated by the FA pathway, promotes BRCA2 loading into chromatin complexes. These complexes appear to be required for normal homology-directed DNA repair. (Homo sapiens) PubMed
625.
BRCA2 germline mutations may have a role in primary cancer of the fallopian tube (Homo sapiens) PubMed
626.
Results suggest that BRCA2 expression levels are regulated by ubiquitination in response to DNA damage and that USP11 participates in DNA damage repair functions within the BRCA2 pathway independently of BRCA2 deubiquitination. (Homo sapiens) PubMed
627.
Patients with bilateral breast cancer having BRCA2 mutations are significantly younger than non-carriers. (Homo sapiens) PubMed
628.
A novel pathogenic germline mutations,BRCA2 c.2259delT, was found in a screening of sporadic Korean breast cancer patients, along with 4 polymorphic and 8 intronic variants of unknown clinical significance. (Homo sapiens) PubMed
629.
results show that BRCA2 deficiency impairs the completion of cell division by cytokinesis (Homo sapiens) PubMed
630.
prevalence of BRCA2 mutations in a large hospital based series of unselected breast cancer cases (Homo sapiens) PubMed
631.
Quantitative-PCR and Northern analysis confirmed down-regulation of UCRP and UBE2L6 with BRCA2 knockdown, respectively. (Homo sapiens) PubMed
632.
FANCD2 mediates double strand DNA break repair independently of BRCA2- and Rad51-associated homologous recombination (Homo sapiens) PubMed
633.
Identification of a potential novel domain in the BRCA2 protein. (Homo sapiens) PubMed
634.
results reveal unique characteristics of BRCA1/2 mutation, genotype-phenotype & prognosis in moderate- & low-risk individuals of Greek ancestry; breast cancer due to mutations in BRCA1 & BRCA2 appears to be a heterogeneous syndrome in Greek population (Homo sapiens) PubMed
635.
SLUG is a negative regulator for BRCA2 gene expression (Homo sapiens) PubMed
636.
results indicate that S3291 phosphorylation might provide a molecular switch to regulate RAD51 recombination activity, providing new insight into why BRCA2 C-terminal deletions lead to radiation sensitivity and cancer predisposition (Homo sapiens) PubMed
637.
BRCA1/2 mutation screening should be considered for all women diagnosed before age 41. (Homo sapiens) PubMed
638.
No association was found for the N372H polymorphism in BRCA2 and breast cancer among Caucasian women. (Homo sapiens) PubMed
639.
There is no significant effect of AIB1 genetic variation on breast cancer risk in BRCA2 mutation carriers. (Homo sapiens) PubMed
640.
role of BRCA1 and BRCA2 mutation in pre-disposition to ovarian cancer. (Homo sapiens) PubMed
641.
Expression of BRCA2 and MAGE-D1 synergistically suppresses cell proliferation independently of the p53 pathway. (Homo sapiens) PubMed
642.
Germline mutations within breast cancer susceptibility genes, such as BRCA1 and BRCA2 are associated with a major risk of breast cancer during lifetime. (Homo sapiens) PubMed
643.
BRCA2 BRC motifs bind distinct regions, and form stable complexes with RAD51-DNA nucleoprotein filaments. (Homo sapiens) PubMed
644.
Distribution of BRCA1 and BRCA2 mutations in a cohort of young women with breast cancer, compared as a function with race. (Homo sapiens) PubMed
645.
women with a BRCA1 protein mutation and 4 or more children had a 38% decrease in breast cancer risk compared to nulliparous women, while among BRCA2 protein carriers, increasing parity was associated with an increased risk of breast cancer (Homo sapiens) PubMed
646.
ells lacking the fully functional protein have consistently been found to show increased sensitivity to a variety of DNA-damaging agents. (Homo sapiens) PubMed
647.
analysis of Alu element insertions within the BRCA1/2 coding sequences (Homo sapiens) PubMed
648.
Mutational analysis of BRCA1/2 genes in 151 high-risk patients characterized the spectrum of gene alterations and demonstrated the dominant role of the BRCA1 c.5266dupC allele in hereditary breast and ovarian cancer. (Homo sapiens) PubMed
649.
Conclusive evidence that the S384F variant of BRCA2 is not a disease causing mutation in breast cancer. (Homo sapiens) PubMed
650.
Weight loss in early adult life (age 18 to 30) protects against early-onset BRCA2 associated breast cancers. (Homo sapiens) PubMed
651.
large genomic deletions inactivate the BRCA2 gene in breast cancer families (Homo sapiens) PubMed
652.
results of this study suggested that the polymorphism N372H in BRCA2 gene may be associated with idiopathic male infertility with azoospermia or severe oligozoospermia (Homo sapiens) PubMed
653.
BRCA2 mutations are associated with breast and ovarian cancer (Homo sapiens) PubMed
654.
the Met1915Thr polymorphism in the BRCA2 gene may be considered as an independent marker of breast cancer (Homo sapiens) PubMed
655.
The frequency of hereditary ovarian carcinoma is attributed to BRCA2 gene mutation. (Homo sapiens) PubMed
656.
The data suggest applying an increased level of clinical alertness to those with defects in BRCA-related pathways. (Homo sapiens) PubMed
657.
the data are not compatible with selective pressures during tumorigenesis promoting the functional loss of BRCA2 and MRE11 in microsatellite unstable tumors, but fit closely with an absence of selective pressures acting on BRCA2 and MRE11 gene status (Homo sapiens) PubMed
658.
there is a decrease in p53 apoptotic rate associated with the No Ins-72Pro haplotype in BRCA2 mutation carriers (Homo sapiens) PubMed
659.
Salpingo-oophorectomy, despite being quite a radical preventive method, might offer protection for the carriers against life-threatening silently-developing cancer. (Homo sapiens) PubMed
660.
Recurrent BRCA2 mutations in French Canadian breast and/ovarian cancer families could be attributed to common founders. (Homo sapiens) PubMed
661.
Carrying a BRCA1 or BRCA2 mutation is not a risk factor for spontaneous abortions but may be associated with frequency of induced abortion. (Homo sapiens) PubMed
662.
Preeminent associations were identified in SNPs mapping to genes pivotal in the DNA damage-response and cell-cycle pathways, including ATM F858L and P1054R, CHEK2 I157T, BRCA2 N372H, and BUB1B Q349R. (Homo sapiens) PubMed
663.
The effects of BRCA2 intron variants on mRNA splicing and expression. (Homo sapiens) PubMed
664.
FANCG-XRCC3 and FANCG-BRCA2 interactions did not require the presence of other FA proteins from the core complex (Homo sapiens) PubMed
Women who had developed breast cancer under the age of 40 and who were identified as BRCA1 or BRCA2 mutation carriers experienced devastation, loneliness and isolation. (Homo sapiens) PubMed
667.
These results provide insight into the recently discovered diversity of BRCA2 domain structures in different organisms. (Homo sapiens) PubMed
668.
Analysis resulted in the identification of 25 and 52 variants in the BRCA1 and BRCA2 genes, respectively in breast or ovarian cancer. (Homo sapiens) PubMed
669.
two recurrent BRCA2 mutations predisposing to male breast cancer may facilitate the analyses aimed at the identification of mutation carriers in our geographic area (Homo sapiens) PubMed
670.
BRCA2 mutation is common (9%) among unselected young breast cancer patients undergoing BCT. (Homo sapiens) PubMed
671.
No BRCA1/2 genomic rearrangements found in high-risk French-Canadian breast/ovarian cancer families. (Homo sapiens) PubMed
672.
Missense mutation in exon 13 in BRCA2, c.7235G>A, results in skipping of exon 13. (Homo sapiens) PubMed
673.
PALB2 colocalizes with BRCA2 in nuclear foci, promotes its localization and stability in key nuclear structures (e.g., chromatin and nuclear matrix), and enables its recombinational repair and checkpoint functions (Homo sapiens) PubMed
674.
The small group of patients with biallelic mutations in BRCA2 is distinctive in the severity of the phenotype, and early onset and high rates of leukaemia and specific solid tumours, and may comprise an extreme variant of Fanconi anaemia. (Homo sapiens) PubMed
675.
Study identified a specific spectrum of germline BRCA1/BRCA2 mutations in Portuguese families with inherited predisposition to breast/ovarian cancer and found evidence for genetic anticipation regarding age of diagnosis in succeeding generations. (Homo sapiens) PubMed
676.
The objective in this study was to determine the frequency of large genomic rearrangements in BRCA1 and BRCA2 in a large group of Danish families with increased risk of breast and ovarian cancer. (Homo sapiens) PubMed
677.
BRCA2 participates in repair of replication-mediated double-strand breaks generated when replication forks encounter interstrand cross-link (Homo sapiens) PubMed
678.
Identification of 13 novel variants including two deleterious truncating mutations and two potentially pathogenic missense mutations on the BRCA1 and BRCA2 genes (Homo sapiens) PubMed
679.
Results suggest that breast tumours with mutations in BRCA2 or TP53 could be promising candidates for Aurora-A targeted treatment. (Homo sapiens) PubMed
680.
BRCA2 mutation may have a role in developing hematologic malignancy (Homo sapiens) PubMed
681.
Testing strategy with an initial test using a panel of reported recurrent mutations, followed by full sequencing predicts prevalence of breast and ovarian cancer. (Homo sapiens) PubMed
682.
Prevalence of BRCA2 mutations in breast cancer cases among racial and age groups and show key predictors of carrier status for both White and Black women and women. (Homo sapiens) PubMed
683.
Human BRCA2 has multiple BRC repeats, motifs of approximately 30 residues, that associate in a ternary complex with RAD51 on single-stranded DNA and double-stranded DNA. (Homo sapiens) PubMed
684.
Ninteen percent of the women who developed both invasive breast and ovarian tumors carried one of the analyzed BRCA1 gene mutations but none of the women were positive for the analyzed BRCA2 mutation. (Homo sapiens) PubMed
685.
analysis of BRCA1 and BRCA2 mutations from Korean breast cancer patients using denaturing HPLC (Homo sapiens) PubMed
686.
Novel and distinct BRCA2 deletions were detected in three families and their boundaries were determined. (Homo sapiens) PubMed
687.
Effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management. [REview] (Homo sapiens) PubMed
688.
Breast cancers arising in BRCA1 and BRCA2 mutation carriers appear to have specific pathological and gene expression profiles, which show a high level of concordance.BRCA2 overexpress some DNA repair. [REVIEW] (Homo sapiens) PubMed
689.
Findings show that BRCA2 mutations account for a substantial proportion of hereditary breast/ovarian cancer and early-onset breast and ovarian cancer cases in Pakistan. (Homo sapiens) PubMed
690.
Tumor cells having disruptions in BRCA1/2 network genes and TP53 together are more sensitive to cisplatin than cells with either disruption alone. (Homo sapiens) PubMed
691.
BRCA2 mutations appear to account for a lower proportion of breast cancer patients at increased risk of harboring such mutations in Northern India (Homo sapiens) PubMed
692.
The 5164del4 BRCA2 mutation is not likely to be a founder mutation in non-Ashkenazi Jewish families with high risk of breast and ovarian cancer. (Homo sapiens) PubMed
693.
BRCA1 and BRCA2 mutation status have roles in inter-cell-line phenotypic variability after irradiation of lymphoblastoid cell lines (Homo sapiens) PubMed
694.
analysis of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil (Homo sapiens) PubMed
695.
findings show that BRCA mutations account for a substantial proportion of hereditary breast/ovarian cancer in Colombia (Homo sapiens) PubMed
696.
These results identify a novel role for FoxM1 in the transcriptional response during DNA damage/checkpoint signaling and show a novel mechanism by which Chk2 protein regulates expression of DNA repair enzymes. (Homo sapiens) PubMed
697.
Large genomic BRCA2 rearrangements were not found among our 36 Finnish male breast cancer patients (Homo sapiens) PubMed
698.
BRCA1 and BRCA2 mutations may be more frequent in general populations than previously thought and may be associated with various types of cancers. (Homo sapiens) PubMed
699.
These data suggest that BRCA2 mutation carriers with ovarian cancer may have better survival than BRCA1 carriers and non-carriers. (Homo sapiens) PubMed
700.
A novel BRCA2 frame-shift mutation, 3951del3insAT, which produces a protein truncated at codon 1258, was observed in six patients with BC from the same village in Sardinia. (Homo sapiens) PubMed
701.
investigation of the contribution of BRCA-1 and BRCA-2 germline mutations to the clinical features and outcome in 66 Italian women with early-onset breast cancer (Homo sapiens) PubMed
702.
BRCA2 mutations are associated with breast ans ovarian cancer (Homo sapiens) PubMed
703.
Results implicate BRCA2 in the regulation of the centrosome cycle and provide new insight into the aneuploid nature of many breast cancers. (Homo sapiens) PubMed
704.
low mRNA and protein expression in the BRCA1/BRCA2 and XRCC5 genes occur in lung adenocarcinoma and squamous cell carcinoma, respectively, and promoter hypermethylation is the predominant mechanism in deregulation of these genes (Homo sapiens) PubMed
705.
no evidence was found in this study for an association between BRCA2 mutations and susceptibility to hereditary prostate cancer in men selected from high-risk families (Homo sapiens) PubMed
706.
substantial levels of aberrant methylation, in the fluid from the breasts of healthy BRCA mutation carriers (Homo sapiens) PubMed
707.
BRCA2 genomic rearrangements is associated with breast and ovarian cancer (Homo sapiens) PubMed
708.
Our findings suggest that in Central Sudan BRCA1/2 represent an important etiological factor of breast cancer in males and young women less exposed to pregnancy and lactation. (Homo sapiens) PubMed
709.
Borderline ovarian tumors are neither part of the BRCA1- nor the BRCA2- related tumor spectrum. (Homo sapiens) PubMed
710.
unlikely that annual screening will reduce mortality from ovarian cancer in BRCA1/2 mutation carriers. (Homo sapiens) PubMed
711.
common polymorphisms in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are not shown to increase breast cancer risk (Homo sapiens) PubMed
712.
the genomic instability observed in normal cells from BRCA1 and BRCA2 mutation carriers is associated with a down-regulation of nuclear BRCA1 protein accumulation in dot like structures (Homo sapiens) PubMed
713.
a total of 287 Greek breast/ovarian cancer families, 46 and 13 carry a deleterious mutation in BRCA1 and BRCA2, respectively. (Homo sapiens) PubMed
714.
presence of BRCA1 and BRCA2 rearrangements among Asian patients with early onset or familial history of breast or ovarian cancer (Homo sapiens) PubMed
715.
Regular surveillance in women at increased familial risk of breast cancer is associated with a good outcome if they carry BRCA2 mutations (Homo sapiens) PubMed
716.
among carriers of BRCA1 or BRCA2 mutations, the cumulative lifetime risk of developing breast cancer is 50-60% and the equivalent risk of ovarian cancer is 20-40% in Australian women (Homo sapiens) PubMed
717.
Novel germline mutations in BRCA2 gene is associated with hereditary breast and breast-ovarian cancer (Homo sapiens) PubMed
718.
Productive recombination results from the functional balance between the different RAD51-binding modes of the BRC repeat and exon 27 regions of BRCA2. (Homo sapiens) PubMed
719.
Interactions of the BRCA2 C-terminal region with RAD51 may facilitate efficient nucleation of RAD51 multimers on DNA and thereby stimulate recombination-mediated repair. (Homo sapiens) PubMed
720.
BRCA2 is a universal regulator of RAD51/DMC1 recombinase actions (Homo sapiens) PubMed
721.
The output 3D molecular structure from the combination between BRCA2-RAD51 is derived (Homo sapiens) PubMed
722.
BRCA2 c.9079 G>A is not a predisposing variant for early onset breast cancer (Homo sapiens) PubMed
723.
the Icelandic BRCA2 999del5 founder mutation was strongly associated with rapidly progressing lethal prostate cancer (Homo sapiens) PubMed
724.
BRCA2 mutation carriers without cancer had increased breaks as well as breaks and gaps per cell (Homo sapiens) PubMed
725.
review of some of the most well-known and significant examples of founder mutations in BRCA genes found in European and non-European populations [review] (Homo sapiens) PubMed
726.
XRCC1 down-regulation in HeLa cells leads to a decrease in the DNA ligase 3 protein level, significantly increased sensitivity to alkylating agents, elevated level of sister chromatid exchange and decrease in the survival of BRCA2-deficient cells. (Homo sapiens) PubMed
727.
High-risk patients with BRCA1-negative tumors should be screened first for BRCA2 gene. (Homo sapiens) PubMed
728.
Mutations found in a significant proportion of women with ductal carcinoma in situ who presented for hereditary risk assessment. (Homo sapiens) PubMed
729.
The researchers found 17 pathogenic changes in the BRCA2 genes in 64 families with a pedigree of male breast neoplasms. (Homo sapiens) PubMed
730.
families appear to exhibit features most consistent with BRCA1 and BRCA2 carrier status (Homo sapiens) PubMed
BRCA2-8765delAG has an independent origin in geographically and ethnically distinct populations, acting as a founder mutation in North but not in South Sardinia. (Homo sapiens) PubMed
733.
From a population database of BRCA1 and 2 mutation carriers in Southwestern Ontario, Canada, we identified three women with advanced-stage endometrial cancer. (Homo sapiens) PubMed
734.
The identified BRCA2 c.7806-9T > G [Genbank: DQ889340] was found to be pathogenic in a Chinese family, based on aberrant splicing events resulting in the formation of truncated protein products. (Homo sapiens) PubMed
735.
BRCA1/2 rearrangements is not advantageous in male breast neoplasm (MBC) cases not belonging to high-risk breast cancer families and that common CHEK2 mutations play an irrelevant role in MBC predisposition in Italy. (Homo sapiens) PubMed
736.
Results point to a critical role for BACH1 helicase activity not only in the timely progression through the S phase by association with BRCA1/BRCA2, but also in maintaining genomic stability. (Homo sapiens) PubMed
737.
Higher BTAK expression was found in ovarian cancer cells compared to ovaries without cancer but with known BRCA1/2 mutation or strong family history. (Homo sapiens) PubMed
738.
Inactivation of a single gene within the BRCA2 pathway can increase risks for multiple cancers and inactivation of a different gene in the same pathway may have similar effects. (Homo sapiens) PubMed
739.
ectopically BRCA2-expressing cells have different intracellular levels of Aurora A, Aurora B, p21, E2F-1, and pRb, suggesting a BRCA2-mediated suppression of polyploidy via stabilization of the checkpoint proteins levels (Homo sapiens) PubMed
740.
Data indicate that BRCA2 are the major susceptibility genes for ovarian cancer but that other susceptibility genes may exist. (Homo sapiens) PubMed
741.
Results suggest that protein-truncating BRCA2 mutations confer an elevated relative risk of early-onset prostate cancer (Homo sapiens) PubMed
742.
A suspicious deleterious BRCA2 variant is identified in 15 of 197 cases of esophageal squamous cell carcinoma in the Iranian Turkmen population. (Homo sapiens) PubMed
743.
The greatest proportion of serous cancer risk in BRCA mutation-positive women should be assigned to the fimbria rather than the ovary. (Homo sapiens) PubMed
744.
the BRCA2 HH homozygous genotype might be positively associated with an increased risk of male breast cancer in men younger than 60 years. (Homo sapiens) PubMed
745.
analysis of BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families (Homo sapiens) PubMed
746.
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality. (Homo sapiens) PubMed
747.
Study found that Fanconi anemia pathway activation is triggered mainly by the HPV type 16 (HPV-16) E7 oncoprotein and is associated with an enhanced formation of large FANCD2 foci and recruitment of FANCD2 as well as FANCD1/BRCA2 to chromatin. (Homo sapiens) PubMed
748.
analysis of a subset of unclassified sequence variants in BRCA2 that may adversely affect splicing and thereby contribute to BRCA2 disruption (Homo sapiens) PubMed
749.
Self-image and self-disclosure concerning prophylactic mastectomy (PM) for women with a BRCA1/2 mutation. (Homo sapiens) PubMed
750.
prevalence of BRCA1 & BRCA2 mutations in breast cancer patients with affected relatives in Tunisia; two frameshift mutations (c.1309del4 and c.5682insA) were observed in BRCA2 (Homo sapiens) PubMed
751.
The clinical significance of 1,433 sequence variants of unknown significance (VUSs) in the BRCA genes, was assessed. (Homo sapiens) PubMed
752.
Tumors are unlikely to arise directly from BRCA2 heterozygous cells without other genetic events such as loss of the wild-type BRCA2 allele and/or loss of p53 function or other cell cycle inhibitors. (Homo sapiens) PubMed
753.
5' UTR polymorphism in BRCA2 is associated with breast cancer, which is further influenced by the germline genetic backgrounds of codon 72 polymorphism of p53 (Homo sapiens) PubMed
754.
The site of first distant metastasis is different between BRCA1- and BRCA2-associated and sporadic breast cancer patients. (Homo sapiens) PubMed
755.
High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer. (Homo sapiens) PubMed
756.
BRCA1 or BRCA2 mutations have roles in breast cancer in smokers (Homo sapiens) PubMed
757.
We found six differentially expressed proteins; among them, the checkpoint mediator protein MDC1 whose expression was disrupted in FANCC-/- cells. (Homo sapiens) PubMed
758.
RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/2 mutation carriers. (Homo sapiens) PubMed
759.
MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. (Homo sapiens) PubMed
760.
Germline mutations in the BRCA1 or BRCA2 tumour-suppressor genes are strong predictors of breast and/or ovarian cancer development. (Homo sapiens) PubMed
761.
study describes a family with multiple cases of MEN1-associated cancers as well as pancreatic adenocarcinoma, ovarian cancer, and male breast cancer, in which we identified germline mutations in both MEN1 and BRCA2 (Homo sapiens) PubMed
762.
evaluation of the risks of developing breast carcinoma for male BRCA1 and BRCA2 mutation carriers; both the relative and cumulative risks were higher for BRCA2 mutation carriers than for BRCA1 mutation carriers (Homo sapiens) PubMed
763.
there is no evidence of sex ratio skewing in offspring of female BRCA mutation carriers (Homo sapiens) PubMed
764.
BRCA1/2 mutations predispose to early onset breast and ovarian cancers, modified by factors such as IGF-I. (Homo sapiens) PubMed
765.
depletion of normal BRCA2 proteins in the cytoplasm leads to centrosome amplification and binucleated cells. Our results suggest that disruption of NES function by genetic changes results in deregulation of BRCA2 export, which leads to centrosome disorder (Homo sapiens) PubMed
766.
BRCA2 mutations are associated with breast and ovarian cancer. (Homo sapiens) PubMed
767.
BRCA1/2 mutations are significantly more common in Italian women who developed breast cancer (Homo sapiens) PubMed
768.
analysis of breast cancer genes that may modify risk in BRCA1/2 mutation carriers (Homo sapiens) PubMed
769.
Loss of heterozygosity of the BRCA2 gene region was found to be common in the cutaneous squamous cell carcinoma. (Homo sapiens) PubMed
770.
Sixty-four Polish families with a history of breast and/or ovarian cancer were screened for mutations in the BRCA1/2 genes (Homo sapiens) PubMed
771.
models used to analyze age-incidence curve of breast cancer in women carrying gerrmline BRCA1 or BRCA2 mutations; results suggest in carriers there are 2 events which may occur at rates similar to mutation rates for normal cells leading to breast cancer (Homo sapiens) PubMed
772.
Founder BRCA2 mutation is associated with male breast cancer (Homo sapiens) PubMed
773.
study confirms that, among Ashkenazi ovarian cancer patients, BRCA1/2 mutations are associated with improved long-term survival (Homo sapiens) PubMed
774.
BRCA2 protein is lost in carcinoma cells compared to normal and hyperplastic prostate epithelium (Homo sapiens) PubMed
775.
The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation (Homo sapiens) PubMed
776.
heterogeneous ethnicity increases the variety of BRCA1 and BRCA2 mutations that can be found in Spanish populations (Homo sapiens) PubMed
777.
In summary, BRCA2 clearly accounts for a proportion of LFS/LFL (Li-Fraumeni syndrome, LFS-like) families negative for TP53. mutations. (Homo sapiens) PubMed
778.
Since BRCA1/2 mutation carrier status is associated with more aggressive disease, it is a prognostic factor for PRCA outcome. (Homo sapiens) PubMed
779.
Mutation of BRCA2 gene is an indication of susceptibility to breast and ovarian neoplasms. (Homo sapiens) PubMed
780.
Allelic imbalance affecting BRCA1 and to a lesser extent BRCA2 may contribute to both familial and non-familial forms of breast cancer. (Homo sapiens) PubMed
781.
FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. (Homo sapiens) PubMed
782.
The 4088insA mutation appears to be associated with a favourable clinical course of breast and ovarian cancer (Homo sapiens) PubMed
783.
incidence of mutations in the BRCA1 and BRCA2 genes in the studied sampling of 74 patients with ovarian cancer was 19%; majority of mutations (86%) were detected in BRCA1 gene, where 5382insC mutation predominated (58%) (Homo sapiens) PubMed
784.
review of BRCA1/2 associated hereditary breast cancer [review] (Homo sapiens) PubMed
785.
we review the DNA-damage response network consisting of FA and BRCA proteins and what is known about their involvement in breast cancer susceptibility (Homo sapiens) PubMed
786.
This articles reviews the evidence for the association of BRCA2 polymorphisms and the development of breast neoplasms. (Homo sapiens) PubMed
Association between BRCA2 mutations and the presence of breast cancer in a Cuban population. (Homo sapiens) PubMed
789.
The BRCA2 N372H and the IVS21-66T>C polymorphisms increase breast cancer risk. (Homo sapiens) PubMed
790.
A novel BRCA2-interacting protein, BJ-HCC-20A, which is reported to be a potential cancer-testis antigen, was idenified. (Homo sapiens) PubMed
791.
56 mutations were identified in BRCA2 in families containing at least one reported ovarian cancer diagnosed less than 50 years or at any age with family history of breast or ovarian cancer for mutations in BRCA1 and BRCA2. (Homo sapiens) PubMed
792.
Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage (Homo sapiens) PubMed
793.
Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases. (Homo sapiens) PubMed
794.
Tubal p53 signature merits serious consideration as an important early event in serous carcinogenesis in BRCA+ women. (Homo sapiens) PubMed
795.
The differences in the effects of the FGFR2 and MAP3K1 SNPs between BRCA1 and BRCA2 carriers point to differences in the biology of BRCA1 and BRCA2 breast cancer tumors and confirm the distinct nature of breast cancer in BRCA1 mutation carriers. (Homo sapiens) PubMed
796.
contribution of Alu insertion in BRCA2 exon 3(c.156_157insAlu) to inherited predisposition to breast/ovarian cancer in families mostly from northern/central Portugal; findings show it accounts for more that one-fourth of deleterious BRCA1/BRCA2 mutations (Homo sapiens) PubMed
797.
We studied 10 BRCA1 and 12 BRCA2 variants identified in Australian families with breast cancer. (Homo sapiens) PubMed
798.
Down-regulation of BRCA2 leads to radio-sensitization mainly through the inhibition of homologous recombination repair type double-strand break repair. (Homo sapiens) PubMed
799.
The most current evidence suggests that it may be more beneficial in those with BRCA2 mutations because tumors associated with these mutations are likely to be estrogen-receptor positive. (Homo sapiens) PubMed
800.
BRCA2 may play an important role in the familial breast cancer in eastern Shandong Chinese population, but not in the early-onset breast cancer. (Homo sapiens) PubMed
801.
Survival from diagnosis of ovarian cancer was calculated using Kaplan-Meier and compared for proven BRCA1/2 carriers with non-carriers; 5 & 10 year survival in BRCA1/2 mutation carriers was 58.6% and 36%, which was sig. worse than for non-BRCA carriers. (Homo sapiens) PubMed
802.
Dinucleotide CA repeat polymorphism at RAD51 and BRCA2 gene regions might be associated with genetic susceptibility to breast cancer. (Homo sapiens) PubMed
803.
A total of 14 BRCA1 and 17 BRCA2 sequence alterations, of which eight are novel, are reported. (Homo sapiens) PubMed
804.
BRCA2 mutation may not contribute to increases in the risk for both sporadic and familial pancreatic cancer in Korea. (Homo sapiens) PubMed
805.
caspase 3 cleavage of Rad51 resulted in a functional decrease in Rad51 strand exchange activity and that inhibition of caspase 3 activity increased Rad51 protein levels and Rad51 foci (Homo sapiens) PubMed
806.
BRCA2 gene mutation was identified in 4 male breast cancer (MBC) patients; 3 carried the Slovenian founder mutation IVS16-2A>G; all 4 mutations were confined to patients with a family history of breast cancer (Homo sapiens) PubMed
807.
In Ashkenazi Jews, mutations in BRCA1/2 may constitute a major cause for pancreatic cancer. (Homo sapiens) PubMed
808.
These observations are consistent with the idea that BRCA2, but not BRCA1, is a tumor suppressor of prostate cancer. (Homo sapiens) PubMed
809.
An excellent method for identifying inactivating missense mutations in the BRCA2 DBD predicting likelihood of cancer in carriers. (Homo sapiens) PubMed
810.
The mutation distributions are comparable with those from Scandinavian and European studies and indicate that the Danish BRCA1 and BRCA2 mutations are a mixture of Scandinavian mutations and European mutations including two of the Ashkenazi mutations. (Homo sapiens) PubMed
811.
deleterious genetic variants in the BRCA2 gene in the Czech population (Homo sapiens) PubMed
812.
BRCA1 and BRCA2 mutation carriers had similar expression profiles, with some subclustering of missense mutation carriers. (Homo sapiens) PubMed
813.
No large genomic rearrangements were identified in BRCA2 in Finnish breast and/or ovarian cancer families (Homo sapiens) PubMed
814.
A case-control study is reported on infertility, treatment of infertility, and the risk of breast neoplasms among women with BRCA2 mutations. (Homo sapiens) PubMed
815.
TGFB1 L10P genotype does not modify the risk of breast cancer in BRCA1 or BRCA2 mutation carriers (Homo sapiens) PubMed
816.
Single nucleotide polymorphism in BRCA2 is associated with breast cancer. (Homo sapiens) PubMed
817.
There is a highly significant reduction in life expectancy in BRCA1 compared to BRCA2 carriers in ovarian cancer. (Homo sapiens) PubMed
818.
BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. (Homo sapiens) PubMed
819.
BRCA2-associated cancers were characterized by the higher relative expression of FGF1 and FGFR2 (Homo sapiens) PubMed
820.
our findings suggest no difference in the occurrence of miscarriage between BRCA2 carriers and non-carriers when parental consanguinity was taken into consideration (Homo sapiens) PubMed
821.
The median survival from diagnosis of prostate cancer was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant. (Homo sapiens) PubMed
822.
A syngeneic variance library for functional annotation of human variation in BRCA2. (Homo sapiens) PubMed
823.
the novel BRCA2 splice variant is a de novo mutation introduced in the male spermatozoa that can be classified as a disease causing mutation (Homo sapiens) PubMed
824.
BRCA2 deficiency is partially rescued by Rad51 overexpression (Homo sapiens) PubMed
alteration in RAD51 region may contribute to the disturbances of DNA repair involving RAD51 and/or BRCA2 penetration and thus enhance the risk of breast cancer development. (Homo sapiens) PubMed
827.
we determined the methylation statuso f the promoter in putative modifier genes: BRCA1, BRCA2, ATM, ATR and P53 in Jewish BRCA1/BRCA2 mutation carriers with or without breast cancer. hypermethylation was detected only in the BRCA1 promotor (Homo sapiens) PubMed
828.
a limited role for the three Ashkenazi BRCA1/2 founder mutations in cutaneous malignant melanoma risk among the Ashkenazi Jewish population (Homo sapiens) PubMed
829.
characterized BRCA1 and BRCA2 gene polymorphic variants in familial breast cancer (Homo sapiens) PubMed
830.
BRCA1 and BRCA2 genomic rearrangement testing be considered in all non-Ashkenazi Jewish women with an estimated mutation prevalence >or=10% (Homo sapiens) PubMed
831.
analysis of breast cancer risk variation in BRCA1 and BRCA2 mutation carriers (Homo sapiens) PubMed
832.
Our aim was to ascertain the pathological effect of the BRCA1 IVS6-1G>A (c. 302-1G>A) and the BRCA2 IVS15+1G>A (c. 7617+1G>A) variants detected in Spanish breast/ovarian cancer families (Homo sapiens) PubMed
833.
The study demonstrates for the first time that microsatellite-stable FHIT-negative sebaceous gland carcinomas accumulate mutations that target central components of the HRR network. (Homo sapiens) PubMed
834.
BRCA1/2 in high-risk African-American women with breast cancer: providing genetic testing through various recruiment strategies is reported. (Homo sapiens) PubMed
835.
Different from ERbeta, p53 interacts with HDAC1 and CtBP1 and forms an inhibiting transcriptional complex that could compete for binding to Sp1 sites with ERalpha transcriptional complex and inhibit BRCA2 transcription more significantly (Homo sapiens) PubMed
836.
Methylation status of CpG islands at sites -59 to +96 in exon 1 varies in mammary tissue among women with sporadic breast cancer (Homo sapiens) PubMed
837.
A high mutation detection rate and the frequent occurrence of a limited array of recurring mutations allow a simple and fast initial test for BRCA1/2 mutation screening in families with Slovenian ancestry (Homo sapiens) PubMed
BRCA2 mutation is associated with male breast cancer. (Homo sapiens) PubMed
840.
possible relationship between defects in the FA/BRCA pathway of genomic stability and potential pathogenesis of T and B cell lymphoma. (Homo sapiens) PubMed
841.
In a population well beyond the average age of breast/ovarian cancer onset, 21 different sequence variants in the BRCA1 gene (one novel) and 36 variants in the BRCA2 gene (7 novel) were detected. (Homo sapiens) PubMed
842.
no association between duration of epithelial ovarian cancer symptoms and BRCA mutation status (Homo sapiens) PubMed
843.
C-terminally truncated BRCA2 hinders RAD51 nuclear translocation, possibly contributing to genetic instabilities in homozygous as well as heterozygous individuals. (Homo sapiens) PubMed
844.
germ-line BRCA1 or BRCA2 mutations may have a role in response to primary platinum-based chemotherapy (Homo sapiens) PubMed
845.
Parp-1 down-regulates BRCA2 expression through an interaction with a repression region of the BRCA2 promoter (Homo sapiens) PubMed
846.
Carriers of mutations in the genes BRCA1/2 may present a specific high risk group for PABC especially at younger ages. (Homo sapiens) PubMed
847.
no defect in FANCD2 ubiquitination, BRCA2 and FANCJ expression; absence of FANCN protein in three cell lines: HT, Sudhl4 and JEKO-1. (Homo sapiens) PubMed
848.
Studied BRCA1 and BRCA2 exp'n in young breast cancer patients;BRCA1 & BRCA2 expression correlated in healthy, but not in tumor tissues. Neither BRCA1 nor BRCA2 exp'n was assoc'd with tumor histology, diff'n, nodal metastasis or p53 and HER-2 exp'n. (Homo sapiens) PubMed
849.
Cross-sectional analysis of germ-line BRCA2 mutations in Japanese patients suspected to have breast/ovarian cancer is reported. (Homo sapiens) PubMed
850.
BRCA2 T1915M polymorphism alone might be associated with a reduced risk of breast cancer, but among CHEK2 mutation carriers, it may lead to an unexpectedly high risk. (Homo sapiens) PubMed
851.
analysis of the effectiveness of screening in diagnosing early stage ovarian cancer in BRCA1 and BRCA2 mutation carriers (Homo sapiens) PubMed
852.
Consistent with previous reports, BRCA2 mutations are associated with an increased risk of PAC. (Homo sapiens) PubMed
853.
BRCA2 gene mutation is associated with breast and ovarian cancer. (Homo sapiens) PubMed
The BRCA2 gene, found on the long arm of chromosome 13, encodes for an even larger protein of 3418 amino acids.BRCA 1 and 2 mutations account for 5% to 10% of breast cancer cases. (Homo sapiens) PubMed
856.
The oral contraceptive pill (OCP) reduces the risk of both endometrial and ovarian cancer in the general population and BRCA carriers (Homo sapiens) PubMed
857.
Three hundred and forty-five probands were examined for specific mutations of BRCA1/2 genes. The estimated penetrance for the age groups among BRCA1/2 carriers was 31.9% (<50 years) and 46.2% (> or =50 years (Homo sapiens) PubMed
858.
BARD1 has BRCA1-dependent and BRCA1-independent functions in mitosis. BARD1, but not BRCA1, localizes to the midbody at telophase and cytokinesis, where it colocalizes with Aurora B. (Homo sapiens) PubMed
859.
Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. (Case report) (Homo sapiens) PubMed
860.
Genetic variants in the BRCA2 gene is associated with breast cancer. (Homo sapiens) PubMed
861.
MDM2SNP309G/G main effect on BRCA1/2 positive mutation carriers is linked to its effect on patients survival. (Homo sapiens) PubMed
862.
two codon-usage-changing variants were detected in BRCA2 in familial breast cancer but showed no association with breast cancer risk (Homo sapiens) PubMed
863.
In Sardinian breast cancer population, effects of BRCA2 germline mutations on survival varied within the first 2 years from diagnosis. After longer follow-up, breast cancer-specific rates of death were similar for BRCA2 mutation carriers and non-carriers. (Homo sapiens) PubMed
864.
BRCA1 is an upstream regulator of BRCA2 in the DNA-damage response, and PALB2 is the linker between BRCA1 and BRCA2 in breast and ovarian cancer. (Homo sapiens) PubMed
865.
Study shows that the solitary BRC4 amino motif of BRCA2 promotes assembly of RAD51 onto single-stranded DNA, but not dsDNA, to stimulate DNA strand exchange. (Homo sapiens) PubMed
866.
promoter methylation is a not a frequent "second-hit" in tumors from BRCA1 or BRCA2 carriers. (Homo sapiens) PubMed
867.
We identified seven (7/22, 31.8%) new deleterious mutations and also confirmed and reported a BRCA2 founder mutation in our Hong Kong Chinese cohort (Homo sapiens) PubMed
868.
impaired homologous recombination repair is one of the fundamental causes for genomic instability and tumorigenesis observed in patients carrying BRCA1, BRCA2, or PALB2 mutations (Homo sapiens) PubMed
869.
It was shown that the presence of the mutations in the BRCA1/2 genes among patients with bilateral breast cancer is associated with an earlier occurrence of the first and the second breast cancer than in patients without hereditary mutations. (Homo sapiens) PubMed
870.
The prevalence of germline mutations in the BRCA1 and BRCA2 genes found was lower than reported on high-risk Brazilian populations. (Homo sapiens) PubMed
871.
REVIEW: BRCA1 and BRCA2 gene mutations which predispose to the hereditary breast-ovarian cancer syndrome (Homo sapiens) PubMed
872.
REVIEW: BRCA1 and BRCA2 gene mutations which predispose to the hereditary breast-ovarian cancer syndrome (Homo sapiens) PubMed
873.
REVIEW: Germline mutations of the BRCA1 and BRCA2 genes confer a high life-time risk of ovarian cancer (Homo sapiens) PubMed
874.
review of available data on ovarian cancers in the context of other investigations of BRCA-related transcriptional alterations , and highlight areas for future research. (Homo sapiens) PubMed
875.
Primary human fibroblasts derived from heterozygous BRCA2 mutation carriers show significantly prolonged cytokinesis. (Homo sapiens) PubMed
876.
Prevalence of BRCA2 mutation and risk of secondary malignancies across diverse racial groups in young women with breast cancer are reported. (Homo sapiens) PubMed
877.
The proportion of Korean ovarian cancer patients with a strong family history was significant, and the prevalence of BRCA1 and BRCA2 mutations in such patients was high. (Homo sapiens) PubMed
878.
two siblings diagnosed with central nervous system embryonal tumors at an early age in association with biallelic BRCA2 inactivation, including the first reported case of a spinal cord primitive neuroectodermal tumor (PNET) in a BRCA2/FANCD1 kindred (Homo sapiens) PubMed
879.
Results suggest that Rad51 binding by the C-terminal Brca2 motif is dispensable for the execution of homologous DNA recombination but instead links the disassembly of Rad51 complexes to mitotic entry. (Homo sapiens) PubMed
880.
BRCA mutation carriers, as well as women with a significant family history of breast and ovarian cancer are more vulnerable to exogenous hormones in oral contraceptives (Homo sapiens) PubMed
881.
Role of MCPH1 in the DNA damage response is in part associated with the ability to localize BRCA2 to sites of DNA double-stand breaks. (Homo sapiens) PubMed
882.
CBP-mediated post-translational N-glycosylation of BRCA2. (Homo sapiens) PubMed
883.
Show here that PALB2 physically and functionally connects BRCA1 and BRCA2 into a DNA damage response network that also includes the RAD51 recombinase. (Homo sapiens) PubMed
884.
Data show that variants in genes that interact biologically with BRCA1 and/or BRCA2 may be associated with modified ovarian cancer risk in women who carry BRCA1/2 mutations. (Homo sapiens) PubMed
885.
structure explains the effects of both cancer-associated truncating mutants in PALB2 and missense mutations in the amino-terminal region of BRCA2. (Homo sapiens) PubMed
886.
analysis of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population (Homo sapiens) PubMed
887.
immunohistochemistry-based test (which takes only 4 hours) appears to identify BRCA2 hereditary cancer with high accuracy. (Homo sapiens) PubMed
888.
BRCA2 targets RAD51 to ssDNA while inhibiting dsDNA binding and that these contrasting activities together bolster one another to stimulate homologous DNA recombination. (Homo sapiens) PubMed
889.
restoration of BRCA2 due to secondary BRCA2 mutation is involved in acquired drug resistance of BRCA2-mutated ovarian carcinoma. (Homo sapiens) PubMed
890.
Alterations in BRCA2 gene sequence, copy number, or expression are extremely common in clear cell carcinoma of the ovary and may contribute to a paradoxical better clinical outcome. (Homo sapiens) PubMed
891.
This study suggests the possibility of the first true founder mutation of BRCA1/BRCA2 identified in the Korean population. (Homo sapiens) PubMed
892.
Heterozygosity and homozygosity of any of the examined nine BRCA1 and BRCA2 missense polymorphisms cannot explain the increased risk of breast and/or ovarian cancer observed in families with hereditary breast and/or ovarian cancer. (Homo sapiens) PubMed
893.
BRCA1/2 genomic rearrangement is likely to make only a small contribution to breast cancer in the Korean population. (Homo sapiens) PubMed
894.
PCNA may function as a molecular platform to facilitate the mono-ubiquitination of FANCD2 and activation of the FA-BRCA pathway (Homo sapiens) PubMed
895.
There was no evidence that TP53 Arg72Pro or MDM2 309T>G, either singly or in combination, influence breast cancer risk in BRCA1 or BRCA2 mutation carriers. (Homo sapiens) PubMed
896.
BRCA2-plectin interaction plays an important role in the regulation of centrosome localization and also that displacement of the centrosome may result in genomic instability and cancer development. (Homo sapiens) PubMed
897.
among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition (Homo sapiens) PubMed
Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication. (Homo sapiens) PubMed
900.
Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer is reported. (Homo sapiens) PubMed
901.
BRCA2 germ-line mutation analysis among Indian women from south India identified novel mutations and a high-frequency occurrence of a base-pairing gene deletion. (Homo sapiens) PubMed
902.
AR allelotype length did not correlate with survival in this statistically representative cohort of patients with BRCA1/2 mutations. Associations between short AR and outcome in BRCA2-associated ovarian cancers remain to be determined. (Homo sapiens) PubMed
903.
Examine contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. (Homo sapiens) PubMed
904.
5382insC and 185delAG mutations in BRCA1 and 6174delT in BRCA2 have much less frequency in Iranian breast cancer patients. (Homo sapiens) PubMed
905.
Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. (Homo sapiens) PubMed
906.
the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers. (Homo sapiens) PubMed
907.
surveillance and prevention strategies may have different outcomes in BRCA1 and BRCA2 mutation carriers (Homo sapiens) PubMed
908.
there was no significant difference in cyclin D1 expression between BRCA2 and BRCAX cancers (Homo sapiens) PubMed
909.
SNP rs13281615 at 8q24 was not associated with breast cancer for either BRCA1 or BRCA2 mutation. (Homo sapiens) PubMed
910.
Study identified linkage disequilibrium between KL-VS and BRCA2 6174delT mutation on 13q12. (Homo sapiens) PubMed
911.
BRCA2 mutation testing is associated with ovarian cancer prevention. (Homo sapiens) PubMed
912.
analysis of novel mutations identified in Slovak HBOC families, c.80 + 3del4 (IVS2 + 3delAGTC) in BRCA1 gene and mutation c.6589delA (6817delA) in BRCA2 gene [case report] (Homo sapiens) PubMed
913.
a predisposing mutation in BRCA2,is present in approximately 6% of French-Canadian women with early-onset breast cancer (Homo sapiens) PubMed
914.
the CASP8 D302H polymorphism diminishes the high risk of breast cancer conferred by BRCA1 and BRCA2 mutations (Homo sapiens) PubMed
915.
parity appears to be associated with protection from breast cancer in women with mutations in BRCA1 and BRCA2 (Homo sapiens) PubMed
916.
The genotype HH of the N372H locus in BRCA2 is associated with breast cancers. (Homo sapiens) PubMed
917.
Study investigated the role of genetic variation in IGF signaling and breast cancer risk in women carrying deleterious mutations in BRCA1 and BRCA2. (Homo sapiens) PubMed
918.
a novel pathogenic mutation in BRCA2; (c.2999delCT,frameshift mutation consists of a deletion of two bases in exon 11) (Homo sapiens) PubMed
919.
151 consecutive primary ovarian tumors (including 21 with BRCA1/2 mutations and 130 without the mutations) were screened for loss of heterozygosity at loci on chromosomes 17 and 13q. (Homo sapiens) PubMed
920.
It is possible that GATA3 mutations occur earlier in the evolution of breast tumors, compared to BRCA1, BRCA2 or sporadic tumors, and are therefore easier to detect by direct sequencing in the presence of some stromal contamination. (Homo sapiens) PubMed
921.
variant genotypes of the Thr1915Met and Met784Val polymorphisms of the BRCA2 gene may be indicative factors in therapy of ductal breast cancer (Homo sapiens) PubMed
922.
Review states that referral criteria for BRCA1 genetic testing may differ between European countries based on BRCA2 mutation prevalence. (Homo sapiens) PubMed
923.
In this prospective study of women who were unaffected at the time of genetic testing and who were negative for the known familial mutation in BRCA1/2, no excess risk of invasive breast cancer was observed. (Homo sapiens) PubMed
924.
analysis of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary (Homo sapiens) PubMed
925.
the BRCA2 silent mutation Lys172Lys is a disease-causing mutation. (Homo sapiens) PubMed
926.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
927.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
928.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
929.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
930.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
931.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
932.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
933.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
934.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
935.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
936.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
937.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
938.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
939.
The prophylactic procedure is highly effective in preventing invasive breast cancer in BRCA2 mutation carriers (Homo sapiens) PubMed
940.
Rates of new primaries are predicted to some extent by mutation status (Homo sapiens) PubMed
941.
There was no difference in mean parity between carriers (1.9) and noncarriers (1.9)of BRCA mutations. (Homo sapiens) PubMed
942.
Multifactorial likelihood analysis indicates that the BRCA1 c.135-1G>T and BRCA2 c.7977-1G>C variants are disease-associated mutations which should be managed clinically in the same fashion as classical truncating mutations. (Homo sapiens) PubMed
943.
Data show that although SNPs in BRCA2 and ERCC2 showed stronger associations with high Gleason score, results were not statistically significantly different between clinically aggressive and non-aggressive tumors. (Homo sapiens) PubMed
944.
These results suggest that, compared to BRCA1 and BRCA2 mutation carriers, non-BRCA1/2 (BRCAX) individuals are genetically heterogeneous. (Homo sapiens) PubMed
945.
A synonymous variant (Ser51) in TOX3 (previously TNRC9) was associated with an increased risk of breast cancer (OR=1.82, p<0.001) in BRCA2 mutation carriers. (Homo sapiens) PubMed
946.
The risks of subsequent contralateral breast cancer are substantial for women who carry a BRCA1/BRCA2 mutation. (Homo sapiens) PubMed
947.
BRCA2 gene promoter has bi-directional activity, expressing BRCA2 and a novel C4-type zinc finger containing transcription factor ZAR2. (Homo sapiens) PubMed
948.
The observed physical association of p53 and BRCA2 may have important functional implications in the p53 transactivation-independent suppression of homologous recombination. (Homo sapiens) PubMed
949.
A high proportion of DNA variants of BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. (Homo sapiens) PubMed
950.
Interaction between BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility. (Homo sapiens) PubMed
951.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
952.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
953.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
954.
Meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
955.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
956.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
957.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
958.
Observational study and genome-wide association study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
959.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
960.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
961.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
962.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
963.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
964.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
965.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
966.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
967.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
968.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
969.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
970.
Meta-analysis of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
971.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
972.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
973.
The study results suggest that genes that act upstream of p53, or participate in the DNA damage response, may modify the risk of cancer in women with mutant BRCA1/2 alleles. (Homo sapiens) PubMed
974.
plays important role in susceptibility to breast cancer in middle aged Chinese women (Homo sapiens) PubMed
975.
analysis of locally prevalent BRCA1/2 mutations in all breast cancer patients might extend substantially the percentage of identified mutation carriers. (Homo sapiens) PubMed
976.
we identified a novel germ line mutation in the BRCA2 gene (c.51dupA) in a patient with early onset bilateral breast cancer and no family history of the disease (Homo sapiens) PubMed
977.
the population of Eastern Spain showed a great heterogeneity in the BRCA1 and BRCA2 mutations (Homo sapiens) PubMed
978.
BRCA2 does not regulate cytokinesis in human cells. (Homo sapiens) PubMed
979.
We report a novel germline 5369delATTT mutation in BRCA2 gene, detected in a 45-year-old woman with bilateral breast cancer. This deletion was also detected in her father with prostatic cancer and her sister with breast cancer. (Homo sapiens) PubMed
980.
Authors studied 103 women with fallopian tube cancer (48 with a BRCA1 mutation, 12 with a BRCA2 mutation and 43 with no identified BRCA mutation) and 980 matched controls. (Homo sapiens) PubMed
981.
Analysis of BRCA2 c.8308 G > A by mRNA analysis, and BRCA2 c.8962A > G, BRCA2 c.8972G > A, BRCA2 c.9172A > G, and BRCA2 c.9213G > T by a minigene assay, revealed no evidence for aberrant splicing. (Homo sapiens) PubMed
982.
Cancers with a BRCA2 germ line mutation are less frequent and resemble sporadic cases with a comparably higher proliferative activity and a lack of Her2 overexpression. (Homo sapiens) PubMed
983.
BRCA2 mutation carriers had an increased risk of prostate cancer and a higher histologic grade, and BRCA1 or BRCA2 mutations were associated with a more aggressive clinical course. (Homo sapiens) PubMed
984.
None of the associations between reproductive factors and contralateral breast cancer risk differed between BRCA2 mutation carriers and non-carriers. (Homo sapiens) PubMed
985.
Approximately 30% of women with fallopian tube cancer have a mutation in BRCA1 or BRCA2. (Homo sapiens) PubMed
986.
Of the 173 patients, 43 (25%) were found to have a tubal lesion, including 23% of the BRCA1 mutation carriers and 27% of the BRCA2 mutation carriers. (Homo sapiens) PubMed
987.
In total, 5-10% of all breast cancer cases are related to gen mutations. In most cases a mutation in the BRCA1-gen and BRCA2-gen is responsible for insufficient repair of DNA damages that cause breast and ovarian cancer. (Homo sapiens) PubMed
988.
Data extend the ovarian BRCAness phenotype, imply BRCA1/2-deficient ovarian cancer is biologically distinct, and suggest that patients with visceral metastases should be considered for BRCA1/2 sequencing. (Homo sapiens) PubMed
989.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
990.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
991.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
992.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
993.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
994.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
995.
Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
996.
Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
997.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
998.
Observational study of genetic testing. (HuGE Navigator) (Homo sapiens) PubMed
999.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
1000.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
1001.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
1002.
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) (Homo sapiens) PubMed
1003.
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) (Homo sapiens) PubMed
1004.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
1005.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1006.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1007.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
1008.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1009.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1010.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
1011.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1012.
Meta-analysis of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
1013.
The aim of this study is to outline the uptake of risk-reducing surgery in the Danish population of BRCA mutation positive women and to search for factors affecting this decision. (Homo sapiens) PubMed
1014.
germ line BRCA2 gene mutation may play a role in familial aggregation of ESCC in high-risk region of India. (Homo sapiens) PubMed
1015.
Characteristic pathological features and older age of onset among BRCA1-mutated estrogen receptor positive breast cancers. (Homo sapiens) PubMed
1016.
Letter: Developed high-resolution melting analysis for mutation screening assays for two BRCA2 founder mutations in Chinese breast cancer patients. (Homo sapiens) PubMed
1017.
New loci appeared to interact multiplicatively for breast cancer risk in BRCA1 and BRCA2 carriers. (Homo sapiens) PubMed
1018.
Data identified splicing aberration for BRCA1c.4868C>G(p.Ala1623Gly) and BRCA2c.7988A>T(p.Glu2663Val) and c.8168A>G(p.Asp2723Gly). (Homo sapiens) PubMed
1019.
Report BRCA2 Spanish proven founder mutations which predispose to breast cancer in young women. (Homo sapiens) PubMed
1020.
Hereditary breast and ovarian cancer due to mutations in BRCA2 (Review) (Homo sapiens) PubMed
1021.
Testing women with triple negative breast cancers who were younger than 50 years for BRCA mutations is a cost-effective strategy and should be adopted into current guidelines for genetic testing. (Homo sapiens) PubMed
1022.
Multivariate analysis confirmed that the poorer survival of PrCa in BRCA2 mutation carriers is associated with the germline BRCA2 mutation per se (Homo sapiens) PubMed
1023.
analysis of cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families (Homo sapiens) PubMed
1024.
BRCA2 mutation does not affect either short-term or long-term survival rate in breast cancer. Review. (Homo sapiens) PubMed
1025.
analysis of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer (Homo sapiens) PubMed
1026.
BRCA2 germline mutation in a juvenile breast carcinoma diagnosed at 21 years of age, 4 years after an early full-term pregnancy, in absence of cancer family history (Homo sapiens) PubMed
1027.
BRCA2 genes mutations are responsible for a significant proportion of breast cancer. (Homo sapiens) PubMed
1028.
A new human breast cancer xenograft obtained from a BRCA2-mutated patient. (Homo sapiens) PubMed
1029.
Case Report: Report BRCA2 mutation in astrocytoma patient who was part of a large breast cancer lineage. (Homo sapiens) PubMed
1030.
BRCA2 is a key mediator of homologous recombination; a molecular basis for understanding how this DNA repair process is disrupted by BRCA2 mutations, which lead to chromosomal instability and cancer (Homo sapiens) PubMed
1031.
This study assessed the pathological mutation detection rates for BRCA1, BRCA2 and the CHEK2c.1100 delC mutation in 2022 women with breast cancer, including 100 with breast/ovary double primary and 255 with bilateral breast cancer. (Homo sapiens) PubMed
1032.
BRCA2 germline mutation is associated with breast and ovarian cancer. (Homo sapiens) PubMed
1033.
BRCA2 binds selectively to ssDNA & to ssDNA in tailed duplexes & replication fork structures. directed the binding of RAD51 recombinase to ssDNA, reduced the binding of RAD51 to duplex DNA and stimulated RAD51-mediated DNA strand exchange. (Homo sapiens) PubMed
1034.
Full-length BRCA2 binds to ~6 RAD51 molecules and promotes RAD51 binding to ssDNA coated by replication protein A in a manner that is stimulated by DSS1. (Homo sapiens) PubMed
1035.
PALB2 can function synergistically with a BRCA2 chimera (termed piccolo, or piBRCA2) to further promote strand invasion. (Homo sapiens) PubMed
1036.
we report the first identification of a Danish breast and ovarian cancer family heterozygote for mutations in the BRCA1 and BRCA2 genes (Homo sapiens) PubMed
1037.
8 novel molecular changes were identified in the BRCA2 gene in 105 investigated breast cancer patients (Homo sapiens) PubMed
1038.
the prevalence of BRCA2 mutations in the German familial pancreatic cancer population is less frequent than previously reported (Homo sapiens) PubMed
1039.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
1040.
Meta-analysis of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1041.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1042.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1043.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1044.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
1045.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1046.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1047.
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
1048.
Observational study and genome-wide association study of gene-disease association and gene-gene interaction. (HuGE Navigator) (Homo sapiens) PubMed
1049.
Observational study of gene-disease association. (HuGE Navigator) (Homo sapiens) PubMed
1050.
Report a novel complex mutation that consists of a deletion of 12 bp and an insertion of 2 bp (c.8402_8413del12ins2bp) in the exon 18 of the BRCA2 gene in a Spanish hereditary male/female breast cancer family. (Homo sapiens) PubMed
1051.
Chemotherapy and tamoxifen reduced the risk of contralateral breast cancer in BRCA1/BRCA2 carriers and non-carriers to a similar relative degree. (Homo sapiens) PubMed
1052.
Meta-analysis suggests that the BRCA2 372H allele may be a low-penetrant risk factor for developing breast cancer. (Homo sapiens) PubMed
1053.
Major gene rearrangements involving the BRCA1 and BRCA2 genes appear to contribute little to the burden of inherited predisposition to breast and ovarian cancer in the Ashkenazim. (Homo sapiens) PubMed
1054.
Prioritizing candidate genetic modifiers of BRCA1 and BRCA2 using a combinatorial analysis of global expression and polymorphism association studies. (Homo sapiens) PubMed
1055.
The coding sequence and exon-intron junctions of BRCA1 and BRCA2 were amplified in 24 multiplex PCRs using a single condition. (Homo sapiens) PubMed
1056.
Development of a scoring method to screen for BRCA1/2 mutations. (Homo sapiens) PubMed
1057.
Functional analysis of BRCA2 variants using a mouse embryonic stem cell-based assay. (Homo sapiens) PubMed
1058.
study has informed the development of an appropriate support network based on a hub and spoke model to help BRCA1/BRCA2 carriers and their families adapt to living and coping with their genetic risk (Homo sapiens) PubMed
1059.
analysis of germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients (Homo sapiens) PubMed
1060.
Suggest that the frequency of BRCA1/2 gene rearrangements is very low in Turkish breast/ovarian cancer patients. (Homo sapiens) PubMed
1061.
findings support PALB2 and BRCA2 as risk genes specifically for bipolar disorder, and suggest that altered DNA repair related to neurogenesis may be involved in BD pathophysiology (Homo sapiens) PubMed
1062.
A review of MEDLINE from 1989 through 2010 for the terms BRCA1, BRCA2, breast cancer, ovarian cancer, risk assessment, and genetic testing is presented. (Homo sapiens) PubMed
1063.
results suggested that a complex consisting of BRCA2, NPM, and ROCK2 maintains the numerical integrity of centrosomes and accurate cell division and that dysfunction of this regulation might be involved in the tumorigenesis of breast cancer (Homo sapiens) PubMed
1064.
A common genetic variant in BRCA2 (1342A > C) occurred less frequently in deleterious mutation carriers of breast cancer. (Homo sapiens) PubMed
1065.
Occult ovarian cancers may be found at the time of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. (Homo sapiens) PubMed
1066.
Case Reports: Report double heterozygosity for BRCA1 and BRCA2 mutations and the pathological features of breast/ovarian neoplasms that develop. (Homo sapiens) PubMed
1067.
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer. (Homo sapiens) PubMed
1068.
Study in a multi-ethnic (Malay, Chinese, Indian) cohort suggests that large genomic rearrangements are present at a low frequency but should nonetheless be included in the routine testing for BRCA1 and BRCA2. (Homo sapiens) PubMed
1069.
Receipt of BRCA1/2 mutation test results impacts how carriers see the positive aspects of risk reducing oophorectomy/mastectomy and their surgical intentions. (Homo sapiens) PubMed
1070.
BRCA1 and BRCA2 genetic test in high risk patients and families. (Homo sapiens) PubMed
1071.
No large genomic rearrangements were detected in the BRCA2 gene in Czech high-risk breast/ovarian cancer patients. (Homo sapiens) PubMed
1072.
The incidence of breast and ovarian cancer in BRCA2 mutation carriers and of ovarian cancer in BRCA1 mutation carriers is still high after 60 years. (Homo sapiens) PubMed
1073.
Data suggest that the risk for breast cancer among BRCA1 or BRCA2 carriers may be modified by reproductive characteristics and alcohol use. (Homo sapiens) PubMed
1074.
study evaluated the associations of SNPs, rs4973768 in SLC4A7/NEK10, rs6504950 in STXBP4/COX11, and rs10941679 at 5p12, and reanalyzed the previous associations using additional carriers in a sample of 12,525 BRCA1 and 7,409 BRCA2 carriers (Homo sapiens) PubMed
1075.
Rad52 can respond to DNA double-strand breaks and replication stalling independently of BRCA2 (Homo sapiens) PubMed
1076.
Among the mutations detected in the Slovenian population, 5 mutations in BRCA1 and 4 mutations in BRCA2 have not been described in other populations until now. (Homo sapiens) PubMed
1077.
Results indicate that SNPs that modify BRCA2 penetrance identified by an agnostic approach thus far are limited to variants that also modify risk of sporadic BRCA2 wild-type breast cancer. (Homo sapiens) PubMed
1078.
BRCA2 mutation is associated with basal cell carcinoma. (Homo sapiens) PubMed
1079.
The ITGB3 Leu33Pro polymorphism does not modify breast or ovarian cancer risk in BRCA2 mutation carriers. (Homo sapiens) PubMed
1080.
BRCA2 mutation is associated with breast and ovarian cancer predisposition families from a North-Eastern Romanian population. (Homo sapiens) PubMed
1081.
BRCA2 mutation is associated with breast and ovarian Neoplasms. (Homo sapiens) PubMed
1082.
BRCA2 mutation is associated with very young age of onset of breast cancer. (Homo sapiens) PubMed
1083.
Data suggest that breast cancer risk among mutation-negative women from BRCA1/2 mutation-positive families is similar to that observed in the general population. (Homo sapiens) PubMed
1084.
BRCA2 mutation is associated with increases in breast cancer worry in African American women. (Homo sapiens) PubMed
1085.
BRCA1 mutations are associated with breast carcinoma In Situ. (Homo sapiens) PubMed
1086.
among BRCA1/2 mutation carriers, prophylactic surgery is cost effective compared to chemoprevention and screening (Homo sapiens) PubMed
1087.
the minor allele del of CASP8 rs3834129 is associated under a dominant model with increased breast cancer risk in carriers of BRCA1 mutations but not in carriers of BRCA2 mutations (Homo sapiens) PubMed
1088.
BRCA2 mutation is associated with menopausal status modifying the association between body weight and breast cancer and disease progression. (Homo sapiens) PubMed
1089.
EMSY amplification may mimic BRCA2 deficiency, at least by overriding RPA and PALB2, crippling the BRCA2/RAD51 complex at DNA-damage and replication/transcription sites (Homo sapiens) PubMed
1090.
7-fold increase in Endometrial Cancer risk with tamoxifen exposure is asscoiated with female family members from BRCA2 mutation. (Homo sapiens) PubMed
1091.
BRCA2 founder mutations are associated with breast cancer and/or ovarian cancer. (Homo sapiens) PubMed
1092.
This high rate of BRCA germline mutations in uterine serous carcinoma(USC) patients coupled with a high rate of personal and familial cancer histories may suggest that USC is associated with the hereditary breast-ovarian syndrome. (Homo sapiens) PubMed
1093.
Higher levels of AI in BRCA1/2 were associated with a 4.22-fold increased risk of familial ovarian cancer. (Homo sapiens) PubMed
1094.
BRCA2 frame shift mutations are associated with defective protein translocation. (Homo sapiens) PubMed
1095.
BRCA2 mutations are associated with breast cancer and/or ovarian cancer. (Homo sapiens) PubMed
1096.
BRCA1 and BRCA2 mutations are common in women with invasive ovarian cancer. All women diagnosed with invasive non-mucinous ovarian cancer should be considered to be candidates for genetic testing. (Homo sapiens) PubMed
This multicenter study demonstrates a significant survival advantage in advanced stage ovarian cancer patients with non-AJ BRCA mutations, confirming the previous studies in the Jewish population. (Homo sapiens) PubMed
1099.
An association was observed between p.Arg280His-rs25489 in XRCC1 and breast cancer risk for BRCA2 mutation carriers, with rare homozygotes at increased risk relative to common homozygotes. (Homo sapiens) PubMed
1100.
analysis of early BRCA1 and 2-associated ovarian and fallopian tube tumorigenesis (Homo sapiens) PubMed
1101.
males who develop breast cancer may have mutations in BRCA2, and possibly in PALB2 (Homo sapiens) PubMed
1102.
Studies indicate that most of these breast cancers are caused by mutations in the high penetrance genes BRCA1 and BRCA2 accounting for about 5% of all breast cancers. (Homo sapiens) PubMed
1103.
BRCA2 prevents rather than repairs nucleolytic lesions at stalled replication forks to maintain genomic integrity and hence likely suppresses tumorigenesis through this replication-specific function. (Homo sapiens) PubMed
1104.
BRCA2 germline mutations are associated with uterine serous carcinoma. (Homo sapiens) PubMed
1105.
the rate of BRCA1/2 mutations in double primary breast and ovarian cancer (DPBOC) patients is probably less than 60%. (Homo sapiens) PubMed
1106.
following a diagnosis of breast cancer, the annual risk of ipsilateral breast cancer risk in BRCA mutation carriers is 1.2% per year. (Homo sapiens) PubMed
1107.
there are no predominant recurring germline mutations in BRCA1 or BRCA2 genes among ethnically diverse Jewish and non Jewish high risk families in Israel. (Homo sapiens) PubMed
1108.
Skp2 overexpression reduced BRCA2 protein and promoted cell growth and migration of prostate cancer cells (Homo sapiens) PubMed
1109.
Loss of function of various proteins involved in double strand break repair other than BRCA1/2 has been suggested to be synthetically lethal with PARP inhibition. (Homo sapiens) PubMed
1110.
FANCD1/BRCA2 played notably important roles in the repair of TMZ-induced DNA damage. (Homo sapiens) PubMed
1111.
BRCA2 helps restore and maintain integrity of the genome. (Homo sapiens) PubMed
1112.
the interaction between BRC repeat 4 (BRC4) and RAD51 was strengthened by the substitution of a single BRC4 amino acid from valine to isoleucine (V1532I). (Homo sapiens) PubMed
1113.
AURKA expression is an unfavorable prognostic factor in patients with endometrioid ovarian cancer and BRCA2 is favorable. (Homo sapiens) PubMed
1114.
This study has assessed the possible pathogenicity of 26 intronic BRCA1 or BRCA2 variants in breast cancer. (Homo sapiens) PubMed
1115.
18 individuals (1.51%) who concomitantly carried the 185delAG BRCA1 and the 6174delT BRCA2 mutations and four individuals (0.34%) who carried the 5382insC BRCA1 and the 6174delT mutations (Homo sapiens) PubMed
1116.
propose that the BRC repeats in BRCA2 cooperate in a partially redundant but reinforcing manner to ensure a high probability of RAD51 filament formation (Homo sapiens) PubMed
1117.
hierarchical statistical modeling of data observed in a case-control study of contralateral breast cancer in which all the participants were genotyped for variants in BRCA1 and BRCA2 (Homo sapiens) PubMed
1118.
Elevated expression of BRCA2 correlates with TGF-beta1 and HER2 in breast cancer and these three factors may act in synergy to promote cancer. (Homo sapiens) PubMed
1119.
Data show that hyperthermia (41-42.5 degrees C) induces degradation of BRCA2 and sensitize innately HR-proficient tumor cells to PARP-1 inhibitors. (Homo sapiens) PubMed
1120.
The comparison between the two different populations did not show any significant difference regarding BRCA2 methylation but exhibited a trend in the decrease of BRCA2 promoter methylation in peripheral blood DNA of sporadic ovarian cancer. (Homo sapiens) PubMed
1121.
a novel function for HMG20b in cytokinesis is regulated by its interaction with the BRC repeats of BRCA2 (Homo sapiens) PubMed
1122.
40 novel sequence variations in BRCA1 and BRCA2 in high risk breast and/or ovarian cancer familiesin Denmark. (Homo sapiens) PubMed
1123.
BRCA2 and PALB2 are main regulators of G2 checkpoint maintenance following DNA-damage. (Homo sapiens) PubMed
1124.
evaluation of prevalence of de novo mutations in BRCA1 and BRCA2 in a clinic-based cohort of women seeking risk assessment; results suggest de novo mutations in BRCA1 and BRCA2 are less common than in other hereditary cancer syndromes (Homo sapiens) PubMed
1125.
Promoter hypermethylation of PAX6, BRCA2, PAX5, WT1, CDH13 and MSH6 seems to be a frequent early event in breast cancer (Homo sapiens) PubMed
1126.
Findings reveal how sequence variation in the BRC repeats directly affects affinity with RAD51 and provide significant new insights into the control of RAD51 by human BRCA2. (Homo sapiens) PubMed
1127.
Single nucleotide polymorphisms in BRCA1 and BRCA2 mutation carriers from 42 studies from the Consortium of Investigators of Modifiers of BRCA1/2, were genotyped. (Homo sapiens) PubMed
1128.
BRCA2 mutations from multiple breast cancer families are associated with prostate cancer. (Homo sapiens) PubMed
1129.
Case Report: cure following platinum-resistant stage III ovarian carcinoma in a woman with a BRCA2 mutation. The patient was subsequently treated with oral melphalan therapy and has not recurred in over 25 years. (Homo sapiens) PubMed
1130.
demonstrate significant quantitative differences regarding the production of the BRCA2 full length RNA and the transcript lacking exon 3 in c.156_157insAlu BRCA2 mutation carriers and in controls (Homo sapiens) PubMed
1131.
results suggest that routine testing of early onset PrCa cases for germline BRCA2 mutations will further help to refine the prevalence and risk associated with BRCA2 mutations and may be useful for guiding management options (Homo sapiens) PubMed
1132.
found no significant associations between any single-single-nucleotide polymorphisms or haplotypes of BRCA1 or BRCA2 and risk of contralateral breast cancer among all women (Homo sapiens) PubMed
1133.
first large rearrangement of the BRCA2 gene that includes all of exon 3 and leads to an in frame deletion of exon 3 at the transcriptional level (Homo sapiens) PubMed
1134.
among women with high-grade serous ovarian cancer, BRCA2 mutation, but not BRCA1 deficiency, was associated with improved survival, improved chemotherapy response, and genome instability compared with BRCA wild-type (Homo sapiens) PubMed
1135.
We identified seven different truncating mutations in seven families, five in BRCA2 three in site-specific breast cancer families and two in breast-ovarian cancer families (Homo sapiens) PubMed
1136.
More than 50% of the Ashkenazi Jewish chromosomes with the BRCA1 185delAG mutation share an identical 2.1 Mb haplotype and nearly 16% of Ashkenazi Jewish chromosomes carrying the BRCA2 6174delT mutation share a 1.4 Mb haplotype. (Homo sapiens) PubMed
1137.
Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers. (Homo sapiens) PubMed
1138.
TAS106 induces the down-regulation of BRCA2 and the subsequent abrogation of the homologous recombination pathway, leading to a radiosensitizing effect. (Homo sapiens) PubMed
1139.
Data provide insight into the genomic effects of loss of BRCA2 function. (Homo sapiens) PubMed
1140.
Women with BRCA-associated ovarian tumors demonstrate a greater sensitivity to cytotoxic therapy with Doxil. (Homo sapiens) PubMed
1141.
BRCA2 mutation is associated with high risk of pelvic serous cancer. (Homo sapiens) PubMed
1142.
prevalence of BRCA1 mutations in triple negative breast cancer (Homo sapiens) PubMed
1143.
Among patients with invasive epithelial ovarian cancer, having a germline mutation in BRCA1 or BRCA2 was associated with improved 5-year overall survival. BRCA2 carriers had the best prognosis. (Homo sapiens) PubMed
1144.
Associations were found between risk of breast cancer and linkage disequilibrium blocks in IGF2 for BRCA1 and BRCA2 mutation carriers, HTRA1 for BRCA1 carriers, and MMP3 for BRCA2 carriers. (Homo sapiens) PubMed
1145.
We found that haplotypes in APEX1, BRCA2, ERCC2, and RAD51 were significantly associated with total childhood acute lymphoblastic leukemia (Homo sapiens) PubMed
1146.
Tetraploidy was significantly 3 times more common in BRCA2 breast cancers than sporadic but no differences were found in the overall ploidy distribution between BRCA2-mutation carriers and non-carriers. (Homo sapiens) PubMed
1147.
Fifteen mutations were identified (two in BRCA2 and thirteen in BRCA1) representing 15.6% of the total (95% CI: 7.8% to 21.3%). (Homo sapiens) PubMed
1148.
Our results reveal functional redundancy within the BRCA2 protein and emphasize the plasticity of this large protein built for optimal homologous recombination function in mammalian cells (Homo sapiens) PubMed
1149.
Our results confirm the existence of a central low BC risk region in BRCA1 (LR1) and one in BRCA2 (LR2). (Homo sapiens) PubMed
1150.
BRCA2 has an important role in telomere stabilization and protection. (Homo sapiens) PubMed
1151.
BRCA2 is required for telomere homeostasis and may be particularly important for the replication of G-rich telomeric lagging strands. (Homo sapiens) PubMed
1152.
Fifteen patients, five male, with a BRCA1 or BRCA2 mutation and PAC and one patient with a BRCA1 mutation and acinar cell carcinoma of the pancreas were identified. (Homo sapiens) PubMed
1153.
Women who had ductal carcinoma in situ and a family history of ovarian cancer or who had BRCAPRO scores >/=10% had a high rate of BRCA positivity regardless of age at diagnosis. (Homo sapiens) PubMed
1154.
Pathologic characteristics of BRCA1 and BRCA2 tumors may be useful for improving risk-prediction algorithms and informing clinical strategies for screening and prophylaxis. (Homo sapiens) PubMed
1155.
Here, the authors use proteomic profiling to identify APRIN (PDS5B), a cohesion-associated protein, as a BRCA2-associated protein. (Homo sapiens) PubMed
1156.
BRCA1 and BRCA2 mutations are observed with nearly equal distribution in Ashkenazi Jewish breast-pancreas cancer families, suggesting that both genes are associated with pancreatic cancer risk (Homo sapiens) PubMed
1157.
Data show that RBMX accumulated at DNA lesions through multiple domains in a poly(ADP-ribose) polymerase 1-dependent manner and promoted HR by facilitating proper BRCA2 expression. (Homo sapiens) PubMed
1158.
Age and grade differed significantly between BRCA1 and BRCA2 carriers in our study population. (Homo sapiens) PubMed
1159.
Several common alleles have been found to modify breast or ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. These common alleles explain a small proportion of the genetic variability in breast or ovarian cancer risk for mutation carriers. (Homo sapiens) PubMed
1160.
Overweight BRCA mutation carrier women seem to be at risk of developing more cortical invaginations than women of normal weight. (Homo sapiens) PubMed
1161.
A frequent founder BRCA2 mutation in non-Afrikaner breast cancer patients of the Western Cape of South Africa. (Homo sapiens) PubMed
1162.
This study suggests that prior appendectomy is more frequently noted in BRCA2 carriers with breast and ovarian cancer than in unaffected mutation carriers. (Homo sapiens) PubMed
1163.
the decreased DSB repair capacity of heterozygous BRCA2 mutations suggests gene dosage effects in G2 fibroblasts (Homo sapiens) PubMed
1164.
T-C transitions at positions 29 bp and 44 bp in relation to the total sequence of BRCA2 exon 8 were identified. (Homo sapiens) PubMed
1165.
The expression of DNA repair proteins, including PARP, FANCD2, BRCA1, PTEN, H2AX, ATM, as well as p53, was studied to see if it correlated with response to treatment, recurrence rate, and survival in ovarian cancer. (Homo sapiens) PubMed
1166.
New pathogenic mutation in BRCA2 gene identified in women in Croatia. (Homo sapiens) PubMed
1167.
Only tumor cell lines with a combination of high Aurora-A and -B expression, BRCA2 mutation and p53 defects showed more sensitivity towards Aurora inhibition than other cell lines. (Homo sapiens) PubMed
1168.
Breast and ovarian cancer risk are high in women with BRCA2 genetic mutation. (Homo sapiens) PubMed
1169.
Promoter hypermethylation patterns of of BRCA2 germ line mutation carriers are associated with fallopian tube neoplasms. (Homo sapiens) PubMed
1170.
The rate of phenocopy breast cancer in non-carriers from Israeli BRCA1 BRCA2 mutation carrier families is 2.26% with no increased breast cancer risk over the average-risk population. (Homo sapiens) PubMed
1171.
Built a classification method that is able to distinguish BRCA2-mutated from sporadic breast tumors based on their chromosomal aberrations with an accuracy of 86.5%. (Homo sapiens) PubMed
1172.
Spectrum and characteristics of BRCA1/2 mutations in Chinese familial breast cancer exhibit some unique features, and Chinese women with familial breast cancer whose tumors are diagnosed at or before the age of 40 are good candidates for BRCA1/2 testing. (Homo sapiens) PubMed
1173.
The associations of the 12 SNPs with risk for BRCA1 and BRCA2 carriers differ by ER-positive or ER-negative breast cancer status. (Homo sapiens) PubMed
1174.
There was no observed difference in the proportion of male breast cancer tumors with abnormal BRCA2 protein expression in Egypt compared to Morocco. (Homo sapiens) PubMed
1175.
evaluation of frequency and distribution of common BRCA1 and BRCA2 mutations which associated with breast cancer risk (Meta-Analysis) (Homo sapiens) PubMed
1176.
report of four interactions between mutations in the breast cancer susceptibility genes ATM and CHEK2 with BRCA1 and BRCA2 (Homo sapiens) PubMed
1177.
Germline mutations in the BRCA2 gene is associated with pancreatic cancer. (Homo sapiens) PubMed
1178.
women who are carriers of BRCA1/2 mutations living in natural fertility conditions have excess fertility as well as excess post-reproductive mortality in relation to controls (Homo sapiens) PubMed
1179.
Mutations in the BRCA2 gene is associated with osteopenia and osteoporosis after risk-reducing salpingo-oophorectomy in breast cancer patients. (Homo sapiens) PubMed
1180.
Mutations in the BRCA2 gene is associated low with sporadic breast cancer of Spanish population. (Homo sapiens) PubMed
1181.
Germline mutations in the BRCA2 gene is associated with Iranian breast cancer patients. (Homo sapiens) PubMed
1182.
polymorphisms in BRCA2 do not contribute to cancer risk in a population of Lynch syndrome patients with colorectal cancer (Homo sapiens) PubMed
1183.
Our results suggest an important role of BRCA1 and BRCA2 promoter methylation in breast cancer development in the Tunisian population. (Homo sapiens) PubMed
1184.
The germline mutation frequency of BRCA2 in esophageal squamous cell carcinoma patients from a low-risk Chinese population was significantly higher than that in healthy controls. (Homo sapiens) PubMed
1185.
Indicate potential strong associations between morphology and BRCA1/2 genotype in high-grade serous carcinomas. (Homo sapiens) PubMed
1186.
BRCA1 and BRCA2 mutations occurred more frequently in platinum-sensitive EOC than platinum-resistant disease. (Homo sapiens) PubMed
1187.
PWC has the potential to detect occult peritoneal carcinoma in patients with BRCA1 or BRCA2 mutations. (Homo sapiens) PubMed
1188.
Data suggest that BRCA1 and BRCA2 mutations are responsible for a significant proportion of familial breast cancer in Moroccan patients. (Homo sapiens) PubMed
1189.
findings not only show that Mre11 activity is required for the survival of BRCA2 mutant cells but also elucidate roles for both the BRCA2 and PARP1 proteins in protecting stalled replication forks (Homo sapiens) PubMed
1190.
C-myc up-regulated miR-1245 expression which led to down-regulation of BRCA2. (Homo sapiens) PubMed
1191.
Loss of heterozygosity at BRCA2 locus had no associations with estrogen receptor or progesterone receptor status and prognosis. (Homo sapiens) PubMed
1192.
functional KL gene variants had no discernable effect on either breast or ovarian cancer risk in a large group of ethnically diverse BRCA1 and BRCA2 mutation carriers. (Homo sapiens) PubMed
1193.
12 novel BRCA1 and BRCA2 mutations, leading to aberrantly expressed transcripts, were identified in a cohort of hereditary breast and ovarian cancer syndrome patients. (Homo sapiens) PubMed
1194.
Abnormal splicing patterns expected to lead to non-functional proteins were observed for 7 BRCA1 and BRCA2 variants in a cohort of patient screening for hereditary breast and ovarian cancer. (Homo sapiens) PubMed
1195.
in patients with triple-negative breast cancer, BRCA1 mutation prevalence was lower, and BRCA2 mutation prevalence was higher, than previously described (Homo sapiens) PubMed
1196.
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. (Homo sapiens) PubMed
1197.
Four novel structural alterations at the BRCA2 locus in hereditary breast and ovarian cancer syndrome families. (Homo sapiens) PubMed
1198.
The first report identifying BRCA2 mutations in Puerto Rico. (Homo sapiens) PubMed
1199.
8 new missense unclassified variants were identified in the BRCA1 and BRCA2 genes in Algerian breast/ovarian cancer families. (Homo sapiens) PubMed
1200.
The results from this study suggest that height, weight, or weight gain do not influence the risk of ovarian cancer among carriers of a BRCA1 or BRCA2 mutation. (Homo sapiens) PubMed
1201.
Treatment with 18.5 muM Genistein or 78.5 muM Daidzein might reverse DNA hypermethylation and restore the expression of the oncosuppressor genes BRCA1 and BRCA2. (Homo sapiens) PubMed
1202.
The penetrance of the mutation and the aggressiveness of the related tumor could depend on a dosage effect of the mutated allele transcript. (Homo sapiens) PubMed
1203.
Oral contraceptive use and paternal origin of mutation affect breast cancer penetrance in Jewish BRCA1 and BRCA2 mutation carriers. (Homo sapiens) PubMed
1204.
BRCA2 N372H polymorphism is associated with follicular lymphoma. (Homo sapiens) PubMed
1205.
BRCA2 mutations are associated with unselected Nigerian breast cancer patients. (Homo sapiens) PubMed
1206.
show a repair-independent requirement for FA genes, including FANCD2, and BRCA1 in protecting stalled replication forks from degradation (Homo sapiens) PubMed
1207.
the in frame BRCA2 deletion c.9203_9328del126 is a rare mutation strongly associated with familial breast cancer. (Homo sapiens) PubMed
1208.
In patients diagnosed with breast and ovarian cancer the study found 4 novel deleterious mutations (c.2805_2808delAGAT and c.3124_3133delAGCAATATTA in BRCA1; c.2639_2640delTG and c.5114_5117delTAAA in BRCA2). (Homo sapiens) PubMed
1209.
A specific role for BRCA2 in the regulation of midbody structure and function is identified that is separate from DNA damage repair and is an explanation of whole-chromosomal instability in BRCA2-deficient tumors. (Homo sapiens) PubMed
1210.
Data indicate taht BRC repeat is a common RAD51 recombinase interaction module that can either promote homologous recombination (HR), as in the case of BRCA2, or to suppress HR, as in RECQL5 helicase. (Homo sapiens) PubMed
1211.
PARP inhibitors may represent a new and promising targeted therapy for patients with BRCA1/2 -associated cancer. (Homo sapiens) PubMed
1212.
The aim is to determine whether DNA-direct is an acceptable procedure for BRCA1/2 testing, in order to provide customized care to patients with breast cancer (Homo sapiens) PubMed
1213.
BRCA2 mutation frequency in triple-negative breast cancer (Homo sapiens) PubMed
1214.
high levels of BRCA2 perturb Rad51-mediated homologous recombination (Homo sapiens) PubMed
1215.
No new rearrangements were found in the BRCA2 gene in 472 patients with breast cancer predisposition. (Homo sapiens) PubMed
1216.
Case Report: Ovarian cancer with metastasis to the brain in patient with BRCA2 mutation. (Homo sapiens) PubMed
1217.
Although there was an association between two SNPs in BRCA2 and cardiovascular disease in a multi-ethnic population, these results were not replicated in two South Asian case-control studies of incident myocardial infarction. (Homo sapiens) PubMed
1218.
Sixty-two patients (index cases) with invasive breast cancer belonging to sixty families and their asymptomatic female first-degree relatives (300 cases) were studied for germline mutations of BRCA1 and BRCA2 genes. (Homo sapiens) PubMed
1219.
BRCA2 mutations for non-familial Korean breast cancer patients were detected at a high rate, particularly, in patients with early onset of less than 35 years of age, bilateral breast cancer, and breast and ovarian cancer. (Homo sapiens) PubMed
1220.
The rate of some seemingly recurring germline mutations in the BRCA2 gene in breast/ovarian high risk Israeli women of diverse ethnic origin were determined. (Homo sapiens) PubMed
1221.
For breast cancer, BRCA mutation status is not associated with the rate of optimal tumor debulking at primary surgery after accounting for differences in patient age. (Homo sapiens) PubMed
1222.
IVS7 + 2T > G produces an alternatively spliced transcript lacking exons 4-7. BRCA2(Delta105) is proficient in homologous recombination-mediated DNA repair. p.L2510P, p.R2336H, & p.W2626C are deleterious. p.I2490T & p.K2729N probably are neutral. (Homo sapiens) PubMed
1223.
the deletion of the wild-type BRCA2 allele, together with co-occurring changes at 6 q, 11 q, and 17 q, are important events in progression toward advanced breast cancer. (Homo sapiens) PubMed
1224.
A locus on chromosome 6q22.33 (rs2180341) was evaluated to see if it modifies breast cancer risk in 3,361 BRCA1 and 2,020 BRCA2 carriers. (Homo sapiens) PubMed
1225.
Caucasian female with double heterozygosity for disease-causing BRCA1 and BRCA2 mutations carriers seem to develop breast cancer at a younger age and have a more severe disease than carriers of a single BRCA mutation. (Homo sapiens) PubMed
1226.
Among the 1017 women referred for BRCA testing, 63 women younger than 52 years of age who had been diagnosed with breast cancer were found, subsequent to this diagnosis, to have BRCA1 or BRCA2 gene mutations. (Homo sapiens) PubMed
1227.
studies suggest substantial mortality benefits in using MRI to screen BRCA1/2 mutation carriers aged 25 to 60 years (Homo sapiens) PubMed
1228.
Low doses of mammography X-rays have the potential to induce chromosomal instability in fibroblasts from BRCA mutation carriers. (Homo sapiens) PubMed
1229.
Functional characterization of 12 cancer associated BRCA2 mutations. (Homo sapiens) PubMed
1230.
study genotyped recurrent BRCA1/BRCA2 mutations among Nigerian, African American, and Barbadian breast cancer patients (Homo sapiens) PubMed
1231.
characteristics of BRCA1/2 germline mutations in Korean patients with breast and ovarian cancer; 420 (150 distinct) pathogenic mutations were identified, 211(73 distinct)in BRCA1 and 209 (77 distinct)in BRCA2; majority of distinct mutations resulted in premature termination codon of the BRCA1/2 translation (Homo sapiens) PubMed
1232.
Methylation types of the BRCA2 promoter in different genotypes of the MTHFRa1298c polymorphism is not associated with ovarian cancer (Homo sapiens) PubMed
1233.
HGPIN is considered a precursor to cancer, as no LOH was observed, this assay does not provide a genetic marker that may be considered a positive predictor of tumorigenesis in BRCA2 carriers. (Homo sapiens) PubMed
1234.
Invasive tubal carcinoma and TIC were limited to BRCA-mutation carriers, whereas hyperplasia and minor epithelial atypia were commonly found in both BRCA-mutation carriers and controls. (Homo sapiens) PubMed
1235.
BRCA2 mutation is associated with breast and ovarian cancer. (Homo sapiens) PubMed
1236.
Article presents a comprehensive review of the relevant literature on the role of BRCAness in ovarian cancer with respect to BRCA function. (Homo sapiens) PubMed
1237.
Studies across multiple ethnicities demonstrate that BRCA1 and BRCA2 mutations not only increase the risk of prostate cancer, but also predispose patients to early onset of potentially lethal disease. (Review) (Homo sapiens) PubMed
1238.
It is concluded that a proportion of patients with therapy related myeloid neoplasms carry cancer susceptibility mutations,including BRCA2 mutations, which is likely to contribute to therapy related leukaemogenesis. (Homo sapiens) PubMed
1239.
Human Rad51 paralogs facilitate BRCA2-Rad51-dependent homologous recombination at different stages in the pathway and function independently of Rad52. (Homo sapiens) PubMed
1240.
Single nucleotide polymorphisms in BRCA2 gene modify the association between occupational exposure to solvents and is associated with non-Hodgkin's lymphoma. (Homo sapiens) PubMed
1241.
IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers and breast cancer risk in BRCA1 class II mutation carriers. (Homo sapiens) PubMed
1242.
BRCA2 exon 7 splicing is regulated by multiple exonic elements and is sensitive to disease-associated sequence variations. (Homo sapiens) PubMed
investigation of the effect on splicing of BRCA2 variants c.8488-1G > A (exon 20) and c.9026_9030del (exon 23), and 41 BRCA2 variants reported in the Breast Cancer Information Core mutation database; a relevant proportion of BRCA2 variants are correlated with splicing disruptions (Homo sapiens) PubMed
1245.
Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families. (Homo sapiens) PubMed
1246.
Identification of a new mutation located deep into intron 12, c.6937+594T > G, which systematically activates splicing of a cryptic exon introducing a premature termination codon in the coding sequence. (Homo sapiens) PubMed
1247.
PARP inhibitor resistance correlated with the emergence of a secondary BRCA2 mutation in patients following an initial favorable response. (Homo sapiens) PubMed
1248.
Two BRC3 mutations (K1440R and K1440E), reported in human breast cancer patients, occur at amino acids corresponding to those of the K1435R mutation in dogs. These mutations affected the interaction of canine BRC3 with RAD51 (Homo sapiens) PubMed
1249.
Association of a BRCA2 mutation with inflammatory breast cancer with two members of the same family. (Homo sapiens) PubMed
1250.
Data show a substantial proportion of germ-line mutations in triple-negative breast cancer (TNBC), with a preponderance of BRCA1 mutations over mutations in BRCA2 or PALB2, but no evidence to implicate BRD7 mutations in the etiology of TNBC. (Homo sapiens) PubMed
1251.
three cis-acting BRCA2 polymorphisms that alter the binding of transcription factors at regulatory sites and could possibly affect the risk in mutation carriers through altering expression levels of the wild-type allele (Homo sapiens) PubMed
1252.
Our findings do not support the usefulness of X chromosome inactivation analysis for the identification of BRCA mutation carriers and cancer risk assessment. (Homo sapiens) PubMed
1253.
High frequency of BRCA2 founder mutations are associated with gastrointestinal and tongue neoplasias in breast cancer. (Homo sapiens) PubMed
1254.
BRCA1/2 mutation carriers exhibited no significant increase in proliferation in the fallopian tube epithelial cells either in the ampulla or fimbriated ends of the tube. (Homo sapiens) PubMed
1255.
BRCA mutations account for a substantial proportion of hereditary breast/ovarian cancer in Southern Chinese population. (Homo sapiens) PubMed
1256.
review of progress in understanding of BRCA1 and BRCA2 mutations in ovarian cancers and how these findings affect therapeutics; differing prognostic effects of BRCA2 and BRCA1 mutations is likely due to differing roles of BRCA1 and BRCA2 in homologous recombination repair and stronger association between the BRCA2 mutation and hypermutator phenotype (Homo sapiens) PubMed
1257.
for women with invasive ovarian cancer, the short-term survival advantage of carrying a BRCA1 or BRCA2 mutation does not lead to a long-term survival benefit (Homo sapiens) PubMed
1258.
Evidence based on spontaneous chromosome abnormalities and epidemiologic data indicates strong effects from exogenous mutagens and does not support the inevitability of cancer in all BRCA1/2 mutation carriers. (Homo sapiens) PubMed
1259.
This follow-up study suggests that, contrary to our initial report, this variant is not associated with breast cancer risk among individuals with germline BRCA2 mutations. (Homo sapiens) PubMed
1260.
Data indicate that younger patients with BRCA1 and BRCA2 (BRCA1/2)-mutated ovarian cancers (BMOC) (<53 years) appeared to have a poorer progression-free-survival compared with patients with BMOC who were older at the point of commencing paclitaxel. (Homo sapiens) PubMed
1261.
In TNBC cells that PI3K inhibition leads to DNA damage, downregulation of BRCA1/2, gain in poly-ADP-ribosylation, and subsequent sensitization to PARP inhibition. (Homo sapiens) PubMed
1262.
Combined SEER database and retrospective study data analysis of lifetime risk of developing ductal carcinoma in situ and BRCA1 and BRCA2 carrier status. (Homo sapiens) PubMed
1263.
This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers (Homo sapiens) PubMed
1264.
BRCA2 mutation status did not appear to correlate with a distinct clinicopathological phenotype or disease behaviour, and a strong trend was seen suggesting a possible BRCA2 male breast cancer phenotype. (Homo sapiens) PubMed
1265.
review summarizes the recent findings on the epidemiology of BRCA1/2 mutations among ovarian carcinoma patients in various geographical areas with special reference to racial/ethnic groups and the common founder mutations (Homo sapiens) PubMed
1266.
Older age, absence of a strong family history, and poor survival are all associated with decreased clinical identification of inherited BRCA1/2 mutations in women with ovarian cancer. (Homo sapiens) PubMed
1267.
Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations. (Homo sapiens) PubMed
1268.
in a study of US Hispanics, deleterious BRCA mutations were detected in 189 of 746 clinic patients(124 BRCA1, 65 BRCA2); a significant proportion were large rearrangement mutations (Homo sapiens) PubMed
1269.
BRCA1/2 germ-line mutations confer a more aggressive prostate cancer phenotype with a higher probability of nodal involvement, distant metastasis and poor survival. (Homo sapiens) PubMed
1270.
Data indicate an increase of VEGF, HIF-1alpha expression and microvessel density (MVD) in BRCA1-2 carriers and BRCAX compared to the sporadic control group. (Homo sapiens) PubMed
1271.
Mean age at natural menopause is 48.8 years for BRCA1 carriers, 49.2 years for BRCA2 carriers, and 50.3 years for control subjects. (Homo sapiens) PubMed
1272.
the imbalance in expression of Aurora-A and BRCA2 regulates RAS-induced genomic instability and tumorigenesis (Homo sapiens) PubMed
1273.
found BRCA1/2 mutations in 15/103 probands. Among these, a BRCA2 gene mutation has not been described previously. In addition, we identified five novel BRCA2 variants (Homo sapiens) PubMed
1274.
data indicate that BRCA1 carriers diagnosed with MBC have worse outcomes compared to BRCA2 carriers and non-carriers. However, the differences in outcome did not reach statistical significance likely due to small sample sizes (Homo sapiens) PubMed
1275.
BRCA1 and BRCA2 germline mutation-related DCIS show a high frequency of overexpression of HIF-1alpha. (Homo sapiens) PubMed
1276.
Data indicate that interruption of ATR signaling strikingly further sensitized BRCA1- and BRCA2-deficient ovarian cancer cells to PARP inhibition. (Homo sapiens) PubMed
1277.
The SIR for BRCA1 carriers was 1.91 (95% CI: 1.06-3.19, p=0.03) and for BRCA2 carriers was 1.75 (95% CI: 0.55-4.23, p=0.2). (Homo sapiens) PubMed
1278.
study examined BRCA1/BRCA2 gene mutations/SNPs and BRCA1 haplotypes in early-onset breast cancer patients of Indian ethnicity; findings indicate a high incidence of BRCA1/BRCA2 gene mutations in the Indian patients (Homo sapiens) PubMed
1279.
Four BRCA2 mutations including three novel BRCA2 frameshift mutations and one previously known BRCA2 frameshift mutation and one BRCA1 splicing mutation were identified in a group of consecutive breast cancer patients. (Homo sapiens) PubMed
1280.
Germline BRCA1 and BRCA2 mutations were detected in 13% and 7% of the early-onset breast cancer Brazilian patients. (Homo sapiens) PubMed
1281.
Data suggest that if survival rates are based on tested patients, all of whom are alive at the time of testing, then the survival experience will be overestimated, both for women who test positive for BRCA1 or BRCA2 mutations and for non-carriers. (Homo sapiens) PubMed
1282.
findings support the hypothesis that the majority of non-BRCA1/BRCA2 breast cancer families might be explained by the action of moderate and/or low penetrance susceptibility alleles (Homo sapiens) PubMed
1283.
Genotypes of AIB1 polyglutamine polymorphism analyzed do not appear to be associated to a modified risk of breast cancer development in BRCA1 and BRCA2 mutation carriers. (Homo sapiens) PubMed
1284.
Eleven variants in BRCA1 and 8 in BRCA2, including 8 not previously characterized at transcript level, were ascertained to affect mRNA splicing (Homo sapiens) PubMed
1285.
Two new susceptibility loci. rs11571836 located in the BRCA2 3'-untranslated region. (Homo sapiens) PubMed
1286.
present the proof of principle of a NGS-based mutation screening procedure allowing the detection of inherited Alu insertions within any predefined sequence by investigating 2 cases: c.1739_1740insAlu in BRCA1 and c.156_157insAlu in BRCA2 (Homo sapiens) PubMed
1287.
BRCA2 mutation is associated with response to therapy in sporadic cancer. (Homo sapiens) PubMed
1288.
Heterogeneous nuclear ribonucleoprotein C is a key regulator of BRCA gene expression and homologous recombination-based DNA repair. (Homo sapiens) PubMed
1289.
Data indicate that the median levels of Ang-1, Ang-2 and VEGF mRNA were significantly higher in patients harboring BRCA1/2 germline mutations. (Homo sapiens) PubMed
1290.
provides evidence that tamoxifen use is associated with a reduction in contralateral breast cancer risk for BRCA1 and BRCA2 mutation carriers (Homo sapiens) PubMed
1291.
BRCA2 mutations confer a survival advantage compared with the BRCA1 mutation in BRCA-mutated epithelial ovarian cancer patients. (Homo sapiens) PubMed
1292.
Classified 88 missense VUS in BRCA1 and BRCA2 on the basis of an in silico analysis and compared the classification of a subset of 60 VUS of which additional information including family, genetic and tumour data was available. (Homo sapiens) PubMed
1293.
Results indicate that this workflow performed analysis of BRCA1 and BRCA2 genes point mutations with a specificity of 100% and a sensitivity >/=97.5%. (Homo sapiens) PubMed
1294.
in a sample of Black women with early onset breast cancer, study evaluated BRCA mutations; BRCA mutation prevalence and the high prevalence of variants of uncertain significance in participants are consistent with prior studies (Homo sapiens) PubMed
1295.
Deleterious BRCA2 mutation in women with ovarian cancer was an independent risk factor for carboplatin hypersensitivity reactions. (Homo sapiens) PubMed
1296.
Findings suggest treatment decisions and the clinical management for patients harbouring deleterious BRCA1/BRCA2 mutations. (Homo sapiens) PubMed
1297.
findings suggest a mechanism for the regulation of the nucleocytoplasmic distribution of BRCA2 and RAD51 and its impairment by a heterozygous disease-associated mutation (Homo sapiens) PubMed
1298.
All patients with BRCA1 and BRCA2 risk factors need large genomic rearrangement screening for breast cancer. (Homo sapiens) PubMed
1299.
Results suggest that increased production of E(2) may have a role in the pathogenesis of BRCA2-mutation-related breast cancer. (Homo sapiens) PubMed
1300.
simplified BRCA2 classifier based on the co-occurrence of Loss of heterozygosity at 13q13 and 14q32 could provide an indication to test for BRCA2 mutation in patients with ER-positive invasive ductal carcinomas. (Homo sapiens) PubMed
1301.
The idea that BRCA1/2 mutations have antagonistic pleiotropic effects (enhancing fertility while reducing survival) was supported in the natural fertility study. (Homo sapiens) PubMed
1302.
Our data confirm the previously reported highly skewed distribution of FMR1 genotypes and sub-genotypes toward a high preponderance of low FMR1 alleles in BRCA1/2 carriers. (Homo sapiens) PubMed
1303.
Carriers of BRCA1/BRCA2 mutations are exposed to higher titres of oestradiol and progesterone-known risk-factors for breast cancer. (Homo sapiens) PubMed
1304.
This study characterises the mutation, expression and methylation status of BRCA1/2 in 41 ovarian cancer cell lines. (Homo sapiens) PubMed
1305.
In BRCA2 mutation carriers there was significant association between overall breast cancer risk SNP score and age at breast cancer onset. (Homo sapiens) PubMed
1306.
Rare variants of uncertain significance affecting phosphorylation may be a novel and important mechanism for which BRCA1 and BRCA2 functions are disrupted in breast cancer. (Homo sapiens) PubMed
1307.
Breast tumors from BRCA1 and BRCA2 mutation carriers display characteristic RNA expression patterns. (Homo sapiens) PubMed
1308.
The parental mutation origin did not affect the risk in women with a BRCA2 mutation. (Homo sapiens) PubMed
1309.
found no evidence that BRCA1 and BRCA2 mutation carriers are at higher risk of natural menopause at a given age than their noncarrier relatives (Homo sapiens) PubMed
1310.
We detected 28 distinct pathogenic mutations (16 in BRCA1 and 12 in BRCA2), of which 3 mutations in BRCA1 and 5 in BRCA2 had not been previously described. (Homo sapiens) PubMed
1311.
A new common BRCA2 pathogenic mutation c.7235_7236insG was detected in Algerian and Moroccan families. [review] (Homo sapiens) PubMed
1312.
Association between BRCA2 mutation and SULT1A1 gene deletion in male breast cancer emerged. (Homo sapiens) PubMed
Studies suggest that associations between ever use of oral contraceptive (OC) and ovarian and breast cancer among women who are BRCA1 or BRCA2 mutation carriers are similar to those reported for the general population. (Homo sapiens) PubMed
1315.
BRCA2 homeostasis in prostate cancer cells has been found to be critical in determining cell fates during prostate cancer progression (Homo sapiens) PubMed
1316.
We show a high prevalence of BRCA1/2 mutations with LOH in an Ashkenazi Jewish cohort of surgically resected PDAC and neoplastic lesions, suggesting that these germline mutations are causal in selected individuals. (Homo sapiens) PubMed
1317.
BRCA1/2 mutation carriers seemed to be more at risk of neutropenia after the first cycle of the treatment in early breast cancer patients (Homo sapiens) PubMed
1318.
Studies indicate that germline mutations in BRCA1/2 and related genes, such as PALB2, are associated with pancreatic cancer. (Homo sapiens) PubMed
1319.
women who are positive for BRCA mutations and who are treated for stage I or II breast cancer with bilateral mastectomy are less likely to die from breast cancer than women who are treated with unilateral mastectomy. (Homo sapiens) PubMed
1320.
The goal of this study was to determine the prevalence of PALB2 mutations in a population of BRCA1/BRCA2 negative breast cancer patients selected from either a personal or family history of pancreatic cancer. (Homo sapiens) PubMed
1321.
Tumor size estimation using breast MRI in high risk patients is comparable to its performance in sporadic cancers. (Homo sapiens) PubMed
1322.
This article reviews current recommendations and limitations of using MR imaging of the breast to screen asymptomatic women at high risk for breast cancer. [review] (Homo sapiens) PubMed
1323.
Our results indicate that carriers of BRCA1/2 mutations among non-Caucasian breast cancer patients showed no enhancement in radiation sensitivity. (Homo sapiens) PubMed
1324.
p53 suppresses BRCA2-stimulated ATPase and strand exchange functions of human RAD51 to control homologous recombination. (Homo sapiens) PubMed
1325.
The imbalance of DSS1 over-expression associated with BRCA2 expression could affect breast cancer development. (Homo sapiens) PubMed
1326.
Breast cancer patients who carry the Icelandic founder BRCA2 mutation have inferior long-term survival than noncarriers, but the adverse prognosis is restricted to mutation carriers with diploid (Homo sapiens) PubMed
1327.
The BRCA2 gene was screened for mutations in well-characterized, Finnish, high-risk hereditary breast and/or ovarian cancer individuals. (Homo sapiens) PubMed
1328.
this study argues that tumor suppression by BRCA1 and BRCA2 originates from their fundamental role in controlling the assembly and activity of macromolecular complexes that monitor chromosome duplication, maintenance, and segregation across the cell cycle. (Homo sapiens) PubMed
1329.
Results show that age of onset in carriers of BRCA mutations is earlier than expected. Especially for BRCA1 (Homo sapiens) PubMed
1330.
genetic associations studies in populations of women in South Korea: Data suggests that consumption of soy foods is associated with lower breast cancer risk and this lower risk of breast cancer extends to subjects with BRCA1 and BRCA2 mutations. (Homo sapiens) PubMed
1331.
BRCA2 mutation is associated with triple-negative breast cancer. (Homo sapiens) PubMed
1332.
BRCA2 is cleaved into two fragments by membrane type-1 matrix metalloproteinase (MT1-MMP), and knockdown of MT1-MMP prevents the removal of BRCA2 from centrosomes during metaphase. (Homo sapiens) PubMed
1333.
A lack of association of the rs2910164:G>C single nucleotide polymorphism with breast cancer risk in a series of 1,166 BRCA1 and 560 BRCA2 mutation carriers, is reported. (Homo sapiens) PubMed
1334.
both BRCA1 and PALB2 are required for BRCA2-focus formation when the DBD is absent. (Homo sapiens) PubMed
Aim of this study was to determine types and frequencies of BRCA mutations in individuals from high-risk families from Serbia. (Homo sapiens) PubMed
1337.
PCAT-1 expression produces a functional deficiency in homologous recombination through its repression of the BRCA2 tumor suppressor. (Homo sapiens) PubMed
1338.
there is emerging evidence of relative resistance of tumors containing BRCA1 or BRCA2 mutations (or BRCAness) to taxanes. (Homo sapiens) PubMed
1339.
As 60%-80% of all advanced ovarian cancers are high-grade serous type, exhibiting HRD in at least 50% (BRCA1/2 mutations ) future antitumor strategies may depend on identifying these defects through molecular testing (Homo sapiens) PubMed
1340.
Our data demonstrate a wide variety of BRCA mutations in a highly ethnically diverse EOC population, and confirm that EOC BRCA mutation carriers have better prognosis with longer median survival than patients with nonhereditary disease. (Homo sapiens) PubMed
1341.
new insights into the mechanisms underlying genetic instability mediated by hypoxia and BRCA involvement in sporadic breast cancers. (Homo sapiens) PubMed
1342.
Pregnancy concurrent with or after a diagnosis of breast cancer does not appear to adversely affect survival among BRCA1/2 mutation carriers. (Homo sapiens) PubMed
1343.
Preventive oophorectomy was associated with an 80% reduction in the risk of ovarian, fallopian tube, or peritoneal cancer in BRCA1 or BRCA2 carriers and a 77% reduction in all-cause mortality. (Homo sapiens) PubMed
1344.
BRCA2 gene mutation is associated with breast and ovarian cancers. (Homo sapiens) PubMed
1345.
The first comprehensive analysis of large mutations in BRCA1 and BRCA2 genes in Poland, is reported. (Homo sapiens) PubMed
1346.
Recurrent BRCA2 gene mutation is associated with breast and ovarian cancers. (Homo sapiens) PubMed
1347.
The risk of finding a BRCA1/2 mutation in women 40 years or younger is comparable to women of all ages with epithelial ovarian cancer. (Homo sapiens) PubMed
1348.
BRCA2 accumulates DNA damage, which triggers checkpoint signalling and ARF activation (Homo sapiens) PubMed
1349.
the total mutation burden coupled with BRCA1 or BRCA2 mutations in ovarian cancer is a genomic marker of prognosis and predictor of treatment response. (Homo sapiens) PubMed
1350.
6 (BRCA1) and 8 (BRCA2) microsatellite markers in a multiplex PCR. (Homo sapiens) PubMed
1351.
the global spectrum of BRCA2 mutations in breast cancer (Review) (Homo sapiens) PubMed
1352.
Female brca2 mutation carriers born in 1958 or later were at a significantly higher risk of developing breast cancer at a younger age (p<0.001), while no such age cohort-dependent correlation was found for ovarian cancer. (Homo sapiens) PubMed
1353.
Data indicate that BRCA mutation status did not influence the generational difference in age at diagnosis . (Homo sapiens) PubMed
1354.
Studies may implicate the BRCA2 pathway in tumorigeneis. (Homo sapiens) PubMed
1355.
Loss-of-function mutations in PALB2 are an important cause of hereditary breast cancer. Our data suggest the breast-cancer risk for PALB2 mutation carriers may overlap with that for BRCA2 mutation carriers. (Homo sapiens) PubMed
1356.
TREX-2 complex prevents genome instability, as determined by the accumulation of gamma-H2AX and 53BP1 foci and single-cell electrophoresis in cells depleted of the TREX-2 subunits PCID2, GANP and DSS1 (Homo sapiens) PubMed
1357.
LUDLU-1 contains somatic mutations in TP53 and BRCA2, allelic imbalance in the expression of two cancer-associated BRCA1 germline polymorphisms and reduced transcription of a potentially endogenous PARP2 inhibitor. (Homo sapiens) PubMed
1358.
variations of the BRCA2may contribute to breast cancer susceptibility along with variations in other low penetrating genes in sporadic types of breast cancer in this cohort of the population (Homo sapiens) PubMed
these data support the hypothesis that the presence of BRCA mutations does not alter the clinical outcome for hereditary breast cancer patients. (Homo sapiens) PubMed
1362.
This finding indicates involvement of hereditary factors in non-BRCA1/2 breast cancer families. (Homo sapiens) PubMed
1363.
BRCA1 mutation carriers conferred lower overall breast and ovarian cancer risks than reported so far, while the estimates of BRCA2 mutations were among the lowest in a Dutch cohort. (Homo sapiens) PubMed
1364.
For some populations, the number of Fanconi anaemia-patients with biallelic BRCA2 disruption is smaller than that expected from the carrier frequency. [Review] (Homo sapiens) PubMed
1365.
The study identified one of seven founder mutations in BRCA1 and BRCA2 in 27% of breast cancer patients in the Bahamas. (Homo sapiens) PubMed
1366.
We demonstrate that circulating PE and EM are strongly and positively correlated with tissue-specific PE and EM measured in NAF and DLS among postmenopausal BRCA1/2 mutation carriers (Homo sapiens) PubMed
1367.
There was no evidence for association between developing breast/ prostate cancer or being a BRCA1 or BRCA2 mutation carrier and telomere length. (Homo sapiens) PubMed
1368.
BRCA2 mutation is asssociated with low response to chemotherapy in breast cancer. (Homo sapiens) PubMed
1369.
poor prognosis of young BRCA1/2 mutation carriers with breast cancer is mainly explained by the prevalent occurrence of negative prognostic factors rather than mutation status (Homo sapiens) PubMed
1370.
Studies suggest that in the majority of cases with BRCA1 and BRCA2 negative familial breast cancer the etiology is due to interactions of intermediate or low risk alleles with environmental and lifestyle factors. (Homo sapiens) PubMed
1371.
Noncarriers remain at risk in the prospective follow-up of women who tested negative for BRCA1/2. (Homo sapiens) PubMed
1372.
PALB2 and BRCA2, in addition to their functions in D loop formation, play crucial roles in the initiation of recombination-associated DNA synthesis by Poleta-mediated DNA repair. (Homo sapiens) PubMed
1373.
Genetic analysis revealed 32 different pathogenic germline BRCA1/2 mutations: 20 in the BRCA1 gene and 12 in the BRCA2 gene, including four different large genomic rearrangements in the BRCA1 gene. (Homo sapiens) PubMed
1374.
the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2 (Homo sapiens) PubMed
1375.
This pilot study evaluates the relation between carrying a BRCA1/2 mutation and fertility, using the level of anti-mullerian hormone (AMH), which has been previously shown to be an accurate marker of ovarian reserve and fertility potential. (Homo sapiens) PubMed
1376.
BRCA mutations in prostate cancer patients.[review] (Homo sapiens) PubMed
1377.
Exon 11 of BRCA2, an important genetic determinant for hereditary breast and ovarian cancers, was sequenced from diverse primate species including humans; found that this gene, like BRCA1, bears the surprising signature of positive selection. (Homo sapiens) PubMed
1378.
our study did not find association between the three most common BRCA1 & BRCA2 mutations and endometriosis (Homo sapiens) PubMed
1379.
BRCA2 germline mutation carrier has Ampulla of vater adenocarcinoma. (Homo sapiens) PubMed
1380.
The survival of men with screen-detected prostate cancer and a BRCA2 mutation is much poorer than expected. (Homo sapiens) PubMed
1381.
Five BRCA2 mutations and ten variants of unknown significance (VUS) were identified in familial and aggressive prostate cancer. (Homo sapiens) PubMed
1382.
BRCA2 mutation is associated with breast and ovarian cancer. (Homo sapiens) PubMed
1383.
May be associated with cancer risk in BRCA1/2 mutation carriers. (Homo sapiens) PubMed
1384.
three different cancer susceptibility and FA proteins function in a DNA repair pathway based upon the PALB2 WD40 domain binding to RAD51C and BRCA2. (Homo sapiens) PubMed
1385.
PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer. (Homo sapiens) PubMed
1386.
Data indicate that tumour suppressor RASSF1A triggers large tumor suppressor kinase 1 (LATS)-CDK2 interaction and restricts CDK2 kinase activity towards BRCA2. (Homo sapiens) PubMed
1387.
Germline mutations in two major genes, BRCA1 and BRCA2, may have an important influence on the predisposition and development of familial breast cancer. (Homo sapiens) PubMed
1388.
BRCA2 mutation is associated with response to chemotherapy in ovarian cancer. (Homo sapiens) PubMed
1389.
BRCA2 directly represses the expression of IFN-related genes (Homo sapiens) PubMed
1390.
This study used multifactorial likelihood analysis and/or bioinformatically-directed mRNA assays to assess pathogenicity of 19 BRCA1 or BRCA2 variants. (Homo sapiens) PubMed
1391.
BRCA2 exists as a dimer and that two oppositely oriented sets of RAD51 molecules bind the dimer RAD51 to facilitate rad51-mediated homologous-recombinational repair. (Homo sapiens) PubMed
1392.
Findings contribute significantly to the types of germline BRCA1/BRCA2 mutations and their biological effects in Turkish women. (Homo sapiens) PubMed
1393.
knockdown of BRCA2 using small interference RNA suppression increased the sensitivity to 5-FU of human oral cancer cell lines (Homo sapiens) PubMed
1394.
The negative interplay between Aur A/B and BRCA1/2 inversely controls the cell proliferation, cell cycle progression, cell multinuclearity, and tetraploidization to modulate tumorigenesis. (Homo sapiens) PubMed
1395.
The article summarizes the multiple functions for BRCA2 in the preservation of chromosome stability which explain its tumour suppressive function. [review] (Homo sapiens) PubMed
1396.
The distribution of FMR1 CGG repeat numbers in BRCA mutation carriers and non-carriers is similar in contrast to previous reports. (Homo sapiens) PubMed
1397.
conclude that contralateral risk-reducing mastectomy is associated with improved overall survival in BRCA1/2 mutation carriers with a history of primary breast cancer (Homo sapiens) PubMed
1398.
No association between FMR1 low genotypes and BRCA1/2 mutations in a cohort of 125 Ashkenazi women. (Homo sapiens) PubMed
1399.
Neither BRCA1 nor the BRCA2 studied variant show any significant association with the disease. (Homo sapiens) PubMed
1400.
Report show a Fanconi anemia family with a novel mutation in the splice donor site of intron 1 of BRCA2 leading to reduced expression of a transcript that lacks part of the 5'-UTR. (Homo sapiens) PubMed
1401.
BRCA1/2 mutation carriers are potentially at higher risk of cardiovascular diseases due to early surgical menopause, and cardiotoxic effects of adjuvant treatment for breast cancer. (Homo sapiens) PubMed
1402.
This work highlights the contribution of DNA, RNA, and in silico data to assess the pathogenicity of BRCA1/2 variants of uncertain significance, which, in turn, allows more accurate genetic counseling and clinical management of the families carrying them. (Homo sapiens) PubMed
1403.
In conclusion, our result shows that large genomic rearrangement in the BRCA1 and BRCA2 genes account for a very low proportion of BRCA mutations and does not seem like a major determinant of breast cancer susceptibility in Korean, breast cancer patients. (Homo sapiens) PubMed
1404.
Stratification of patients and controls based on gender revealed no association between rs1799943 of the BRCA2and the risk of CVD in either gender. (Homo sapiens) PubMed
1405.
depletion of genes within the ataxia telangiectasia and Rad3 related (ATR) and BRCA1/BRCA2 pathways, chromatin modification, and transcription-coupled repair reduced the synergy between mitomycin C and MLN4924 (Homo sapiens) PubMed
1406.
The study shows evidence of the modulation effect of BRCA mutation on the expression of microRNA-200c in Triple negative breast cancer progression. (Homo sapiens) PubMed
1407.
The observed rate of 3 of 5754 cases (0.052%) of head and neck cancers in BRCA-positive probands warrants further investigation into the nature of a possible linkage between germline BRCA mutations and salivary gland cancer. (Homo sapiens) PubMed
1408.
Tumor-associated inflammation density was the strongest predictor for recurrence-free survival in this series of BRCA1/2 breast cancer patients (Homo sapiens) PubMed
1409.
BRCA2 rs10492396 (AG vs. GG: adjusted hazard ratio (adjHR)=1.85, 95% confidence interval (CI)=1.16-2.95, P=0.010), rs206118 (CC vs. TT+TC: adjHR=2.44, 95% CI=1.27-4.67, P=0.007), rs3752447 and FANCA rs62068372 (Homo sapiens) PubMed
1410.
absence of BRCA/FMR1 correlations in women with ovarian cancers (Homo sapiens) PubMed
1411.
targeting relevant exons in BRCA1 and BRCA2 genes allows detection of a substantial percentage of mutations in the Tunisian population. (Homo sapiens) PubMed
1412.
Mutations were most frequent in BRCA1 and BRCA2, with 84 EOC cases (3.8%) carrying a BRCA1 mutation and 94 epithelial ovarian cancer cases (4.2%) carrying a BRCA2 mutation. (Homo sapiens) PubMed
1413.
CRCs may be part of the tumour spectrum associated with FANCD1/BRCA2 biallelic mutations and that the presence of such mutations should be considered in families with CRCs, even in the absence of cardinal features of FA. (Homo sapiens) PubMed
1414.
BRCA2 protein is modulator of anoikis sensitivity through an evolutionarily-conserved molecular mechanism involving regulation of reactive oxygen spessies production and/or detoxification by BRCA2 during PCD processes. (Homo sapiens) PubMed
1415.
Report roles BRCA1 status and tubual intraepithelial carcinoma on prognosis in women with high grade serous carcinoma. (Homo sapiens) PubMed
1416.
Intentions to undergo PND or PGD do not appear to change after disclosure of BRCA results. Additional counseling for patients who have undergone BRCA testing may be warranted to educate patients about available fertility preservation options. (Homo sapiens) PubMed
1417.
This review is aimed at exploring the current knowledge on epidemiological and molecular aspects of BRCA-associated (BRCA1 and BRCA2 ) Ovarian cancer predisposition (Homo sapiens) PubMed
1418.
The observed age difference may allow a greater understanding of mechanisms associated with the differences in cancer penetrance in BRCA1/2 mutation carriers, some of which may depend on paternal origin. (Homo sapiens) PubMed
1419.
The study found a robust association between a truncating BRCA2 variant and upper aerodigestive tract cancer risk. (Homo sapiens) PubMed
1420.
By sequencing, one BRCA2 LGR, the Portuguese founder mutation c.156_157insAluYa5. (Homo sapiens) PubMed
1421.
Study showed that large genomic rearrangements were found in 3.7% of the patients who had mutations in BRCA1 or BRCA2, and 7.5% of patients with mutations in BRCA1 only. (Homo sapiens) PubMed
1422.
Metastatic high-grade serous carcinomas with BRCA1 deficiency exhibit characteristic morphological features that appear more sensitive and specific for BRCA1 and BRCA2 mutations than two other morphologically based prediction systems (Homo sapiens) PubMed
1423.
results of this study suggest that homozygosity for the BRCA2 T(-1144) allele is associated with a longer disease-free interval in Chinese women with breast cancer (Homo sapiens) PubMed
1424.
BRCA2 mutation is not associated with nodal metastasis in breast cancer. (Homo sapiens) PubMed
1425.
Mutations in the BRCA2 gene is associated with breast and ovarian cancer. (Homo sapiens) PubMed
1426.
Breast and ovarian cancer risks varied by type and location of BRCA1/2 mutations. With appropriate validation, these data may have implications for risk assessment and cancer prevention decision making for carriers of BRCA1 and BRCA2 mutations. (Homo sapiens) PubMed
1427.
BRCA2 tumors were more likely to be ER and HER2 positive than other non-BRCA familial breast cancers. (Homo sapiens) PubMed
1428.
Our data provide initial evidence for a novel putative ovarian cancer cluster region in BRCA2 exons 13-14. (Homo sapiens) PubMed
1429.
Fertility treatments are not associated with an increased risk of invasive epithelial ovarian cancer in Jewish Israeli BRCA1/2 mutation carriers. (Homo sapiens) PubMed
1430.
A rare BRCA2 genetic variant, known as rs11571833 (K3326X), is strongly associated with squamous-cell cancers of the upper aerodigestive tract (UADT) (Homo sapiens) PubMed
1431.
BRCA2 mutation is associated with breast and ovarian cancer. (Homo sapiens) PubMed
1432.
BRCA2 mutation is associated with triple-negative breast cancer. (Homo sapiens) PubMed
1433.
Women with mutations in BRCA1 and BRCA2 have different risks of developing ovarian and breast cancer, depending on the nature of the mutations (Homo sapiens) PubMed
1434.
Localized correlated spectroscopy recorded significant changes in women with BRCA1 and BRCA2 gene mutations when compared with control subjects. If these changes are ultimately proven to be a premalignant stage, this method may prove useful in screening (Homo sapiens) PubMed
1435.
BRCA1 and BRCA2 contribute to a genetic predisposition for breast cancer. (Homo sapiens) PubMed
1436.
The Russian carriers of BRCA1, BRCA2 and CHEK2 germline mutations have genetic predisposition to breast, ovarian, and colorectal cancer. (Homo sapiens) PubMed
1437.
We hereby report two cases of male breast cancer with neurofibromatosis. (Homo sapiens) PubMed
1438.
Fresh insight into the mechanism by which the HMG20b-BRCA2 complex controls mitotic cell division, and implicate heterozygous HMG20b mutations affecting cytokinesis regulation in the genesis of human cancers (Homo sapiens) PubMed
1439.
TNBC is a strong predictor for the presence of a BRCA1 mutation in this population, but additional risk factors should also be evaluated to ascertain a 10 % or higher prior probability of BRCA1/2 mutation testing. (Homo sapiens) PubMed
1440.
BRCA2 facilitates Rad51 phosphorylation by Plk1, which promotes genome stability. (Homo sapiens) PubMed
1441.
Two cancer syndrome gene variants likely to affect native translation initiation were identified by clinical genetic testing: MLH1:c.1A>G p.(Met1?) and BRCA2:c.67+3A>G. (Homo sapiens) PubMed
1442.
FANCD1 plays a role in gemcitabine drug resistance in biliary tract cancer. (Homo sapiens) PubMed
1443.
Our analyses suggest that BRCA mutations(BRCA1 and BRCA2) are robust predictors of outcomes in both ovarian and breast cancers and these mutations should be taken into account when devising appropriate therapeutic strategies (Homo sapiens) PubMed
Twelve pathogenic mutations were detected (25%); three in BRCA1 (c.211dupA in four families, c.5266dupC in three families and c.1504_1508delTTAAA in one family) and two novel mutations in BRCA2 (c.1313dupT in two families and c.7654dupT in two families). (Homo sapiens) PubMed
genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy (Homo sapiens) PubMed
1448.
Non-founder mutations make up between 7.2 and 13.0 % of all BRCA1 and BRCA2 mutations in Ashkenazi Jews. A wide range of mutations are present, most of which are also seen in non-AJ individuals (Homo sapiens) PubMed
1449.
Mutations in BRCA1 and BRCA2 or another breast cancer gene occur in one in four African American breast cancer patients with early onset disease, family history of breast or ovarian cancer, or TNBC (Homo sapiens) PubMed
1450.
Identification of pathogenic BRCA2 variants resulting in alternative splicing. (Homo sapiens) PubMed
1451.
by targeting RPA and mimicking DNA, DSS1 functions with BRCA2 in a two-component homologous recombination mediator complex in genome maintenance and tumor suppression (Homo sapiens) PubMed
1452.
Germline mutations in DICER1 are rare or absent in familial breast cancer patients with BRCA1/BRCA2-negative familial breast cancers. (Homo sapiens) PubMed
1453.
Well-designed and large-scale studies are needed to substantiate the association between BRCA2 N372H polymorphism and cancer risk. (Homo sapiens) PubMed
1454.
Prospective breast cancer risks in women in the UK are high especially for BRCA2 families ascertained on the basis of high risk. (Homo sapiens) PubMed
1455.
The BRCA2 p.Asn3124Ile (BRCA2 c.9371A > T) variant is a rare mutation with a damaging effect on the BRCA2 protein that is strongly associated with familial breast and ovarian cancer risk, indicating its likely pathogenic nature and clinical relevance. (Homo sapiens) PubMed
1456.
analysis of effect of germline mutations in BRCA1 and BRCA2 on mortality in ovarian cancer patients; BRCA1/2 mutations are associated with better short-term survival, but this advantage decreases over time and, in BRCA1 carriers is eventually reversed (Homo sapiens) PubMed
1457.
The currently presented results validate the suggestion that all patients with FANCD1 should be tested for BRCA2 mutations irrespective of whether the family history meets the BRCA cancer criteria. (Homo sapiens) PubMed
1458.
acinar cell carcinomas show a distinct mutation pattern and often harbor somatic or germline mutations of BRCA2 and FAT genes. (Homo sapiens) PubMed
1459.
BRCA2 mutated intraductal carcinoma of the prostate is common in patients with familial prostate cancer and is associated with poor outcomes. (Homo sapiens) PubMed
1460.
FANCJ and BRCA2 share FANCD2's role in replication fork restart. (Homo sapiens) PubMed
1461.
BRCA2 gene mutations are associated with breast cancer. (Homo sapiens) PubMed
1462.
a causative link between altered function of AURKA-HMMR-TPX2-TUBG1 and breast carcinogenesis in BRCA1/2 mutation carriers (Homo sapiens) PubMed
1463.
Study shows that Jewish BRCA1/2 mutation carriers are at an increased risk for breast and pancreatic, but not prostate cancer. (Homo sapiens) PubMed
1464.
conclude that the woman has two potential disease-causing mutations and that predictive testing of family members should include both the RAD51C and BRCA2 mutation (Homo sapiens) PubMed
1465.
A model designed to yield optimal intervention strategies including prophylactic surgeries and breast screening for BRCA1/2 mutations carriers is presented. (Homo sapiens) PubMed
1466.
Data indicate that three microRNAs hsa-miR-146a, hsa-miR-148a and hsa-miR-545 targeting BRCA1/2 and were associated with overall survival and progression-free survival in patients with wild-type BRCA1/2. (Homo sapiens) PubMed
1467.
Mutations in BRCA2 gene is associated with breast cancer. (Homo sapiens) PubMed
1468.
differences in associations of common breast cancer susceptibility alleles between BRCA1 and BRCA2 carriers and the general population are explained to a large extent by differences in the prevalence of ER-positive and ER-negative tumors (Homo sapiens) PubMed
1469.
Our results demonstrate in a subset of cases that decline in BRCA1 expression that may be associated with potentially compensatory increase in BRCA2 protein, which may depend on tumor grade as well as menopausal status. (Homo sapiens) PubMed
1470.
Pathogenic BRCA1/2 mutations were identified in 4.6% of a large cohort of clinic-based pancreatic adenocarcinoma patients. (Homo sapiens) PubMed
1471.
FBN1 acts downstream of Aur A and BRCA2, promoting ovarian cancer metastasis through p53 and SLUG-associated signaling. (Homo sapiens) PubMed
1472.
From an analysis of the mutation spectrum, 63 BRCA1 and 90 BRCA2 different mutations, including 44 novel mutations, were identified.BRCA mutations in familial breast cancer patients is similar to that among Western cohorts (Homo sapiens) PubMed
1473.
Two novel heterozygous mutations predicted to alter the function of PALB2 were identified (c.2014G>C, p.E672Q and c.2993G>A, p.G998E). Notably, both of these mutations co-existed in BRCA1 and BRCA2 families (Homo sapiens) PubMed
1474.
our findings demonstrate that among young Black breast cancer survivors, socioeconomic factors and physician referral patterns contribute to disparities in access to BRCA testing(BRCA1 and BRCA2 mutation detection) (Homo sapiens) PubMed
1475.
analysis of novel A1/2 mutations in Polish patients with familial breast/ovarian cancer (Homo sapiens) PubMed
1476.
this work gives the first evidence of a BRCA2 germline pathogenic mutation associated with CRC risk. (Homo sapiens) PubMed
1477.
BRCA1 gene mutation is associated with gynecologic cancer. (Homo sapiens) PubMed
1478.
BRCA2 gene mutation is associated with breast cancer. (Homo sapiens) PubMed
1479.
By binding and destabilizing a histone acetyltransferase, p300, beta-HPV 5 and 8 E6 reduce the enrichment of the transcription factor at the promoter of two genes critical to the homology dependent repair of DSBs (BRCA1 and BRCA2) (Homo sapiens) PubMed
1480.
study identified a BRCA1 or BRCA2 germline mutation in 74 of 774 (9.6 %) triple-negative breast cancer patients; mutation prevalence was 9.3 % in Australia and was 9.9 % in Poland (Homo sapiens) PubMed
1481.
BRCA2 mutation carriers demonstrated normal ovarian response in IVF cycles. (Homo sapiens) PubMed
1482.
Taking into account modifier factors, location of mutation might be important for the clinical management of BRCA1/2 mutation carriers. (Homo sapiens) PubMed
1483.
BRCA mutations that survive selection pressure seem to provide significant fertility advantages. (Homo sapiens) PubMed
1484.
In response to replication stress, BRCA2 recruits RAD51 onto nascent DNA at stalled forks, protecting nascent DNA from nucleolitic cleavage. (Homo sapiens) PubMed
The K3326X variant of BRCA2 is associated with risk of developing breast and ovarian cancers independent of other pathogenic variants in BRCA2. (Homo sapiens) PubMed
1487.
Data suggest that the Fanconi anemia group F protein/BRCA1/2 proteins pathway may be a new target to reverse adriamycin (ADR) resistance in leukemia treatment. (Homo sapiens) PubMed
1488.
the analysis of studies to date that have evaluated the risk of BRCA1 and BRCA2 mutations for colorectal cancer (Review) (Homo sapiens) PubMed
1489.
Men carrying genetic mutations in the BRCA gene( BRCA1 and BRCA2) have a greater risk than the general population of developing certain types of cancer, including breast, pancreatic, and prostate cancer. (Homo sapiens) PubMed
1490.
BRCA2 mutation carriers are not associated with worse breast cancer prognosis. (Homo sapiens) PubMed
1491.
Comparison of male breast cancer tumors with female breast cancer tumors demonstrates that male breast cancer tumors arise more frequently from BRCA2 mutations and less frequently from BRCA1 mutations than female breast cancer tumors. (Homo sapiens) PubMed
1492.
Did not observe a significant decline in mortality associated with oophorectomy in breast cancer patients with BRCA2 mutations. b (Homo sapiens) PubMed
1493.
The deletion c.1792delA, in exon 10, and the duplication c.5869dupA, in exon 11 of BRCA2 are novel mutations in Spanish breast cancer patients. (Homo sapiens) PubMed
1494.
IGF1 level is significantly lower in cancer-free BRCA mutation carriers versus BRCA-negative controls, and there is a potential association between estradiol and IGF1 in cancer-free BRCA mutation carriers (Homo sapiens) PubMed
1495.
Prostate cancer patients with germline BRCA mutations had worse outcomes than noncarriers when conventionally treated with surgery or radiation therapy. (Homo sapiens) PubMed
1496.
the N372H polymorphism is associated with susceptibility of ovarian cancer (Meta-Analysis) (Homo sapiens) PubMed
1497.
BRCA2 polymorphisms show no detectable endometriosis risk in Indian population. (Homo sapiens) PubMed
1498.
BRCA2 mutation carriers are at risk for multiple cancers, including contralateral breast cancer (Homo sapiens) PubMed
1499.
A prevalence rate of 5.6% for having deleterious BRCA1 or BRCA2 mutations among Lebanese Arab women with breast cancer (Homo sapiens) PubMed
1500.
Mutation profile of the BRCA1/2 genes in breast cancer Bulgarian patients show 13 disease causing mutations with 4 new. Mutations in BRCA1 gene were found in 14% and in BRCA2, in 5.5% of the cases. The inherited predisposition was identified in 19.5%. (Homo sapiens) PubMed
1501.
Mutation in the BRCA2 gene is associated with Breast and/or Ovarian Cancers. (Homo sapiens) PubMed
1502.
the prevalence of BRCA1 and BRCA2 mutations is high in triple-negative breast cancer patients and BRCA1/2 mutations are not restricted to young women or patients with a positive family history. (Homo sapiens) PubMed
BRCA2 gene mutation is associated with breast cancer. (Homo sapiens) PubMed
1505.
BRCA2 mutation is associated with breast and ovarian Neoplasms. (Homo sapiens) PubMed
1506.
Using human and murine cells defective in FANCD2 or FANCA and primary bone marrow cells derived from FANCD2 deficient mice, we show that the FA pathway removes R loops and that many DNA breaks accumulated in FA cells are R loop-dependent. (Homo sapiens) PubMed
1507.
Germ-line DNA samples from 727 unrelated probands with positive family history (521 met criteria for familial pancreatic cancer) were tested for mutations in BRCA1 and BRCA2, PALB2, and CDKN2A. (Homo sapiens) PubMed
In this unselected Japanese population, approximately 13% of the cases with ovarian cancer appeared to be associated with an inherited risk, BRCA1/2 mutation, regardless of a family history. (Homo sapiens) PubMed
1510.
BRCA1/BRCA2 mutation carriers experienced a sense of disorientation about the most appropriate way of dealing with genetic risk (Homo sapiens) PubMed
1511.
BRCA1-associated DCIS did not express ER, PR or HER2, while most BRCA2-associated DCIS did express ER and PR. BRCA1- as well as BRCA2-associated DCIS had expression of HER3 and C-MET (Homo sapiens) PubMed
Recognition of different invasion patterns of metastatic extrauterine high grade serous carcinoma with BRCA germline mutations has prognostic implications. (Homo sapiens) PubMed
1514.
The aim of this study was to determine the frequency and spectrum of germline mutations in BRCA1, BRCA2 and PALB2 and to evaluate the presence of the CHEK2 c.1100delC allele in these patients. (Homo sapiens) PubMed
BRCA2 mutation is associated with breast and ovarian cancers. (Homo sapiens) PubMed
1517.
Results show that XPG partners with BRCA1 and BRCA2 to maintain genomic stability through homologous recombination, and its loss causes DNA breaks, chromosome aberrations, and replication fork stalling. (Homo sapiens) PubMed
1518.
Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations (Homo sapiens) PubMed
1519.
Treatment for infertility does not significantly increase the risk of ovarian cancer among women with a BRCA2 mutation. (Homo sapiens) PubMed
1520.
DNA from 120 subjects was used to sequence the entirety of BRCA1 and BRCA2 coding regions and splice sites, and validate pathogenic mutations, with a total material cost of $85/subject. Subjects ranged in age from 23 to 81 years (Homo sapiens) PubMed
1521.
BRCA2 Arg372His polymorphism is not associated with ovarian cancer risk. (Homo sapiens) PubMed
1522.
The strongest predictors are the BRCA2 mutations, and the highly penetrant G84E mutation in HOXB13 (Homo sapiens) PubMed
1523.
BRCA2 mutation is associated with Korean ovarian cancer. (Homo sapiens) PubMed
1524.
Risk assessment for healthy BRCA2 mutation carriers should consider the ages of breast cancers diagnosed in first-degree relatives (Homo sapiens) PubMed
1525.
In this cohort of BRCA1/2-associated breast cancer (BC) patients, no association between radiotherapy for primary BC and risk of (BC) contralateral breast cancer was observed in the total group, nor in the patients irradiated before the age of 40 years (Homo sapiens) PubMed
1526.
BRCA2 protein expression at the cell membrane and lack of C-terminal expression in the cytoplasm were associated with a reduced risk of rapidly fatal prostate cancer (Homo sapiens) PubMed
1527.
BRCA2 mutation is associated with breast and ovarian cancer. (Homo sapiens) PubMed
1528.
BRCA2-mutated prostate cancer patients have an adverse prognosis and poor outcome compared to non-mutated. (Homo sapiens) PubMed
1529.
BRCA2 mutation is associated with invasive breast cancer. (Homo sapiens) PubMed
BRCA2 single nucleotide polymorphism is associated with ontralateral breast cancer. (Homo sapiens) PubMed
1532.
The BRCA2 rs11571833, an A > T transversion in the final exon is the risk allele for the development of a familial breast cancer. (Homo sapiens) PubMed
1533.
BRCA2 germ-line mutation is associated with neoplasm recurrence in breast cancer patients. (Homo sapiens) PubMed
1534.
BRCA2 mutation is associated with familial breast and ovarian cancer syndrome. (Homo sapiens) PubMed
1535.
Studies indicate that each of the three neoplasm protein variants in BRCA1, BRCA2 and MSH2 would normally be reported as pathogenic based on widely accepted guidelines. (Homo sapiens) PubMed
1536.
BRCA2 protein stimulates DMC1-mediated DNA strand exchange between RPA-ssDNA complexes and duplex DNA, thus identifying BRCA2 as a mediator of DMC1 recombination function. (Homo sapiens) PubMed
1537.
There was no significant difference in disease-free survival between BRCA2 mutation carriers and patients with sporadic disease. (Review, meta-analysis) (Homo sapiens) PubMed
1538.
Studies suggest that the clinical management of cancer risk in breast cancer 1/2 proteins (BRCA1 and BRCA2) mutation carriers is complex and should consider patient preferences. (Homo sapiens) PubMed
1539.
Breast cancer risk for Korean women with germline mutations in BRCA2. (Homo sapiens) PubMed
1540.
BRCA1 and BRCA2 mutations accounted for a considerable proportion of hereditary breast/ovarian cancer patients from eastern China and the spectrum of the mutations of these two genes exhibited some unique features (Homo sapiens) PubMed
1541.
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-kappaB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers (Homo sapiens) PubMed
1542.
Hypermethylation and low Expression of BRCA2 is associated with Epithelial Ovarian Cancers (Homo sapiens) PubMed
BRCA1/2 male breast cancers display distinct pathologic characteristics compared with BRCA1/2 female breast cancers , and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (Homo sapiens) PubMed
1545.
Lung adenocarcinomas in both male and female patients were associated with (a) genotypic polymorphisms of FANCC and FANCD1. (Homo sapiens) PubMed
1546.
The RNA effect of 28 BRCA1 and BRCA2 VUS identified in our set of HBOCS families. (Homo sapiens) PubMed
Findings show eight distinct pathogenic mutations in eight unrelated families and suggest that BRCA1/2 mutations are responsible for a significant proportion of hereditary and sporadic breast cancer among Algerian young women. (Homo sapiens) PubMed
1549.
BRCA2 mutation is associated with Pancreatic Cancer. (Homo sapiens) PubMed
1550.
After miR-17-5p transfection, cell proliferation, migration, invasion and tumorigenesis in the osteosarcoma cells were significantly promoted. We further demonstrated that BRCC2 is a direct target of miR-17-5p. (Homo sapiens) PubMed
1551.
The study concluded that true HER2-amplified breast cancers are rare amongst BRCA1 mutation carriers and are less common in BRCA2 than background rates (Homo sapiens) PubMed
1552.
The rs144848 mutation of BRCA2 may have a protective effect against lung cancer among women (Homo sapiens) PubMed
1553.
study to estimate the carrier frequency of BRCA1 185delAG and BRCA2 6174delT mutations in eastern Indian breast cancer patients; findings suggest that these BRCA mutations may not have a strong recurrent effect on breast cancer among the eastern Indian populations (Homo sapiens) PubMed
1554.
Genomic profiling of the tumors showed specific alterations associated to BRCA1 or 2 mutation status, and BRCA1 expression in the tumors, affecting relevant cellular processes. Similar cellular functions were found affected in BRCA1 not expressing and BRCA1 or 2 mutated tumors. (Homo sapiens) PubMed
1555.
the current pathogenic mutation spectrum of the BRCA2 gene in patients with breast cancer in various Asian populations (review). (Homo sapiens) PubMed
1556.
There was no difference in overall response rate, progression-free survival and overall survival according to BRCA 1-2 status nor any association between single-nucleotide polymorphisms of genes involved in DNA repair and nucleotide excision repair machinery and response to trabectedin was reported. (Homo sapiens) PubMed
1557.
BRCA pathway germline mutation (in BRCA1, BRCA2 or BARD1 genes) was present in 10 of the 42 investigated triple-negative breast cancer patients rendering them susceptible to homologous recombination deficiency. (Homo sapiens) PubMed
1558.
Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas was studied. (Homo sapiens) PubMed
1559.
BRCA2 mutation is associated with pancreatico-biliary neoplasms. (Homo sapiens) PubMed
1560.
Data indicate that pathogenic mutations were found in 13/47 (28%) ovarian cancers: eight in BRCA1 and five in BRCA2 tumor suppressor proteins. (Homo sapiens) PubMed
1561.
BRCA2 mutation is associated with risk of breast and ovarian cancer. (Homo sapiens) PubMed
1562.
BRCA2 mutation is associated with perturbation in telomere biology resulting in breast cancer. (Homo sapiens) PubMed
1563.
BRCA2 mutations are associated with increased plasma levels of thrombo-coagulating-related proteins, which are independent to breast cancer development (Homo sapiens) PubMed
1564.
BRCA2 mutation is associated with Familial Pancreatic Cancer. (Homo sapiens) PubMed
1565.
Study provides evidence that the prevalence of BRCA1 and BRCA2 mutations is high in triple-negative breast cancer patients. (Homo sapiens) PubMed
1566.
Germline mutation in BRCA2 gene is associated with familial breast cancer. (Homo sapiens) PubMed
1567.
Data show that 11 breast cancer patients were mutated in BRCA1/2 genes, and 29 were not associated to BRCA1/2 mutations. (Homo sapiens) PubMed
1568.
BRCA2 mutations strongly increase the in vitro- and in vivo-sensitivity of cancer cells towards TRAIL-R-mediated apoptosis. (Homo sapiens) PubMed
1569.
For BRCA1 mutation carriers, cumulative estimates of developing cancer by age 70 vary by population, ranging from 40% to 85% for breast cancer and 10% to 59% for ovarian cancer. For BRCA2 mutation carriers, cumulative estimates of developing cancer are 45% to 57% for breast cancer and 11% to 18% for ovarian cancer. (Homo sapiens) PubMed
1570.
Germline mutations in BRCA2 are not associated with reduced ovarian reserve as measured by Anti-Mullerian hormone. (Homo sapiens) PubMed
1571.
the present systematic review collects and analyses the role of BRCA2 alterations to be used in early diagnosis of an inherited syndrome associated with familiar cancer and as a prognostic and predictive biomarker for the management of pancreatic cancer patients. (Homo sapiens) PubMed
1572.
No association between the thyroid hormones and breast cancer in BRCA1/2-mutation carriers was found (Homo sapiens) PubMed
Using Kaplan-Meier analysis, we assessed rates of BRCA testing over time. We found substantial differences in testing rates according to year of diagnosis; for example, only 35% of women who were age 40 years or younger when they received a breast cancer diagnosis in 2005 had undergone BRCA testing by 5 years after their surgical date (Homo sapiens) PubMed
1578.
that BRCA1/2 multicenter mutation testing is well feasible in formalin-fixed and paraffin-embedded tumor tissue (Homo sapiens) PubMed
1579.
The number of patients with uninformative BRCA genetic test(BRCA1 and BRCA2) results in this study is typical of reported high-risk screening populations. Next-generation sequencing has ushered in a new era of broad-spectrum testing for the growing list of potential genetic etiologies for breast cancer beyond BRCA (Homo sapiens) PubMed
1580.
Rates of BRCA1 and BRCA2 mutation testing are increasing in young women with breast cancer. Given that knowledge and concern about genetic risk influence surgical decisions and may affect systemic therapy trial eligibility, all young women with breast cancer should be counseled and offered genetic testing, consistent with the National Comprehensive Cancer Network guidelines. (Homo sapiens) PubMed
1581.
Association of BRCA2 single nucleotide polymorphisms with the breast cancer risk in the Bangladeshi population (Homo sapiens) PubMed
1582.
radiosensitization was at least partly due to the induction of apoptosis, which was only observed in the RKO cells and which may have been induced by BRCA2 degradation or different types of chromosomal aberrations. (Homo sapiens) PubMed
1583.
Reduction in BRCC2 expression induced by miR-603 was responsible for the enhanced colony formation and proliferative ability noted in the MG-63 and U2OS cells. (Homo sapiens) PubMed
1584.
Findings suggest that the miRNA-binding SNPs in BRCA1/BRCA2 and their interaction with reproductive factors might contribute to BC risk, and miR-627 might down-regulate BRCA2 expression in MCF-7 and MDA-MB-231 cells. (Homo sapiens) PubMed
1585.
These results suggested that LIMD1 is a novel BRCA2-interacting protein and is involved in the centrosome localization of BRCA2 and suppression of LIMD1, causing abnormal cell division in EC cells. (Homo sapiens) PubMed
1586.
soluble alpha-fetoprotein is a marker for Fanconi anemia; FANC proteins form multi-protein complexes with BRCA proteins and are involved in homologous DNA repair [review] (Homo sapiens) PubMed
1587.
BRCA2-truncated protein resulted from the frame shift mutation was found to lose two putative nuclear localization signals and a Rad51-binding motif in the extreme C-terminal region by bioinformatic prediction (Homo sapiens) PubMed
1588.
the primary goal of this study was to use multiplex PCR with morphological and immunohistochemical methods for the detection of BRCA mutation(BRCA1 or BRCA2), mtDNA 4977 deletion, and HPV genotyping in familial and nonfamilial breast cancers (Homo sapiens) PubMed
1589.
Implementing germline BRCA testing in all patients with ovarian cancer would be cost-effective in the United Kingdom. (Homo sapiens) PubMed
1590.
Five patients were identified with intragenic mutations predicted to restore BRCA1/2 open reading frames, including two patients with multiple independent reversion alleles. (Homo sapiens) PubMed
We recommend BRCA1/2 genetic testing to all Chinese women diagnosed with EOC to identify HBOC families, to provide genetic counseling and clinical management for at-risk relatives. Mutation carriers may also benefit from PARP-targeted therapies. (Homo sapiens) PubMed
1593.
results suggests that BRCA1 mutation carriers with breast cancer are more likely to have P53 overexpression compared with BRCA2 mutation carriers and non-carriers (Meta-analysis). (Homo sapiens) PubMed
1594.
We found an approximately approximately 3 fold increased rate of high RS among BRCA1 and 2 carriers with ER positive breast cancer (BC)compared with the general BC population. (Homo sapiens) PubMed
1595.
Data suggest that, similar to Caucasians, a significant proportion of Asian ovarian cancer was attributed to germline mutations in BRCA1 and to a lesser extent in BRCA2. (Homo sapiens) PubMed
1596.
uptake of risk-reducing salpingo-oophorectomy among BRCA1/2 mutation carriers who were counseled at our Family Cancer Clinic is extremely high (Homo sapiens) PubMed
1597.
BRCA1 and BRCA2 pathogenic mutations and their prediction have been characterized in the Italian breast and ovarian cancer pedigrees using two genetic models. (Homo sapiens) PubMed
1598.
22 different BRCA2 uncertain significance were detected and p.M784V in BRCA2 was the most common uncertain significance. (Homo sapiens) PubMed
1599.
BRCA2 Mutations are associated with Aggressive Prostate Tumors. (Homo sapiens) PubMed
1600.
the purified RAD51 G151D protein directly and significantly enhances DNA strand exchange activity in the presence of RPA. In concordance with this result, co-incubation of G151D with BRCA2 resulted in a much higher level of strand-exchange activity compared to WT RAD51. Strikingly, the RAD51 G151D variant confers resistance to multiple DNA damaging agents, including ionizing radiation, mitomycin C, and doxorubicin. (Homo sapiens) PubMed
1601.
The Single-molecule molecular inversion probes (smMIP)-based genetic testing enables automated and reliable analysis of the coding sequences of BRCA2. (Homo sapiens) PubMed
1602.
we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 and Trp53 heterozygosity . (Homo sapiens) PubMed
1603.
BRCA2 mutation is associated with pancreatic cancer. (Homo sapiens) PubMed
1604.
Studies indicate almost 20% of women with high-grade serous ovarian cancer are now recognized to harbour a germ line BRCA mutation, and of these, >40% might not have a family history of cancer and would not have received BRCA1 and BRCA2 testing. (Homo sapiens) PubMed
1605.
Structure-activity relationship of the peptide binding-motif mediating the BRCA2:RAD51 protein-protein interaction, is reported. (Homo sapiens) PubMed
1606.
Data show that there are large differences in the absolute cancer risks between breast cancer 1, early onset protein (BRCA1) and breast cancer 2, early onset protein (BRCA2) mutation carriers with higher vs lower values of the polygenic risk scores (PRS). (Homo sapiens) PubMed
1607.
Study suggests an increased risk of leukaemia in women with a BRCA2 mutation who receive chemotherapy for breast cancer. (Homo sapiens) PubMed
1608.
By monitoring DNA double-strand breaks mis-repair using a sensitive bioassay, it was found that depletion of homologous recombination proteins, including BRCA2, BRCA1 or RPA1, resulted in a distinct mutational signature associated with significant increases in break-induced mutation frequencies. (Homo sapiens) PubMed
1609.
BRCA1/2-associated EOC patients with a previous BC have a worse outcome. (Homo sapiens) PubMed
1610.
BRCA2 mutation carriers are at increased risk developing insulin resistance and type-II diabetes mellitus; have an altered expression of circulating proteins associated with venous thrombo-embolism (Review) (Homo sapiens) PubMed
1611.
BRCA2 reversion mutation is associated with resistance to PARP inhibitor-based therapy in a pancreatic ductal adenocarcinoma. (Homo sapiens) PubMed
1612.
Results indicate that aberrant splicing is especially prevalent in breast cancer 2 protein (BRCA2) exons 17 and 18. (Homo sapiens) PubMed
1613.
These results suggest that cytoplasmic dynein 1 binds to BRCA2 through the latter's centrosomal localization signal and BRCA2 mediates the cohesion between centrosomes during the S phase, potentially serving as a cell-cycle checkpoint. (Homo sapiens) PubMed
1614.
We studied effect of food on ABT-767 bioavailability in subjects with advanced BRCA1 or BRCA2 mutated solid tumors or high grade serous ovarian, primary peritoneal or fallopian tube cancer (Homo sapiens) PubMed
1615.
ubiquitination of RAD51 hinders RAD51-BRCA2 interaction, while deubiquitination of RAD51 facilitates RAD51-BRCA2 binding and RAD51 recruitment and thus is critical for proper homologous recombination (Homo sapiens) PubMed
1616.
This is the largest study in Cyprus evaluating the prevalence and spectrum of BRCA1/2 mutations. Thirteen percent of the patients tested were positive for deleterious mutations which are within the range reported in other countries (Homo sapiens) PubMed
1617.
Our aim was to set up a cost-effective and low time-consuming BRCA1-BRCA2 mutation detection workflow using the Ion Torrent PGM technology. A retrospective cohort of 40 patients with familial breast/ovarian cancer previously tested by Sanger sequencing and a prospective cohort of 72 patients (validation set) were analyzed. (Homo sapiens) PubMed
1618.
ER-expression appears to be an effect modifier in patients with BRCA1 mutations, but not among those with BRCA2 mutations (Homo sapiens) PubMed
1619.
Study reports that exposure to naturally occurring concentrations of formaldehyde or acetaldehyde selectively unmasks genomic instability in cells heterozygous for multiple, clinically relevant, truncating BRCA2 mutations. (Homo sapiens) PubMed
1620.
BRCA2 mutation carriers one region, up to 45 kb upstream of BNC2, and containing 100 correlated SNPs was identified as candidate causal (Homo sapiens) PubMed
1621.
In this study, Multiplex ligation-dependent probe amplification (MLPA) assay was used for detection of large rearrangements of BRCA1 and BRCA2 genes in 36 unrelated high-risk breast/ovarian cancer patients negative for BRCA1/2 point mutations. Overall BRCA1/2 LGRs prevalence among high-risk Tunisian patients was 5.5%. (Homo sapiens) PubMed
1622.
In this review, BRCA2 mutation carriers are more likely to have poor risk of prostate cancer and exhibit worse outcomes. (Homo sapiens) PubMed
1623.
Germline mutation in BRCA2 gene is associated with melanoma. (Homo sapiens) PubMed
1624.
Embryos carrying paternally inherited BRCA1 or 2 pathogenic variants were shown to develop more slowly compared with the embryos with maternally inherited BRCA1 or 2 pathogenic mutations. (Homo sapiens) PubMed
1625.
One rare variant in BRCA2 3'UTR was identified in 716 breast cancer cases and 619 controls. Identified variant gives no convincing evidence of potential pathogenicity. (Homo sapiens) PubMed
1626.
Data suggest that modulation of histone deacetylase (HAT) activity by an SNP in BRCA2 (breast cancer type 2 susceptibility protein; rs144848, 1342A>C, N372H) is a plausible mechanism of paclitaxel resistance in breast cancer; after HAT inhibitor treatment, HAT activity, and paclitaxel sensitivity is restored in heterozygous BRCA2 variant breast cancer cells. (Homo sapiens) PubMed
1627.
we generated a Brca2 knock-in mouse model lacking exons 4-7 and demonstrated that these exons are dispensable for viability as well as tumor-free survival. This study provides the first in vivo evidence of the functional significance of a minor transcript of BRCA2 that can play a major role in the survival of humans who are homozygous for a clearly pathogenic mutation. (Homo sapiens) PubMed
1628.
Data suggest that RAD51, BRCA2, and BRCA1 promote stability of nascent DNA at replication forks; RAD51 prevents MRE11 nuclease-mediated degradation of nascent ssDNA; BRCA2 displaces RPA (replication protein A) complex by recruiting RAD51 to protect ssDNA; BRCA1 promotes repair foci following DNA damage and is essential for cell survival. (BRCA = breast cancer recombination protein; RAD51 = Rad51 recombinase) [REVIEW] (Homo sapiens) PubMed
1629.
radiosensitization was evaluated using the glioblastoma cell line, U87MG-E6, which harbors inactivated p53, in comparison with the cell line, HCT116 p53 (-/-). We conclude that radiosensitization by arsenite is related to ROS and BRCA2 function. (Homo sapiens) PubMed
1630.
study demonstrates that the individual and combined expression patterns of the DDR molecules PARP1, gammaH2AX, BRCA1, and BRCA2 could be predictive of the prognosis of STS patients and suggests that controlling the activity of these DDR molecules could be employed in new therapeutic stratagems for the treatment of STS (Homo sapiens) PubMed
1631.
data from our systematic review and meta-analysis suggests a causal relationship between germline BRCA1/2-pathogenic mutations and the development of Uterine serous carcinoma. (Homo sapiens) PubMed
1632.
A patient with an ampulla of Vater carcinoma was incidentally found to carry the BRCA2 c.156_157insAlu mutation. Further testing of a consecutive series of additional 15 ampullary carcinomas for BRCA1/BRCA2 mutations using a combination of direct founder mutation testing and full gene analysis with next generation sequencing. BRCA2 mutations were observed with a frequency of 14.3% in ampulla of Vater carcinomas. (Homo sapiens) PubMed
1633.
Being a male BRCA1 or a BRCA2 mutation carrier or even being clinically defined as having high cancer risk with no known BRCA mutation in men is not associated with any clinically significant risk for developing this rare entity. (Homo sapiens) PubMed
1634.
This study detected monoallelic L1053X mutation causing the same stop codon in BRCA2 protein sequence at the same position in four Sudanese female breast cancer patients out of nine from different families. (Homo sapiens) PubMed
1635.
polygenic risk scores may provide informative cancer risk stratification for male carriers of BRCA1/2 mutations that might enable these men and their physicians to make informed decisions on the type and timing of breast and prostate cancer risk management. (Homo sapiens) PubMed
1636.
cyclin D1 and other cyclins such as cyclin A regulates DNA integrity through RAD51 interaction with the BRCA2 C-terminal domain (Homo sapiens) PubMed
1637.
Even if a BRCA2 mutation is already identified within a family, the presence of early onset breast cancer affected non-carriers hampers accurate risk estimates for both mutation carriers and other negative family members. (Homo sapiens) PubMed
1638.
These findings suggest that R2787H variant of BRCA2 could have potential functional impact. (Homo sapiens) PubMed
1639.
Studies suggest that people with high risk of breast cancer and negative BRCA1/BRCA2 should be tested for PALB2 mutations. (Homo sapiens) PubMed
1640.
This study shows that BRCA mutation carriers could be frequently identified among breast cancer patients with multiple risk factors. Importantly, we established an NGS-based pipeline for BRCA1/2 testing in clinical practice and strongly suggest that breast cancer patients of premier- and moderate-grade risks receive BRCA1/2 mutations testing in China (Homo sapiens) PubMed
1641.
Architectural plasticity of human BRCA2-RPA-RAD51 complexes in DNA break repair has been described. (Homo sapiens) PubMed
1642.
Study showed that the prevalence of BRCA1/2 germline mutations was 19% in epithelial ovarian cancer, mostly detected in different gene locations. Two novel frameshift mutations were identified, one in BRCA1 and one in BRCA2, as well as two large deletions. (Homo sapiens) PubMed
1643.
Sixteen VUS from 51 BRCA1 variants of uncertain significance (VUS) carriers and 28 VUS from 62 BRCA2 VUS carriers were analyzed. There was a slight agreement between the two analyses, with a kappa value of 0.14 (95% confidence interval (CI) = -0.34 to 0.62) for the BRCA1 VUS and a kappa value of 0.17 (95% CI = -0.10 to 0.49) for the BRCA2 VUS (Homo sapiens) PubMed
1644.
Women with BRCA1/2 mutations show at diagnosis higher peritoneal tumor load and increased frequency of bulky lymph nodes compared to patients without germline BRCA mutations. Primary debulking surgery seems to ensure a longer progression-free survival in women with BRCA wild type genotype compared to neoadjuvant chemotherapy. (Homo sapiens) PubMed
1645.
This study implicates novel risk loci as well as highlights the clinical utility for retesting BRCA1/2 negative ovarian cancer patients by genomic sequencing and analysis of genes in relevant pathways. (Homo sapiens) PubMed
1646.
These results reveal a synthetic lethal relationship between FANCD2 and BRCA1/2. (Homo sapiens) PubMed
1647.
BRCA2 c.68-7T>A pathogenic mutation from Norwegian breast or ovarian cancer cohort (Homo sapiens) PubMed
1648.
BRCA2 germline mutation is associated with triple-negative breast cancer. (Homo sapiens) PubMed
1649.
Founder mutations in BRCA2 contribute to an increased risk of ovarian and breast cancer in the western Danish population. (Homo sapiens) PubMed
1650.
WTIP interacts with BRCA2 and might be responsible for BRCA2 centrosome localization in cervical cancer cell. (Homo sapiens) PubMed
1651.
Evidence does not support routine risk-reducing hysterectomy for BRCA1 and BRCA2 mutation carriers. (Homo sapiens) PubMed
1652.
observations indicate that nascent DNA degradation in BRCA1/2-deficient cells occurs as a consequence of MRE11-dependent nucleolytic processing of reversed forks generated by fork remodelers (Homo sapiens) PubMed
1653.
The overall BRCA1/2 mutation prevalence was 24.0% (95% CI 23.4% to 24.6%). (Homo sapiens) PubMed
1654.
Although no founder mutations were identified in this study, two recurrent mutations, BRCA1 (c.3607C>T) and BRCA2 (c.5164_5165 delAG), were found (Homo sapiens) PubMed
1655.
Pre-test genetic counselling prior to BRCA1/2 testing. (Homo sapiens) PubMed
1656.
have confirmed previous reports of an association between breast, ovarian, and pancreatic cancers with BRCA1 and 2 mutations (Homo sapiens) PubMed
Patients with Fanconi anemia have higher incidences of ectopic neurohypophysis, adenohypophysis hypoplasia, platybasia and other midline central nervous system skull base posterior fossa abnormalities than age- and sex-matched controls. Patients with posterior fossa abnormalities, including pontocerebellar hypoplasia, are more likely to have biallelic BRCA2 mutations. (Homo sapiens) PubMed
1659.
Results show the overall prevalence of BRCA1/2 mutations at 3.9 % in the current large cohort of Chinese women with breast cancer, which is comparable with previous findings. Also, 41 % of the BRCA1/2 mutations detected have not been previously reported, suggesting that these mutations could be specific for Chinese women. (Homo sapiens) PubMed
1660.
We demonstrated an association between six previously published single nucleotide polymorphisms (rs15869 [ BRCA2], rs1805389 [ LIG4], rs8079544 [ TP53], rs25489 [ XRCC1], rs1673041 [ POLD1], and rs11615 [ ERCC1]) and subsequent CNS tumors in survivors of childhood cancer treated by radiation therapy. (Homo sapiens) PubMed
1661.
The heterogeneity of the detected mutations confirms the necessity of simultaneous analysis of BRCA1/2 genes in all patients diagnosed with serous ovarian carcinoma. Moreover, the use of tumor tissue for mutational analysis allowed the detection of both somatic and germline BRCA1/2 mutations. (Homo sapiens) PubMed
1662.
Study have shown that mutations in BRCA1, BRCA2, and PALB2 account for more than 10 % of breast cancer in Trinidad and Tobago. 25 different mutations identified; of these, four mutations were seen in two patients each. (Homo sapiens) PubMed
1663.
polygenic risk scores (PRS) may be used to refine risk assessment for women at increased familial risk who test negative/have low likelihood of BRCA1/2 mutations. They may alter the recommended prevention strategy for many women attending family history clinics. (Homo sapiens) PubMed
1664.
We performed the genotyping of the polymorphisms BRCA1/P871L and BRCA1/Q356R by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, and of variant allele BRCA2/N372H through direct sequencing. (Homo sapiens) PubMed
1665.
This is the largest study of comprehensive BRCA testing(BRCA1 and BRCA2) among Brazilians to date. Several criteria that are not included in the NCCN achieved a higher predictive value. Identification of the most informative criteria for each population will assist in the development of a rational approach to genetic testing (Homo sapiens) PubMed
1666.
we saw no increased risk of cardiotoxicity among breast cancer patients with BRCA1 and/or BRCA2 gene mutations treated with standard doses of anthracycline compared to the general population. (Homo sapiens) PubMed
1667.
Data suggest that locus-specific LOH may be a clinically useful biomarker to predict primary resistance to DNA damaging agents in patients with germline BRCA1 and BRCA2 mutations. (Homo sapiens) PubMed
1668.
Germline BRCA1/2 gene mutations could result in genomic instability and an elevated gene mutation rate (such as the p53 gene) in breast luminal cells compared with the general population, predisposing BRCA carriers to develop p53-positive/triple-negative breast carcinomas. (Homo sapiens) PubMed
1669.
Our results provide novel insights regarding the physician-patient interaction and the organizational aspects of the health-care system that may significantly impact the cancer screening practices of BRCA1/2 noncarriers. (Homo sapiens) PubMed
1670.
Anticancer activity was observed in BC and OC and in gBRCAm (BRCA1 or BRCA2)and gBRCA wild-type (gBRCAwt) patient. BKM120 and olaparib can be co-administered, but the combination requires attenuation of the BKM120 dose. Clinical benefit was observed in both gBRCAm and gBRCAwt pts. (Homo sapiens) PubMed
1671.
Data show that mammary epithelial cells are inviable upon BRCA2 loss, which leads to replication stress associated with under replication, causing mitotic abnormalities and G1 arrest. (Homo sapiens) PubMed
1672.
Data show that BRCA2 was required for HDAC2/3 association with acetylated BubR1 in nocodazole (Noc)-arrested cells. (Homo sapiens) PubMed
1673.
Durable responses to olaparib were observed in patients with relapsed germline BRCA1/2 mutation ovarian cancer who had received >/=3 lines of prior chemotherapy (Homo sapiens) PubMed
1674.
In a population without strong germline founder mutations, the likelihood of a BRCA1/2 mutation found in a breast carcinoma being somatic was approximately 1/3 and germline 2/3. This may have implications for treatment and genetic counseling (Homo sapiens) PubMed
1675.
Increasing evidence on the molecular role of the BRCA2 protein in the homologous recombination of DNA damages suggest that BRCA2-related PDAC are sensitive to agents causing DNA cross-linking damage, such as platinum salts, and treatments targeting rescue DNA repair pathways, such as poly(ADP-ribose) polymerase inhibitors that are currently under investigation.[ review] (Homo sapiens) PubMed
1676.
The current model places BRCA2 as a central regulator of genome stability by repairing DNA double strand breaks and limiting replication stress. [review] (Homo sapiens) PubMed
1677.
three patients had biallelic inactivation of BRCA2, a tumor suppressor gene critical for homologous DNA repair. two had germline BRCA2 mutations. The third patient had somatic BRCA2 homozygous copy loss. Biallelic BRCA2 inactivation in Metastatic Castration-resistant Prostate Cancer warrants further exploration as a predictive biomarker for sensitivity to platinum c (Homo sapiens) PubMed
1678.
In this review, we will discuss the emerging importance of somatic and epigenetic alterations of BRCA- and BRCA-related genes(BRCA1 and BRCA2 ) in the management of ovarian cancer. (Homo sapiens) PubMed
1679.
Of note is the recent U.S. Food and Drug Administration breakthrough therapy designation of olaparib for the treatment of BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer. The implications of this new knowledge for clinical practice now and in the future are discussed. (Homo sapiens) PubMed
1680.
BRCA1/2 mutation carriers who have been treated with PS have a substantially reduced breast cancer incidence and mortality. (Homo sapiens) PubMed
1681.
we show that this combined approach allows the rapid and reliable detection of both germline and somatic aberrations affecting BRCA1 and BRCA2 in DNA derived from FFPE OCs, enabling improved hereditary cancer risk assessment and clinical treatment of ovarian cancer patients. (Homo sapiens) PubMed
1682.
In the very high-risk Bladder Cancer patients , several genes had a higher frequency of mutations than reported in the The Cancer Genome Atlas database, including BRCA2 . Mutation associations with receipt of neoadjuvant chemotherapy, nodal involvement, metastatic disease development, and survival were analyzed. (Homo sapiens) PubMed
1683.
IMPACT data were consistent with increased risks of onset among BRCA1 and BRCA2 mutation carriers (Homo sapiens) PubMed
1684.
High BRCA2 expression is associated with drug resistance in ovarian cancer. (Homo sapiens) PubMed
1685.
Patientswith BRCA1/2 mutation had longer OS than thosewith BRCA1/2wild type. Patients with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses. (Homo sapiens) PubMed
1686.
We present two cases of black South African patients with FA diagnosed with biallelic BRCA2 mutations and discuss the phenotypic consequences and implications for them and their families (Homo sapiens) PubMed
1687.
Prevalence of pathogenic and likely pathogenic variants in the hotspots regions of BRCA2 was 23 and 6.3 % respectively in this cohort (Homo sapiens) PubMed
1688.
We examined the intratumor variability of BRCA1/2 mutation, BRCA1 promoter methylation status, and the overall HRD score in small samples from different areas of the same cancer. We observed highly concordant HRD scores across different regions of the same cancer suggesting that HRD, when present, is a homogeneous feature of primary breast cancers (Homo sapiens) PubMed
1689.
miR-151-5p, targeting chromatin remodeler SMARCA5, may act as a useful biomarker for BRCA-related and sporadic breast cancers. (Homo sapiens) PubMed
1690.
Risk-reducing bilateral salpingo-oophorectomy is currently the most effective method for reducing the risk of ovarian cancer in BRCA mutation (BRCA1 and BRCA2) carriers. (Homo sapiens) PubMed
1691.
Breast cancers in BRCA1 mutation carriers are associated with more aggressive tumor characteristics compared to BRCA2 and are less well seen on mammography. Mammography rarely identified cancers not visible on MRI. Thus, the omission of mammography in BRCA1 mutation carriers screened with MRI can be considered. (Homo sapiens) PubMed
1692.
In patients with ovarian cancer, BRCA mutation, irrespective of its subtypes (BRCA1/2, BRCA1 and BRCA2) carriers had better overall survival and progression-free survival than non-carriers.[meta-analysis] (Homo sapiens) PubMed
1693.
BRCA1/2 mutations are common in Taiwanese patients with ovarian carcinoma and occur at mutation rates similar to those seen in other ethnic groups. (Homo sapiens) PubMed
1694.
No association was found between genetic ancestry and BRCA1/2 mutational status in a Brazilian population sample at-risk for hereditary breast cancer. (Homo sapiens) PubMed
1695.
BRCA1 and BRCA2 mutations were associated with poor OS in patients with breast cancer. (Homo sapiens) PubMed
1696.
Report reliable detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples. (Homo sapiens) PubMed
1697.
BRCA1/2 mutations were associated with improved overall survival (OS) and progression-free survival (PFS), but the improved OS was only seen in patients with primary and recurrent ovarian cancer, not in those with advanced state disease. When examined separately, BRCA1 mutations remained significantly associated with improved OS, but not PFS, and BRCA2 mutations alone were not associated with either improved OS or PFS. (Homo sapiens) PubMed
1698.
BRCA1 or BRCA2 overexpression is a significant predictive factor for biochemical recurrence (BCR), in prostate cancer (PC) patients. (Homo sapiens) PubMed
1699.
Women at high familial risk and BRCA1/2 mutation carries develop tumors with different clinical-pathological characteristics and, consequently, are influenced by different protective and risk factors. (Homo sapiens) PubMed
1700.
Data indicate a significant inverse relationship between plasma osteoprotegerin (OPG) levels and breast cancer risk among women with an inherited BRCA1 or BRCA2 mutation. (Homo sapiens) PubMed
1701.
Patients with BRCA2 mutation were almost 25 times more likely to have chronic pancreatitis-like changes compared with sex-matched controls. (Homo sapiens) PubMed
1702.
The present data in this small cohort of 68 mutation carriers suggest that smoking and low physical activity during adolescence are risk factors for developing breast cancer in women with BRCA1 or BRCA2 mutation. (Homo sapiens) PubMed
1703.
Data indicate that c.1310_1313delAAGA mutation of BRCA2 gene is recurrent with high frequency in patients from the North-East region of Morocco. (Homo sapiens) PubMed
1704.
The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system was employed to target and correct a FANCD1 gene deletion. The study shows the ability to correct a patient mutation in primary FANCD1 cells in a precise manner. (Homo sapiens) PubMed
1705.
Results show that amplification of targetable oncogenes is frequent in BRCA1/2 mutation negative MBCs and may identify MBC subsets characterized by aggressive phenotype that may benefit from potential targeted therapeutic approaches. (Homo sapiens) PubMed
1706.
The diagnostic value of BRCA promoter methylation analysis in distinguishing BRCA1/2-related and sporadic breast carcinomas is considerably dependent on the targeted CpG sites. These findings are important for adequate use of BRCA methylation analysis as a prescreening tool for germline genetic testing (Homo sapiens) PubMed
1707.
Clinical outcomes between placebo- and olaparib-treated patients with somatic BRCA1/2 mutations were similar to those with germline BRCA1/2 mutations, indicating that patients with somatic BRCA1/2 mutations benefit from treatment with olaparib. (Homo sapiens) PubMed
1708.
This report summarizes the results of BRCA testing in South-Eastern Norway according to these revised Norwegian guidelines from 1st of January 2014 to 31st of August 2015 -it was to calculate the prevalence of BRCA mutations in this cohort of breast cancer (BC)patients that as a whole had an a priori low risk of being mutation carriers anddescribe the spectrum of mutations (Homo sapiens) PubMed
1709.
This meta-analysis showed that a BRCA2 mutation predicted poor survival outcomes in patients with prostate cancer, especially in those undergoing treatments with radiotherapy. Therefore, the use of BRCA2 mutation as a clinical prognostic factor could help stratify the high-risk patients and provide clinical strategies for more effective targeted treatments for patients with prostate cancer. (Homo sapiens) PubMed
1710.
IGH/MYC-positive Burkitt lymphoma/leukemia cells have decreased BRCA2 and are sensitive to PARP1 inhibition alone or in combination with other chemotherapies. This study postulates that IGH/MYC-induced BRCA2 deficiency may predispose Burkitt lymphoma cells to synthetic lethality triggered by PARP1 inhibitors. (Homo sapiens) PubMed
1711.
BRCA1- and BRCA2- (BRCA)-associated tumors respond to both platinum compounds and PARP inhibitors (PARPi). Potential synergism for carboplatin and the PARPi veliparib was demonstrated in preclinical studies. In a companion phase II trial, veliparib was demonstrated to be active as a single agent in both BRCA1- and BRCA2-associated MBC patients (Homo sapiens) PubMed
1712.
Rucaparib was tolerable and had activity in patients with platinum-sensitive germline BRCA1/2-mutated high-grade ovarian carcinoma (Homo sapiens) PubMed
1713.
In the olaparib LT group, 244 genetic alterations were detected, with TP53, BRCA1, and BRCA2 mutations being most common (90%, 25%, and 35%, respectively). BRCA2 mutations were enriched among the LT responders. BRCA methylation was not associated with response duration. High myriad HRD score (>42) and/or BRCA1/2 mutation was associated with LT response to olaparib (Homo sapiens) PubMed
1714.
These data demonstrate the added benefit of combining Topo I inhibition mediated by IMMU-132 with synthetic lethality provided by PARPi in triple-negative breast cancer, regardless of BRCA1/2 status, thus supporting the rationale for such a combination clinically (Homo sapiens) PubMed
1715.
In this study, we evaluated this novel mechanism of drug resistance in newly diagnosed, early-stage BRCA1/2-mutant breast cancer patients who had a poor response to platinum-based neoadjuvant chemotherapy. (Homo sapiens) PubMed
1716.
Results show frequent BRCA2, EGFR, and NTRK1/2/3 mutations in mismatch repair-deficient colorectal cancers , sugggesting personalized medicine strategies to treat the patients with advanced disease who may have no remaining treatment options. (Homo sapiens) PubMed
1717.
role of BRCA2 splicing for acquired chemo-resistance in BRCA2 mutation associated malignancy (Homo sapiens) PubMed
1718.
Tumours arising in BRCA2 mutation carriers showed significantly higher methylation of candidate genes, than those arising in non-BRCA2 familial MBCs (average AMI 23.6 vs 16.6, p = 0.01, 45% of genes hypermethylated vs 34%, p < 0.01). (Homo sapiens) PubMed
1719.
Inactivation of homologous recombination factors BRCA1, BRCA2, or RAD51 hypersensitizes cells to acetaldehyde treatment, in spite of the Fanconi anemia pathway being functional. (Homo sapiens) PubMed
1720.
BRCA2 rs144848 polymorphism is associated with cancer. (Homo sapiens) PubMed
1721.
The present study shows that the G allele carriers of BRCA2 rs9534275 were associated with increased serum total cholesterol and ApoB levels in the coronary artery disease patients and increased risk of coronary artery disease and ischemic stroke. (Homo sapiens) PubMed
1722.
Statistically significant correlations were identified between breast cancer and 3 not described previously single nucleotide polymorphisms of homologous recombination repair genes BRCA1 and BRCA2: rs59004709, rs4986852 and rs1799950. (Homo sapiens) PubMed
1723.
The work-flow represents a robust and easy-to-use method for full BRCA1/2 screening, which can be easily implemented in routine diagnostic testing and adapted to genes other than BRCA1/2. (Homo sapiens) PubMed
1724.
BRCA2 and CHEK2 play an important role in the genetic susceptibility to urinary tract cancers. (Homo sapiens) PubMed
1725.
We describe twenty-nine novel BRCA1 and BRCA2 variants detected in Italian individuals suffering from hereditary breast and ovarian cancer syndrome (HBOC). (Homo sapiens) PubMed
1726.
Results showed that BRCA2 is down-regulated in epithelial ovarian cancer by lncRNA RP11-552M11.4 which promotes cell proliferation, migration and invasion. (Homo sapiens) PubMed
1727.
In our EOBC cohort, a contralateral breast cancer was diagnosed in ~60% of BRCA1/2 carriers, but only in 8% of non-carriers. These findings show that BRCA1/2 mutations overwhelmingly lead to a contralateral disease when breast cancer is diagnosed at early age. (Homo sapiens) PubMed
1728.
Ovarian response to stimulation, expressed as the number of mature oocytes, was reduced in BRCA1 but not in BRCA2 mutation carriers. Although oocyte yield was in correspondence to a normal response in all subgroups, this finding points to a possible negative influence of the BRCA1 gene on ovarian reserve (Homo sapiens) PubMed
1729.
Results, including a comprehensive co-segregation analysis, indicate that the novel duplication identified has a pathogenic role and would be considered a causing-disease variant in genetic and oncologic counseling. (Homo sapiens) PubMed
1730.
These results will form the basis for a larger randomized trial (LIBRE-2) with an estimated sample size of 600 BRCA1 and BRCA2 mutation carriers aiming at improvement of BMI, aerobic and maximal exercise capacity and adherence to a Mediterranean diet (Homo sapiens) PubMed
1731.
BRCA2 mutation carriers showed earlier onset age of breast tumor and higher risk of developing contra lateral breast cancer in women from Murcia (south-eastern Spain). (Homo sapiens) PubMed
1732.
the physiological significance of GIPC3 as a genetic interactor of BRCA2 is supported by the observation that Brca2-null embryos with Gipc3 overexpression are developmentally more advanced than their control littermates. Taken together, we have uncovered a novel role for GIPC3 as a BRCA2 genetic interactor. (Homo sapiens) PubMed
1733.
chimerism in breast/ovarian cancers in BRCA non-carriers from BRCA-positive families (Homo sapiens) PubMed
1734.
No evidence for a an association between the genotype at BRCA2 c.6937 + 594T>G and breast cancer risk. (Homo sapiens) PubMed
1735.
Putative BRCA1/2 reversion mutations can be detected by cfDNA sequencing analysis in patients with ovarian and breast cancer. Our findings warrant further investigation of cfDNA sequencing to identify putative BRCA1/2 reversion mutations and to aid the selection of patients for PARP inhibition therapy (Homo sapiens) PubMed
1736.
this study identifies the importance of TDP1 as a novel determinant of response to CNDAC across various cancer types (especially non-small cell lung cancers), and demonstrates the differential involvement of BRCA2, PARP1, and TDP1 in the cellular responses to CNDAC, AraC, and CPT (Homo sapiens) PubMed
1737.
Carboplatin and talazoparib showed efficacy in DNA damage mutation carriers, but hematologic toxicity was more pronounced in gBRCA(gBRCA1/2) carriers. Carboplatin is best combined with intermittent talazoparib dosing differentiated by germline and somatic DNA damage mutation carriers (Homo sapiens) PubMed
1738.
BRCA methylation is rare in breast and ovarian carcinomas of BRCA germline mutation carriers, although the frequency of BRCA promoter methylation may be underestimated. This could have major implications for clinical practice, including referral for genetic testing and BRCAness analysis for treatment decision-making. (Homo sapiens) PubMed
1739.
patient-derived xenografts capture the molecular and phenotypic heterogeneity of triple-negative breast cancer . Here we show that PARP inhibition can have activity beyond germline BRCA1/2 altered tumors, causing regression in a variety of molecular subtypes. These models represent an opportunity for the discovery of rational combinations with targeted therapies and predictive biomarkers (Homo sapiens) PubMed
1740.
Overall, 65/648 (10%) study participants were BRCA1/2 mutation carriers. (Homo sapiens) PubMed
1741.
We demonstrate that homologous recombination deficiency (HRD)mutation signatures may offer clinically relevant information independently of BRCA1/2 mutation status and hope this work will guide the development of clinical trials (Homo sapiens) PubMed
1742.
Based on a cumulative risk of 0.55% to age 35 for BRCA1 mutation carriers and of 0.56% to age 45 for BRCA2 mutation carriers, we recommend bilateral salpingo-oophorectomy before age 40, but by age 35, for women with a BRCA1 mutation and by age 45 for those with a BRCA2 mutation to maximize prevention and to minimize adverse effects. (Homo sapiens) PubMed
1743.
Pre-menopausal BRCA1/2 mutation carriers aged 30 to 47years chose screening, RRSO, or BS/DO. For those undergoing BS/DO, the delayed oophorectomy was recommended at age 40years for BRCA1 and age 45years for BRCA2 patients. (Homo sapiens) PubMed
1744.
In this study, we used comprehensive multigene panels that included 35 known or suspected cancer susceptibility genes to examine BRCA1/2 mutation-negative Korean patients who had clinical features indicative of hereditary breast cancer (Homo sapiens) PubMed
1745.
The results of Ion PGM with OTG-snpcaller, a pipeline based on Torrent mapping alignment program and Genome Analysis Toolkit, from 75 clinical samples and 14 reference DNA samples were compared with Sanger sequencing for BRCA1/BRCA2. (Homo sapiens) PubMed
1746.
BRCA2 SNP is associated with Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas. (Homo sapiens) PubMed
1747.
findings provided the evidence that gBRCA1/2 mutation was not associated with survival in Chinese EOC patients, which possibly attributed to more than 37% of the patients without gross residual disease. Survival benefit of gBRCA1/2 mutation was prominent in ovarian cancer patients with gross residual disease. (Homo sapiens) PubMed
1748.
male BRCA1/2 mutation carriers with breast and prostate cancer demonstrated a favorable 5-year survival. (Homo sapiens) PubMed
1749.
BRCA1/2 mutations are not uncommon among selected Jordanian females with breast cancer. (Homo sapiens) PubMed
BRCA2 germ line mutation is associated with ovarian cancer. (Homo sapiens) PubMed
1753.
BRCA2 germ line mutation is associated with unilateral triple-negative breast cancer. (Homo sapiens) PubMed
1754.
region in the N terminus exhibits DNA binding activity and promotes RAD51-mediated homologous recombination (Homo sapiens) PubMed
1755.
The authors propose that BRCA2 antagonizes 53BP1, RIF1, and Artemis-dependent c-nonhomologous end-joining and alt-nonhomologous end-joining to prevent gross genomic instability in a RAD51-independent manner. (Homo sapiens) PubMed
1756.
Letter: BRCA2- and ATM-mutated prostate cancer sensitive to high dose testosterone. (Homo sapiens) PubMed
1757.
We show a strong association between Triple Negative Breast Cancer and mutations in BRCA1/2 genes and the poor outcome of these patients. The survival curve analysis showed that the presence of AKT1, TP53, KDR, KIT, BRCA1 and BRCA2 mutations is correlated with a poor prognosis. (Homo sapiens) PubMed
1758.
Authors found that BRCA1/2 germline mutations in China exhibit distinct characteristics compared to those in Western populations. (Homo sapiens) PubMed
1759.
Germline mutations involving the Fanconi anemia pathway, such as BRCA2 are often implicated in Invasive Pancreatic Ductal Adenocarcinoma. (Homo sapiens) PubMed
1760.
The present study aimed to clarify the clinicopathological features, including the level of p53 protein expression and BRCA mutations, of primary fallopian tube cancer (PFTC) in Japanese women. (Homo sapiens) PubMed
1761.
Overall, 5152 oncogenetic tests were reviewed in the present study, of which 4452 had no a priori known familial mutation. The majority of participants (68.6%) were genotyped because of personal history of cancer; 20.6% were tested because of family history of cancer, and details for the remaining 10.7% were missing. Overall, 256/4452 (5.8%) carriers were detected, 141 BRCA1 and 115 BRCA2 mutation carriers. (Homo sapiens) PubMed
1762.
The present study demonstrates a clear protective effect of early first pregnancy on breast cancer risk in both BRCA1 and BRCA2 mutation carriers. (Homo sapiens) PubMed
1763.
Among BRCA mutation( BRCA1 or BRCA2) carriers, the mortality benefit of preventive mastectomy at age 25 is substantial, but the expected benefit declines rapidly with increasing age at surgery. (Homo sapiens) PubMed
1764.
Both BRCA1 and BRCA2 mutations are associated with an increased risk for Prostate cancer(PC). BRCA2 in particular confers a more aggressive PC phenotype with a higher probability of locally advanced and metastatic disease, and should be considered a prognostic marker associated with poorer survival (Homo sapiens) PubMed
1765.
Evidence has been provided that the majority of the Cas9-induced single nicks at the target DNA strand rely on RAD51 and BRCA2 for efficient and scar-less DNA repair. (Homo sapiens) PubMed
1766.
It has been shown that BRCA2-mutant prostate cancer cells harbor increased genomic instability and a mutational profile that more closely resembles metastatic than localized disease. (Homo sapiens) PubMed
1767.
Male carrying BRCA mutations have significantly lower QMAX than healthy men. BRCA1 patients have on average larger prostate glands and higher PSA than BRCA2 patients. (Homo sapiens) PubMed
1768.
Neither the patients tested nor the control subjects showed germline hypermethylation of the BRCA1 and BRCA2 promoter regions analyzed (Homo sapiens) PubMed
1769.
We conclude that BRCA1 and BRCA2 could be used as clinicopathological biomarkers to evaluate the prognosis of digestive system cancers. (Homo sapiens) PubMed
1770.
The total number of Ovarian Cancer patients captured was 802; of these, 53 and five families carry 22 mutations in BRCA1/2 genes. Of these, eight mutations were unique to the Arab populations, and five mutations were commonly circulated among Arabs (BRCA1: c.5266dupC, c.5095C>T, c.68_69delAG, and c.4041_4042delAG; BRCA 2 c.1310_1313delAAGA). (Homo sapiens) PubMed
1771.
The 2 identified likely pathogenic Unclassified variants in BRCA1 and BRCA2 require further verification with clinical evidence. (Homo sapiens) PubMed
1772.
The overall yield of comprehensive BRCA1/2 testing in ethnically diverse high-risk Israeli individuals is 3.3%. This is lower than expected by probability models. A slightly higher rate of BRCA1/2 carriers was seen among ovarian cancer cases. These data should guide BRCA1/2 optimal testing strategy in Israel. (Homo sapiens) PubMed
1773.
Study show that damage-induced long non-coding RNAs (dilncRNAs) play a role in DNA double-strand breaks (DSBs) repair by homologous recombination (HR) by contributing to the recruitment of the HR proteins BRCA1, BRCA2, and RAD51, without affecting DNA-end resection. BRCA2 directly interacts with RNase H2, mediates its localization to DSBs in the S/G2 cell-cycle phase, and controls DNA:RNA hybrid levels at DSBs. (Homo sapiens) PubMed
1774.
In 7657 consecutive unselected breast cancer patients without BRCA1/2 mutations. (Homo sapiens) PubMed
1775.
It is possible that mutant BRCA1/2 genes are associated with a reduction in ovarian reserve (review) (Homo sapiens) PubMed
1776.
Results identified a novel large BRCA2 deletion in 0.9% of the screened Colombian families in addition to 6310delGA and the recurrent 1991del4 mutations. Among unselected breast cancer cases, 1.1% tested positive for BRCA2/3034del4, and 0.4% for BRCA2/1991del4. (Homo sapiens) PubMed
1777.
our study provides novel data on ovarian BRCA1/2 mutation prevalence worldwide, enhances adequate patient selection for family counseling and prevention, and sheds light on the benefits of iPARP treatment. (Homo sapiens) PubMed
1778.
The study of BRCA1/2 gene in Southern Mediterranean countries revealed low penetrance recurrent mutations in sporadic and familial breast cancer. (Homo sapiens) PubMed
1779.
This study reports familial communication in a BRCA1/BRCA2 screening setting... This suggests that universal BRCA screening does not differentially affect communication or the use of familial genetic information (Homo sapiens) PubMed
1780.
association between family history (FH) of Breast cancer(BC) and ovarian cancer(OC) risks was slightly smaller in magnitude (HR: 0.85, 95% CI: 0.55-1.30; HR: 0.64, 95% CI: 0.34-1.21 for BC-only FH in BRCA1 and BRCA2, respectively; HR: 1.46, 95% CI: 0.80-2.68; HR: 1.49, 95% CI: 0.44-4.02 for OC-only FH in BRCA1 and BRCA2, respectively), indicating that mutation position explains only part of the association. (Homo sapiens) PubMed
1781.
This study provides a comprehensive view of known and novel BRCA1/2 mutations in breast cancer (BC)patients from the Republic of Macedonia and contributes to the global spectrum of BRCA1/2 mutations in breast cancer (Homo sapiens) PubMed
1782.
Our findings, using the largest gene panel for Male breast cancer (MBC) patients so far, indicate that BRCA testing (BRCA1 and BRCA2)should be the primary concern for MBC patients. (Homo sapiens) PubMed
1783.
The overall frequencies of the BRCA germline mutations (BRCA1 and BRCA2 )were 10.2% in breast and 30.7% in ovarian cancer patients. These data shed new light into the prevalence of BRCA mutations in the Arab women population. (Homo sapiens) PubMed
1784.
these results provide a significant insight into certain mutations and proteins involved in the interaction network of BRCA1 and BRCA2, which may have common roles in breast cancer and ovarian cancer. (Homo sapiens) PubMed
1785.
Among BRCA1/2 mutation wild-type patients, homologous recombination (HR) deficient(HRD) patients were more likely to achieve a pathologic complete response (OR 16, 95% CI 1.65-160.41, p = 0.0041) compared with HR non-deficient patients. Further, HRD scores were highly concordant pre- and post-therapy (Homo sapiens) PubMed
1786.
Eligible patients for this study were healthy women with >/= 17% lifetime risk of breast cancer or with a mutation in BRCA1 or BRCA2. A total of 632 women were screened between 2002 and 2012 (each for 6 years). During the study, 30 women were diagnosed with breast cancer, with 10 of these diagnoses occurring between screening visits, and six of the 10 diagnosed women were gene carriers (Homo sapiens) PubMed
1787.
BRCA1/2 mutation status leads to better responses to neoadjuvant chemotherapy in breast cancer. Pathological complete response is the main predictor of disease-free survival and overall survival, independently of BRCA1/2 mutation status. (Homo sapiens) PubMed
1788.
Neoadjuvant versus adjuvant with standard anthracycline- and taxane-containing regimens results in similar disease-free survival and overall survival among patients with stage I and II triple-negative breast cancer regardless of BRCA status (Homo sapiens) PubMed
1789.
Our findings indicate that in the Indian population, there is a high prevalence of mutations in the high-risk breast cancer genes: BRCA1, BRCA2, TP53, and PALB2. (Homo sapiens) PubMed
1790.
Identified two BRCA2 variants of unknown significance. (Homo sapiens) PubMed
1791.
The recalibrated algorithms and new metapredictors significantly improved upon current models for predicting the impact of variants in cancer risk-associated domains of BRCA1 and BRCA2. Prediction of the functional impact of all possible variants in BRCA1 and BRCA2 provides important information about the clinical relevance of variants in these genes. (Homo sapiens) PubMed
1792.
Despite calls for BRCA1/2 population screening, there remains a critical need to identify those most at risk who should receive cancer genetics services. B-RSTtrade mark version 3.0 demonstrates high sensitivity for BRCA1/2 mutations, yet remains a simple and quick screening tool for at-risk individuals. (Homo sapiens) PubMed
1793.
In adjusted analysis, age >/=80 years (odds ratio [OR] 0.10; P = 0.002), psychiatric disorders (OR 0.46; P = 0.006), occupation requiring at least 3 years of university or college education (OR 2.03; P = 0.003), and breast cancer or ovarian cancer in first-degree or second-degree relatives (OR 1.66; P = 0.02) were independently associated with uptake of BRCA1/2 testing. (Homo sapiens) PubMed
1794.
Applying established referral criteria for genetic testing in Serbia will help identify BRCA1/2 mutation carriers but will not help identify mutations in other cancer susceptibility genes. Until better predictors emerge we should be performing wider genetic testing of EOC in order to identify all mutation carriers. (Homo sapiens) PubMed
1795.
the study included all BRCA1/2 germline missense mutations identified in breast and ovarian cancer patients; the Asian population was the most affected by BRCA2 mutant patterns (Systematic Review) (Homo sapiens) PubMed
1796.
We identified a speculative association of germ-line BRCA1/2 alterations with brain metastases in pancreas ductal adenocarcinoma (Homo sapiens) PubMed
1797.
Prevalence of BRCA1/2 germline pathogenic (P) and likely pathogenic (LP) variants is slightly higher than previously described by the largest occidental studies, with a high prevalence of variant c.5266dupC (p.Gln1756Profs*74) in BRCA1 observed. Moreover, we identified a new LP variant. (Homo sapiens) PubMed
1798.
The prevalence of germline BRCA1/2 mutations in patients with peritoneal carcinoma or fallopian tube carcinoma is comparable to that of BRCA1/2 mutations in epithelial ovarian cancer patients. (Homo sapiens) PubMed
1799.
RAD51 can dissociate the very D-loops they create if in stoichiometric excess. BRCA2 regulates HR at a post-synaptic stage by modulating RAD51-mediated D-loop dissociation. Provides a biochemical mechanistic underpinning of homeostasis between RAD51 and BRCA2 previously reported in cellular experiments. (Homo sapiens) PubMed
1800.
BRCA1/2 mutation prevalence in unselected breast cancer patients was 1.8%. (Homo sapiens) PubMed
1801.
These findings might be exploited to assess the relevance for cancer risk of other BRCA2 spliceogenic variants. (Homo sapiens) PubMed
1802.
Our results did not provide evidence for elevated risks of invasivebreast cancer (BC) or epithelial ovarian cancer in BRCA1/BRCA2 predictive test negatives (Homo sapiens) PubMed
1803.
Study shows that BRCA1, PALB2 and BRCA2 can all play a significant role in both checkpoint activation and checkpoint maintenance, depending on cell type and context, and that PALB2 links BRCA1 and BRCA2 in the checkpoint response. The BRCA1-PALB2 interaction can be important for checkpoint activation, whereas PALB2-BRCA2 complex appears to be more critical for checkpoint maintenance. (Homo sapiens) PubMed
1804.
This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. (Homo sapiens) PubMed
1805.
These results suggest a modest association between BRCA1 and BRCA2 and Nonsyndromic cleft lip with or without cleft palate. (Homo sapiens) PubMed
1806.
homologous recombination deficiency (HRD), tumor BRCA1/2 mutations, and absence of CCNE1 amplification are associated with improved survival of ovarian cancer patients treated with platinum monotherapy and HRD-positive patients may benefit from platinum dose intensification. (Homo sapiens) PubMed
1807.
BRCA carriers with and without malignancy exhibit comparable ovarian reserve and responses to ovarian stimulation compared with women with BRCA-negative cancers and cancer-free controls. (Homo sapiens) PubMed
1808.
Different mechanisms inactivating the wild type allele are present within the same tumor sample at various extents. Results indicate that BRCA1/2-linked breast and ovarian cancer cells are predominantly characterized by LOH, but harbor a complex combination of second hits at various frequencies. (Homo sapiens) PubMed
1809.
14 had pathogenic variants in the BRCA1 gene and 5 had pathogenic variants in the BRCA2 gene (Homo sapiens) PubMed
1810.
BRCA2 expression is highly sensitive to promoter variations as most of them induced relevant changes. Moreover, we mapped critical regions of the BRCA2 promoter that may constitute potential targets for regulatory variants. (Homo sapiens) PubMed
1811.
Identified APEX2 and FEN1 as synthetic lethal genes with both BRCA1 and BRCA2 loss of function in tumor cell lines. (Homo sapiens) PubMed
1812.
Assessment of the clinical relevance of BRCA2 missense variants by functional and computational approaches has been presented. (Homo sapiens) PubMed
1813.
Carriers of BRCA1/BRCA2 mutation with sporadic Pancreatic Ductal Adenocarcinoma had a worse survival after pancreatectomy than their BRCA wild-type counterparts. However, platinum-based chemotherapy regimens were associated with markedly improved survival in patients with BRCA1/BRCA2 mutations, with survival differences no longer appreciated with wild-type patients. (Homo sapiens) PubMed
1814.
Among Korean women with the BRCA1/2 mutation, the location of the mutations may influence the risk of breast and ovarian cancers according to the putative functional domain regions (Homo sapiens) PubMed
1815.
The BRCA2 is the most prevalent type mutation among hereditary breast and/or ovarian cancer patients in the Arab region, with an estimated prevalence was 17% with a higher pooled prevalence of BRCA mutations in the Levant Region 28%. When compared with studies from different parts of the world the Arab world appear to have different profiles with varying BRCA frequencies.[meta-analysis] (Homo sapiens) PubMed
1816.
Among ovarian cancer patients, BRCA2 carriers with mutations located in the RAD51-BD (exon 11) have prolonged PFS, PFI, and OS. (Homo sapiens) PubMed
1817.
Knowing a patient's BRCA mutation status is important for prevention and treatment decision-making. Improving the characterization of mutations will lead to better management, treatment, and BCa prevention efforts in African Americans who are disproportionately affected with aggressive BCa and may inform future precision medicine genomic-based clinical studies. (Homo sapiens) PubMed
1818.
oursplicing analysis performed in three independent carriers show thatBRCA2c.7976+5G>T alleles produce a major in-frame transcript Delta17 predicted to encode a non-functional protein, and that even though variable proportions of additional transcripts (Delta16-18, Delta17,18,Delta18 and 17q224) have been detected, none of them arepredicted to rescue BRCA2 functionality. (Homo sapiens) PubMed
1819.
Frequency of BRCA2 breast cancer pathogenic mutations in the Mexican population. (Homo sapiens) PubMed
1820.
Protein truncating variants (PTVs) in specific DNA repair genes were significantly overrepresented among patients with the aggressive phenotype, with BRCA2, ATM and NBN the most frequently mutated genes. (Homo sapiens) PubMed
1821.
we believe we are the first to describe this germline mutation of BRCA2 (c.4211C>G, p.Ser1404Ter) in a patient with PCa, which was effectively treated with ADT and radiotherapy. (Homo sapiens) PubMed
1822.
BRCA1/2 mutation testing thus has important and expanding roles in treatment planning for subsets of patients with breast cancer..Determining BRCA1/2 mutation status in this breast cancer subgroup could potentially expand treatment options beyond the current standard of taxane and anthracycline-based chemotherapy. (Homo sapiens) PubMed
1823.
BRCA 1/2 mutations are associated with a higher hematologic toxicity in patients with ovarian cancer who underwent platinum-based chemotherapy. (Homo sapiens) PubMed
1824.
RAD52 protein, just as BRCA2, interacts with pCHK1 checkpoint protein and helps maintain the checkpoint control in BRCA2 deficient cells during DNA damage response (Homo sapiens) PubMed
1825.
This is the largest study to date comparing outcomes in patients with EOC and BM by mutation status. mBRCA1 and mBCRA2 patients were more likely to have isolated BM, which may be a factor in their long survival. (Homo sapiens) PubMed
1826.
Data found higher BRCA1/2 mRNA-expression in ovarian cancer (OC). BRCA1 mutated OCs exhibited lower BRCA1 but higher BRCA2 mRNA-expression. Low BRCA1-expression was associated with favorable overall survival and low BRCA2-expression with better progression-free and overall survival. (Homo sapiens) PubMed
1827.
BRCA2 variant (rs80359182, 319T/C) is significantly associated with high breast cancer risk in the Pakistani population. BRCA2-tryptophan > arginine substitutions result in altered interaction of BRCA1/PALB2/BRCA2/protein complex and impaired homology-directed DNA repair pathway. (Homo sapiens) PubMed
1828.
Five per cent of unselected Asian patients with breast cancer carry deleterious variants in BRCA2 in Malaysia. (Homo sapiens) PubMed
1829.
The estimated penetrance of breast cancer to age 80 years was 60.8% for BRCA1 and 63.1% for BRCA2. For all BRCA carriers, the penetrance of breast cancer to age 80 for those with no first-degree relative with breast cancer was 60.4% and 63.3% for those with at least 1 first-degree relative with breast cancer (Homo sapiens) PubMed
1830.
All patients in our centre were tested using next-generation sequencing (NGS) panels that included full gene sequencing as well as coverage for large deletions/duplications in BRCA1/2. We calculated MSS1-3 scores for index patients between 2014 and 2017 who had undergone BRCA1/2 genetic testing and recorded their genetic test results (Homo sapiens) PubMed
1831.
Detection of disease-associated variants in the BRCA1 and BRCA2 (BRCA1/2) genes allows for cancer prevention and early diagnosis in high-risk individuals. (Homo sapiens) PubMed
1832.
BRCA1/2 genes are the most commonly mutated pancreatic cancer susceptibility genes that should be considered in all pancreatic cancer cases with young age at onset or a family history of cancer. (Homo sapiens) PubMed
1833.
our study shows that the K3326* variant in BRCA2 associates primarily with cancer types that have strong environmental genotoxic risk factors. We report for the first time an association between the variant and risk of SCLC and SQCSC. (Homo sapiens) PubMed
1834.
The meta-analysis results provide clinicians and health-care regulatory agencies with evidence of the increased risk of colorectal cancer in BRCA1 mutation carriers, but not in BRCA2. (Homo sapiens) PubMed
1835.
Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma (Homo sapiens) PubMed
1836.
Study identified rare single nucleotide variants and small indels mapping to the 5' non-coding region of BRCA2 through targeted sequencing of over 6000 early onset/familial breast cancer patients. Four variants in minimal promoter regions seem to alter gene activity; two others disrupt the binding with PAX5. (Homo sapiens) PubMed
1837.
The germline mutational landscape of BRCA1 and BRCA2 in Brazil. (Homo sapiens) PubMed
1838.
FoxM1 activation occurs secondary to FoxO3a suppression in Idiopathic pulmonary fibrosis (IPF) fibroblasts while restoration of FoxO3a function sensitizes IPF fibroblasts to radiation-induced cell death and downregulates FoxM1, RAD51, and BRCA2. (Homo sapiens) PubMed
1839.
two novel heterozygous pathogenic variants in exons 18 and 11 of the BRCA2 gene in two Lebanese families, are reported. (Homo sapiens) PubMed
1840.
The aims of our study were to assess the clinical validity of BRCA1/2 promoter methylation and BRCA1-like genomic profile to identify BRCAness and to evaluate its correlations with clinicopathological features in triple-negative breast cancers (Homo sapiens) PubMed
1841.
we conducted a prospective study of the relationship between oophorectomy and the risk of contralateral breast cancer in 1781 BRCA1 and 503 BRCA2 mutation carriers with breast cancer. (Homo sapiens) PubMed
1842.
Results found that Israeli BRCA1 or BRCA2 mutation carriers are at an increased risk for developing uterine cancer, especially serous papillary and sarcoma. (Homo sapiens) PubMed
1843.
BRCA1 and BRCA2 play essential roles in maintaining the genome stability. (Homo sapiens) PubMed
1844.
Two mutations in BRCA1 c.224_227delAAAG and c.5431C > T and one mutation in BRCA2 c.5576_5579delTTAA were identified. (Homo sapiens) PubMed
1845.
In pancreatic ductal adenocarcinoma, analysis of persevered tissue, analysis of BRCA expression offered the benefit of yielding results in a short period of time and at a low cost. (Homo sapiens) PubMed
1846.
These findings suggested that the BRCA2 gene mutation is a good prognostic factor and can be used as a gene to predict the prognosis in the bladder cancer patients. (Homo sapiens) PubMed
1847.
Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. (Homo sapiens) PubMed
1848.
Study confirmed the clinical relevance of BRCA1/2 mutations in Korean ovarian cancer (KoOC) patients but not for the early age-of-onset. Possible inconsistency in the ratio of BRCA1-to-BRCA2 mutations and the most common mutation between KoOC and Korean breast cancer (KoBC) may probably suggest presence of mutation sequence-associated penetrance tendency in hereditary Korean breast and ovarian cancer. (Homo sapiens) PubMed
1849.
There was no statistically significant association between sperm DNA fragmentation and the methylation status of the promoter of either BRCA1 or BRCA2 genes in infertile men with oligoasthenoteratozoospermia. (Homo sapiens) PubMed
1850.
Our results demonstrated that germline BRCA2 and CHEK2 mutations are independent unfavorable predictors in patients with mPCa which are associated with decreased time to castration resistance (HR 3.04, 95% CI 1.63-5.66, p<0.001), particularly in subgroup with low volume metastatic disease (HR 4.59, 95% CI 2.06-10.22, p<0,001). (Homo sapiens) PubMed
1851.
systematic genomic analysis of breast tumors with BRCA1 and BRCA2 mutations (Homo sapiens) PubMed
1852.
Numbers for BRCA2 were insufficient to draw conclusions. The rate of local recurrences after breast-conserving therapy did not differ between BRCA1 carriers (10-year risk = 7.3%) and noncarriers (10-year risk = 7.9%). (Homo sapiens) PubMed
1853.
Patients who harbour germline BRCA2 mutations have worse clinical outcomes than noncarriers when treated with surgery or radiotherapy (Homo sapiens) PubMed
1854.
This review summarizes the current evidence for screening/imaging protocols, as well as screening for breast and ovarian cancer susceptibility protein 1 (BRCA1) and breast and ovarian cancer susceptibility protein 2(BRCA2) gene mutations, in breast and ovarian cancer diagnosis in the clinical setting. (Homo sapiens) PubMed
1855.
carrying a BRCA mutation have an increased risk of developing breast and ovarian cancer. The most effective strategy to reduce this risk is the bilateral salpingo-oophorectomy, with or without additional risk-reducing mastectomy. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is recommended between age 35 and 40 and between age 40 and 45 years for women carriers of BRCA1 and BRCA2 mutations, respectively. Consequen (Homo sapiens) PubMed
1856.
Analyses reveal that BRCA(wt) and BRCA(mut) TNBC are similar except for a significant increase of TIL(pos) tumors in the BRCA(mut) group. While BRCA gene mutations may not directly drive immune infiltration, the greater number of TIL(pos) tumors could signal greater immunogenicity in this group. (Homo sapiens) PubMed
1857.
BRRM was associated with lower mortality than surveillance for BRCA1 mutation carriers, but for BRCA2 mutation carriers, BRRM may lead to similar BC-specific survival as surveillance. Our findings support a more individualized counseling based on BRCA mutation type. (Homo sapiens) PubMed
1858.
Findings are the first to provide compelling evidence of the role of BRCA2 in ESCC genetic susceptibility in Chinese, suggesting defective homologous recombination is an underlying cause in ESCC pathogenesis. (Homo sapiens) PubMed
1859.
consensus guide represents a collection of technical recommendations to address the detection of BRCA1/2 mutations in the molecular diagnostic testing strategy for ovarian carcinomas[review] (Homo sapiens) PubMed
1860.
Meta-analysis of cohort, 7 case-control, 4 case-series, 28 frequency, and 11 survival studies shows being a BRCA mutation carrier (BRCA1 and/or BRCA2) was associated with a significant increase in prostate cancer (PCa) risk (OR = 1.90, 95% CI = 1.58-2.29), with BRCA2 mutation being associated with a greater risk of PCa than BRCA1 (OR = 1.35, 95% CI = 1.03-1.76). (Homo sapiens) PubMed
1861.
in the present study we set out to characterize the clinical features of platinum sensitivity that are associated with BRCA 1/2 mutations in ovarian cancer in both primary debulking and interval debulking surgery. (Homo sapiens) PubMed
1862.
This report is the first to describe the highly pathogenic variant in the BRCA2 gene (rs483353122) and the likely damaging germline variant in the MUTYH gene (rs35352891) in Russian Mongoloid BC patients with young-onset and/or bilateral and/or familial BC. (Homo sapiens) PubMed
1863.
observation of a positive association between body mass index and ovarian cancer risk in premenopausal BRCA1/2 mutation carriers is consistent with findings in the general population (Homo sapiens) PubMed
1864.
We identified point mutations in 9 (23%) of 40 T-ALL cases analyzed, with variant allele fractions consistent with heterozygous mutations early in tumor evolution. BRCA2 was the most commonly mutated gene. (Homo sapiens) PubMed
1865.
Among BRCA carrier( BRCA1/2) patients treated for early breast cancer, the addition of contralateral breast irradiation was associated with a significant reduction of subsequent contralateral breast cancers and a delay in their onset. (Homo sapiens) PubMed
1866.
The role of BRCA1 and BRCA2 mutations in cancer susceptibility is REVIEWED. (Homo sapiens) PubMed
1867.
mutant BRCA is an indispensable founding event for some tumours, but in a considerable proportion of other cancers, it appears to be biologically neutral--a difference predominantly conditioned by tumour lineage--with implications for disease pathogenesis, screening, design of clinical trials and therapeutic decision-making (Homo sapiens) PubMed
1868.
Germline variants of unknown significance in BRCA1/2 are more frequent in African-American than Caucasian-American prostate cancer patients; however, the prevalence of pathogenic mutations were similar across the races. Patients carrying BRCA2 pathogenic mutations are more likely to progress to metastasis. (Homo sapiens) PubMed
1869.
12 pathogenic variants (PVs) were identified in 26 cases (9%) , 22 cases harboring BRCA1, and four cases in BRCA2. Eight out of these twelve PVs were reported. novel mutation (c.5760_5770delTTTTGCTGACA) in BRCA2 gene. (Homo sapiens) PubMed
1870.
A large fraction of BRCA2 variants ( approximately 64%) provoked splicing anomalies lending further support to the high prevalence of this disease-mechanism in hereditary breast cancer. (Homo sapiens) PubMed
1871.
next-generation sequencing BRCA1/2 assay could detect most large genomic rearrangements including BRCA1 promoter-region deletion (Homo sapiens) PubMed
1872.
A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers. (Homo sapiens) PubMed
1873.
Anti-mullerian hormone curves according to BRCA status and adjusted by age showed that BRCA2 mutation-positive patients have lower levels of anti-mullerian hormone as compared with BRCA-negative and BRCA1 mutation-positive. (Homo sapiens) PubMed
1874.
The gBRCA mutation detection rate in serous tubal intra-epithelial carcinoma-positive patients was nearly double that of serous tubal intra-epithelial carcinoma-negative patients. Factors such as a positive family history of BRCA-related cancers were seen at a higher proportion in the mutation positive women. (Homo sapiens) PubMed
1875.
The BRCA2 c.67+2T>C splice-site variant may contribute to the pathogenesis of familial breast cancer. (Homo sapiens) PubMed
1876.
Study revealed a potential novel gene and multiple disruptive variants of BRCA2 for breast cancer risk, which may identify high-risk women in Chinese populations. (Homo sapiens) PubMed
1877.
BRCA1/2 mutation prevalence in Chinese ovarian cancer patients is higher than the international rate. (Homo sapiens) PubMed
1878.
BRCA1/2 pathogenic variants have become associated with familial breast and ovarian cancers, and hereditary cancer-predisposition syndrome. (Homo sapiens) PubMed
1879.
Heterozygous c.5722_5723del mutation in the BRCA2 exon 11 of a large Han-Chinese family with breast cancer.This mutation may cause DNA double-strand breaks repair dysfunction by disturbing homologous recombination, further resulting in breast cancer. (Homo sapiens) PubMed
1880.
Although BRCA mutations are known to alter DNA repair mechanism, BRCA 1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro. (Homo sapiens) PubMed
1881.
Our results suggest that single-nucleotide variant rs2910164 does not influence the colorectal cancer risk in Brazilian patients; however, the GG genotype could act as a factor of worse prognosis in patients with advanced disease due to suppression of BRCA1/2 modulated by miR-146a. (Homo sapiens) PubMed
1882.
The study highlights these recent discoveries, which include mechanisms of RFP regulation, DNA damage checkpoint proteins, as well as kinases that regulate BRCA1/2 function. [review] (Homo sapiens) PubMed
1883.
These data assign a definite deficiency to BRCA2 as a primary ovarian insufficiency driver. (Homo sapiens) PubMed
1884.
BRCA2, but not BRCA1 mutations may have a role in uveal melanoma susceptibility that represents a rare source of increased risk (Homo sapiens) PubMed
1885.
BRCA2 bound to PLK1 forms a complex with the phosphatase PP2A and phosphorylated-BUBR1. (Homo sapiens) PubMed
1886.
Mutations of genes BRCA1 and BRCA2 in women with ovarian cancer exposed to factors of Chornobyl nuclear accident have been reported. (Homo sapiens) PubMed
1887.
In the randomized, double-blind, phase III POLO trial progression-free survival was significantly longer with maintenance olaparib, a poly(ADP-ribose) polymerase inhibitor, than placebo in patients with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and metastatic pancreatic cancer whose disease had not progressed during first-line platinum-based chemotherapy. The prespecified HRQoL evaluation is reported here. (Homo sapiens) PubMed
1888.
Women with ovarian cancer at an older age, with few or no affected family members, or with a lower Manchester Score are more likely to carry a BRCA2 PV than a BRCA1 PV, irrespective of the overall higher risk of ovarian cancer associated with BRCA1 PVs. (Homo sapiens) PubMed
1889.
Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. (Homo sapiens) PubMed
1890.
High-throughput functional evaluation of BRCA2 variants of unknown significance. (Homo sapiens) PubMed
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. (Homo sapiens) PubMed
1899.
Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. (Homo sapiens) PubMed
1900.
Functional evaluation of five BRCA2 unclassified variants identified in a Sri Lankan cohort with inherited cancer syndromes using a mouse embryonic stem cell-based assay. (Homo sapiens) PubMed
1901.
Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer. (Homo sapiens) PubMed
1902.
Skipping Nonsense to Maintain Function: The Paradigm of BRCA2 Exon 12. (Homo sapiens) PubMed
1903.
Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. (Homo sapiens) PubMed
1904.
Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study. (Homo sapiens) PubMed
1905.
BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update. (Homo sapiens) PubMed
1906.
Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. (Homo sapiens) PubMed
1907.
Microcephaly family protein MCPH1 stabilizes RAD51 filaments. (Homo sapiens) PubMed
1908.
Conformational flexibility and oligomerization of BRCA2 regions induced by RAD51 interaction. (Homo sapiens) PubMed
1909.
Do BRCA1 and BRCA2 gene mutation carriers have a reduced ovarian reserve? Protocol for a prospective observational study. (Homo sapiens) PubMed
1910.
Distinct roles of BRCA2 in replication fork protection in response to hydroxyurea and DNA interstrand cross-links. (Homo sapiens) PubMed
1911.
Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers. (Homo sapiens) PubMed
Next generation sequencing analysis of BRCA1 and BRCA2 identifies novel variations in breast cancer. (Homo sapiens) PubMed
1914.
miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil. (Homo sapiens) PubMed
1915.
The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1). (Homo sapiens) PubMed
1916.
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. (Homo sapiens) PubMed
1917.
Novel BRCA2 pathogenic genotype and breast cancer phenotype discordance in monozygotic triplets. (Homo sapiens) PubMed
1918.
Analysis of clinicopathologic characteristics of gastric cancer in patients </=40 and >/=40 years of age. (Homo sapiens) PubMed
1919.
Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing. (Homo sapiens) PubMed
1920.
Segregation analysis of the BRCA2 c.9227G>T variant in multiple families suggests a pathogenic role in breast and ovarian cancer predisposition. (Homo sapiens) PubMed
1921.
Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer. (Homo sapiens) PubMed
1922.
Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. (Homo sapiens) PubMed
1923.
BRCA and PALB2 mutations in a cohort of male breast cancer with one bilateral case. (Homo sapiens) PubMed
1924.
Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation. (Homo sapiens) PubMed
A mutation in Cyp6d2, a cytochrome P450 gene, when combined with a brca2 mutation, resulted in synergistic hypersensitivity to camptothecin. (Fly (Drosophila melanogaster dm6)) PubMed
1927.
persistent meiotic DNA double-strand breaks might correspond to crossovers, which are mobilized to the nuclear envelope for their repair; Brca2-Pds5 complexes may be key mediators of this process. (Fly (Drosophila melanogaster dm6)) PubMed
Web services initiated January, 1994 as Portable Dictionary of the Mouse Genome; June 15, 2001 as WebQTL; and Jan 5, 2005 as GeneNetwork.
This site is currently operated by
Rob Williams,
Pjotr Prins,
Zachary Sloan,
Arthur Centeno. Design and code by Pjotr Prins, Zach Sloan, Arthur Centeno, Danny Arends, Christian Fischer, Sam Ockman, Lei Yan, Xiaodong Zhou, Christian Fernandez, Ning Liu, Rudi Alberts, Elissa Chesler, Sujoy Roy, Evan G. Williams, Alexander G. Williams, Kenneth Manly, Jintao Wang, and Robert W. Williams, colleagues.
